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Abstract of the Dissertation 
 
Identification of Bhlhe40 and Irg1 as Essential Regulators of the Inflammatory Response to 
Mycobacterium tuberculosis 
by 
Jeremy P. Huynh 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Microbiology and Microbial Pathogenesis 
Washington University in St. Louis, 2018 
Professor Christina L. Stallings, Chair 
 
Protective immune responses to Mycobacterium tuberculosis (Mtb) must induce 
bactericidal functions while minimizing damage to the lung. Such responses require precise 
control of pro- and anti-inflammatory factors to regulate the recruitment and function of 
protective immune cells but the mechanisms by which this control is exerted remain 
incompletely defined. Basic helix-loop-helix family, member e40 (Bhlhe40) is a transcription 
factor known to regulate production of pro- and anti-inflammatory cytokines that affect 
protective immunity to Mtb. Immune-responsive Gene 1 (Irg1) is an enzyme that generates 
itaconate, a metabolite with potential anti-inflammatory and antibacterial roles during Mtb 
infection. The impact of Bhlhe40 and Irg1 on protective immunity to Mtb was unknown prior to 
the studies detailed in this dissertation. 
We utilized genetically deficient mice to assess the roles of Bhlhe40 and Irg1 expression 
on control of in vivo Mtb infection. We found that Bhlhe40 enables protective immune responses 
to Mtb by restricting expression of the anti-inflammatory cytokine IL-10 and is required in T 
xii 
 
cells and CD11c
+
 cells. Bhlhe40 does so by repressing Il10 transcription, likely by direct binding 
to the Il10 locus. Additionally, we discovered that Irg1 functions in LysM
+
 and CD11c
+
 cells to 
prevent neutrophil-mediated immunopathology. Irg1 expression restricts inflammatory responses 
in myeloid cells at a transcriptional level, likely through production of the metabolite itaconate. 
Thus, Bhlhe40 and Irg1 directly and indirectly tune the inflammatory response to Mtb at a 
transcriptional level. These findings advance our understanding of protective immunity to Mtb 
by revealing novel mechanisms used by specific immune cell types to promote bacterial killing 
and restrict pathologic inflammation. 
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Chapter 1 
 
 
Introduction 
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Tuberculosis 
 
Mycobacterium tuberculosis (Mtb) is an acid-fast bacterium of the phylum 
Actinobacteria and the etiological agent of the disease tuberculosis. Mtb is an obligate human 
pathogen first isolated by Robert Koch in 1882 that has infected and co-evolved with humans for 
an estimated 70,000 years.
1,2
 The burden that tuberculosis imposes on global public health is 
illustrated by a 2017 report by the World Health Organization estimating that 1.7 billion people 
are currently infected with Mtb and that tuberculosis has become the leading cause of death by a 
single infectious agent.
3
 Infection is initiated when aerosolized Mtb bacilli are expelled from an 
infected host and inhaled by a new, susceptible host. Pulmonary tuberculosis is the most 
common form of the disease, but dissemination to extrapulmonary sites can occur.
4
 Tuberculosis 
encompasses a dynamic spectrum of disease states that vary by the presence of disease 
symptoms and transmissibility. Despite this heterogeneity, patients are broadly classified as 
having either latent or active tuberculosis.
4
 Approximately 90% of Mtb infections result in latent 
tuberculosis, a disease state in which the host immune system limits bacterial replication and 
minimizes lung pathology. Latent tuberculosis patients are generally asymptomatic and unable to 
transmit infection but maintain a life-long risk of progression to active tuberculosis. In active 
tuberculosis, which accounts for approximately 10% of cases, the immune response is unable to 
control bacterial replication and patients are able to transmit infection.
5,6
 Active tuberculosis 
patients exhibit symptoms such as fever, fatigue, weight loss, persistent coughing, and coughing 
up blood.
6
 
 Most Mtb infections can be treated by a six month course of antibiotic therapy consisting 
of isoniazid, rifampicin, pyrazinamide, and ethambutol for two months, followed by isoniazid 
and rifampicin for four months. The long duration and potential toxicity of current antibiotic 
3 
 
treatment regimens often leads to problems with patient adherence. Incomplete patient adherence 
promotes the development of multiple drug resistant-tuberculosis (MDR-TB) strains resistant to 
rifampicin or isoniazid and extremely drug resistant-tuberculosis (XDR-TB), defined as MDR-
TB with resistance to a second-line antibiotic.
3
 MDR-TB cases currently comprise 4% of new 
cases and 19% of previously treated cases.
3
 The emergence and spread of difficult to treat MDR-
TB and potentially incurable XDR-TB strains highlights the need for therapeutics with novel 
mechanisms of action and shorter treatment durations. Therapies that target the host immune 
system to enhance bacterial control and minimize lung pathology have gained interest as an 
approach for treating drug resistant Mtb but their development requires a detailed understanding 
of how the immune system succeeds or fails in controlling Mtb infection. 
 Vaccines are another attractive approach for combating Mtb and also rely on knowledge 
of basic host-pathogen interaction. Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is 
currently the only approved vaccine for prevention of tuberculosis. BCG was developed in the 
early 1900s by attenuation of a Mycobacterium bovis isolate through serial passage in vitro for 
13 years.
7
 Over 3 billion doses of BCG have been administered and it has proven effective at 
preventing severe forms of disseminated tuberculosis such as tuberculous meningitis and military 
tuberculosis in infants.
8,9
 However, its efficacy in preventing pulmonary tuberculosis in 
adolescents and adults varies wildly and reports of protective efficacy range from 0-80%.
10–12
 
BCG vaccination has successfully reduced infant mortality, but a vaccine that prevents 
establishment of pulmonary infection in adults will be necessary to halt transmission and 
ultimately eradicate tuberculosis. 
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The immune response to Mycobacterium tuberculosis 
 
 Our current understanding of how the immune system controls Mtb infection is largely 
based on study of humans that develop severe forms of tuberculosis and animal disease models. 
These approaches enable identification of gene signatures and specific genes that are associated 
with or contribute to different disease outcomes. Once identified, protective genes can be 
mechanistically investigated in animal models to determine their function and the quality of the 
immune responses they promote, then further assessed for relevance in humans. Such studies 
have advanced understanding of the pathogenesis of tuberculosis and will inform the 
development of novel diagnostics, therapeutics, and vaccines to treat and prevent tuberculosis. 
The genetically tractable mouse model of Mtb infection has proven to be an invaluable tool 
for dissecting how host genes and immunological processes affect disease outcome. The Cre-
Flox conditional gene deletion system has proven especially useful in this regard.
13
 In this 
system, LoxP DNA recognition sites flanking an exon of a gene of interest are inserted into the 
genome to generate a “flanked by LoxP” or “floxed” allele, denoted by “Genefl/fl.”14 When floxed 
mice are crossed to mice that express Cre recombinase under the control of cell-type specific 
promoters, Cre mediates deletion of the DNA sequence between the LoxP sites. This generates a 
mouse with conditional deletion of the gene of interest only in specified cell types and is a highly 
useful tool for identification of the key cell types that must express the gene as well as study of 
gene function in those cell types. 
Experimental tuberculosis infection in mice is initiated by delivering 100-200 colony-
forming units (CFUs) of aerosolized Mtb to the lungs of each mouse. After deposition in the lung 
bacilli are phagocytosed by lung resident alveolar macrophages. Alveolar macrophages fail to 
clear infection and produce inflammatory signals that recruit other innate immune cell types such 
5 
 
as neutrophils, monocytes, macrophages, and dendritic cells (DCs) to the site of infection. These 
recruited innate immune cell types also fail to clear infection and Mtb replicates logarithmically 
in them until the onset of adaptive immunity. Around 8-9 days post-infection (dpi) DCs 
migrating from the lung arrive in the mediastinal lymph node. Once in the lymph node DCs 
present Mtb antigens to naïve T cells and secrete IL-12, causing the naïve T cells to expand and 
differentiate into T helper (TH) 1-polarized effector cells. T cells are an essential component of 
protective immunity to Mtb, as demonstrated by the propensity of HIV/AIDS patients with latent 
tuberculosis to progress to active tuberculosis as their T cell counts decline.
15,16
 Antigen-specific 
T cells reach the lung 18-20 dpi where they release cytokines, such as interferon (IFN)-γ, that 
activate bactericidal effector mechanisms and limit pathologic inflammatory responses. Mtb 
burden in the lung peaks around 21 dpi, decreases slightly, then remains constant for the 
remainder of the lifetime of the mouse. The arrival of effector T cells in the lung enables the 
formation of structured innate and adaptive immune cell aggregates, referred to as “granulomas” 
in humans and “lesions” in mice that confine Mtb bacilli.17 Human immune responses to Mtb are 
thought to progress in a similar fashion as those in mice, although differences in the amount of 
time before an antigen-specific immune response can be detected suggest that the timing of each 
event differs by species.
18
 These immune responses are sufficient to limit infection to a latent, 
non-transmissible state in 90% of infected humans. Thus, a primary function of the immune 
system is to induce a durable, protective response that activates bactericidal mechanisms and 
limits the spread of Mtb while avoiding pathologic responses. 
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IFN-γ-mediated protective responses to Mtb 
One important component of protective immunity to Mtb is IFN-γ. IFN-γ is a cytokine that 
activates cell-autonomous and non-autonomous mechanisms enabling control of Mtb. The 
importance of IFN-γ for control of Mtb infection is demonstrated by the predisposition to severe 
tuberculosis in humans with in-born errors in genes essential for IFN-γ-producing TH1 responses 
and genes in the IFN-γ signaling pathway.19–22 Protective cell-intrinsic effects of IFN-γ signaling 
include increased fusion of Mtb-containing phagosomes with bactericidal low pH lysosomes via 
induction of LRG47 (also known as IRGM1),
23
 restriction of neutrophil survival,
24
 prevention of 
TH1 cell apoptosis by LRG47-mediated autophagy,
25
 expression of antimicrobial peptides such 
as cathelicidin and β-defensin in human cells26 or ubiquicidin-like peptides in mouse cells,27 
induction of reactive oxygen species (ROS),
28
 divalent cation restriction or 
hyperaccumulation,
29,30
 and tryptophan limitation via indoleamine-2,3-dioxygenase (IDO).
31
 
Although many studies have posited a critical role for IFN-γ-driven canonical autophagy, this 
process is dispensable for in vivo control of Mtb infection.
32
 IFN-γ is typically considered a pro-
inflammatory cytokine but it also prevents pathologic neutrophil-dominated inflammation by 
restricting neutrophil recruitment
24
 and inducing nitric oxide production via nitric oxide synthase 
2 (NOS2).
33
 Mice deficient in IFN-γ production or signaling rapidly succumb to Mtb 
infection.
23,34,35
 TH1-polarized CD4
+
 T cells are the primary source of IFN-γ and production of 
IFN-γ is necessary but not sufficient for the full extent of their protective capacity.24,36,37 Natural 
killer cell production of IFN-γ also contributes to resistance in the context of T cell deficiency.38 
Collectively, these studies demonstrate that IFN-γ is necessary, but not sufficient, for host 
resistance to Mtb and mechanisms that support its production and function play important roles 
in protective immunity to Mtb. 
7 
 
IL-10 is an immunoregulatory cytokine that suppresses the production and effects of 
IFN-γ.39,40 Nearly all innate and adaptive immune cell types, with the exception of plasmacytoid 
DCs, can produce IL-10 during Mtb infection and it is detrimental for control of Mtb 
infection.
41-44
 IL-10 antagonizes IFN-γ-associated pathways by suppressing macrophage 
responsiveness to IFN-γ,39,45,46 modulating T-helper (TH) 1 cell IFN-γ production,
40,42,43,47
 and 
restricting production of the hallmark TH1-inducing cytokine IL-12.
47–51
 IL-10 can also inhibit 
DC migration to the lung-draining lymph node
49
 and limit secretion of myeloid cell-derived 
proinflammatory cytokines.
45,52,53
 Many observations have suggested an important role for IL-10 
in human tuberculosis pathogenesis. Human single nucleotide polymorphisms in the IL10 gene 
promoter have been linked to tuberculosis susceptibility in particular ethnic groups.
54–60
 Patients 
with active tuberculosis express higher amounts of IL-10 in their lung pleural fluid,
61
 
bronchoalveolar lavage fluid,
62
 sputum,
63,64
 and serum
65,66
 as compared to healthy controls or 
controls with non-mycobacterial lung disease. IL-10 has also been shown to decrease the amount 
of IFN-γ produced by Mtb-stimulated peripheral blood mononuclear cells from active 
tuberculosis patients
67,68
 or tuberculin skin test-positive individuals
69
 and can block phagosome  
maturation in Mtb infected human monocyte-derived macrophages.
41
 Surprisingly, studies on 
mice globally deficient in IL-10 production have either reported no role for IL-10
70,71
 or that it 
causes a mild impairment of control during chronic Mtb infection.
42–44,48
 This impairment has 
been attributed to IL-10 production by T cells and CD11c
+ 
cells.
44
 In vivo over-expression of IL-
10 by T cells or macrophages has also supported a negative role for IL-10 during chronic Mtb 
infection, although differences in mouse genetic background and the transgenic promoters used 
have resulted in an unclear picture.
40,50
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 Given that IL-10 has the potential to negatively impact key protective immune responses 
to Mtb but global loss of IL-10 function does not result in excessive reduction of Mtb burden in 
mice, it is likely that cell-autonomous mechanisms that limit IL-10 induction pathways are 
important for control of Mtb. Mycobacteria directly stimulate IL-10 production from monocytes, 
macrophages, DCs, and neutrophils via signaling through pattern-recognition receptors such as 
toll-like receptor 2 (TLR2)
72,73
 and the C-type lectin receptor DC-specific ICAM3-grabbing non-
integrin (DC-SIGN).
74
 In addition, different TH cell subsets and innate immune cell types 
produce IL-10 in response to distinct combinations of cytokines.
75
 These signals lead to the 
binding of diverse transcription factors at promoter and enhancer elements within the Il10 locus 
to activate transcription within myeloid and lymphoid cells.
75–77
 Many transcription factors 
restricting IL-10 production have been identified, but none have been assessed for IL-10-
dependent roles during in vivo Mtb infection. The transcription factors known to repress Il10 in 
innate immune cells include B cell CLL/lymphoma 3 (Bcl3),
78
 histone deacetylase 11 
(HDAC11),
79
 poly(ADP-ribose) polymerase 1 (PARP-1),
80
 nuclear receptor subfamily 1 group D 
member 1 (NR1D1, Rev-erbα),81 programmed cell death protein 4 (PCDP4),82 and interferon 
regulatory factor 5 (IRF5)
83
 in macrophages as well as class II MHC transactivator (CIITA) in 
DCs.
84
 NR1D1 is notable for its role in promoting Mtb control by human macrophages through 
repression of IL-10.
81
 Repressors of Il10 in adaptive immune cells include E26 transformation 
specific 1 (ETS-1)
85
 and PU.1
86
 in T cells as well as forkhead box D3 (Foxd3) in B cells.
87
 The 
ability of IL-10 to suppress the actions of IFN-γ suggests that it must be carefully regulated in 
order to allow the induction and maintenance of protective responses to Mtb but the mechanisms 
of its regulation during Mtb infection are poorly characterized. 
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Pathologic responses to Mtb 
In addition to establishing protective responses the immune system must also avoid responses 
that fail to restrict Mtb replication or cause lung pathology. The importance of strictly controlling 
the immune response to Mtb is illustrated by tuberculosis-associated immune reconstitution 
inflammatory syndrome (TB-IRIS), a condition that occurs in 18% of HIV/Mtb co-infected 
patients as anti-retroviral therapy allows the immune system to recover from the effects of HIV 
infection. During TB-IRIS the recovering immune system mounts an excessive pro-
inflammatory cytokine and cellular response to Mtb that causes immunopathology and worsens 
tuberculosis-associated symptoms.
88
 Murine studies have generated complementary data 
showing that even cellular and cytokine responses normally associated with resistance to Mtb 
can be pathological if produced in excess.
89,90
  
Studies in humans and mice have suggested that neutrophils are key mediators of 
inflammatory responses that poorly control Mtb and cause lung pathology. In active tuberculosis 
patients neutrophils are the predominantly infected cell type
91
 and active tuberculosis patients 
can be identified by a neutrophil-driven transcriptional signature.
92
 Tuberculosis patients with 
higher blood neutrophil counts also have increased disease severity
93
 and higher case fatality 
rates.
94
 Acutely susceptible mouse strains often display neutrophilic inflammation that can cause 
or result from failed immunity to Mtb.
24,32,95,96
 Neutrophils are thought to mediate susceptibility 
to Mtb by releasing pro-inflammatory cytokines that can exacerbate non-protective inflammation 
as well as proteases and reactive oxygen species (ROS) that damage the lung.
32,97,98
 The  
resulting pathology may be an important cause of granuloma breakdown and lung cavitation, 
processes that allow Mtb to re-enter the respiratory tract and transmit to a new host.
4
 In addition 
to causing lung pathology, neutrophils also provide a nutrient-rich replicative niche for Mtb.
33
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Restraint of pro-inflammatory cytokine production and neutrophilic inflammation are important 
components of protective immunity to Mtb, but the mechanisms by which the immune system 
controls these processes remain poorly defined. 
Bhlhe40 
 
 Homologs of the gene now officially named Bhlhe40 (basic helix-loop-helix family 
member e40) were identified by several independent groups and have thus has been referred to 
by multiple names (Bhlhb2, Clast5, Dec1, Sharp2, Stra13) over the course of its study. For 
simplicity, this gene will henceforth be referred to as “Bhlhe40,” regardless of the homolog name 
used in the original study. Bhlhe40 is a 411 amino acid protein of the basic helix-loop-helix 
(BHLH)-Orange subfamily of transcription factors which are characterized by a basic patch that 
enables DNA binding, a helix-loop-helix domain that enables protein dimerization, and an 
Orange domain conferring functional specificities that vary by family member.
99
 Bhlhe40 is 
expressed in a wide range of organs and cell types and can be induced by many different stimuli. 
Cell types that express Bhlhe40 include neurons,
100
 chondrocytes,
101
 epithelial cells,
102–104
 innate 
immune cells,
105–108
 and adaptive immune cells.
109–111
 Stimuli inducing Bhlhe40 transcription 
include growth factors,
100,104
 light,
112
 starvation,
102
 hypoxia,
103,113
 anti-CD3 stimulation,
109
 anti-
CD28 stimulation,
114
 hormones,
101,115–117
 retinoic acid,
101,102
 cytokines,
105,108
 and B cell receptor 
cross-linking.
118
 Roles for Bhlhe40 have been  reported in a wide variety of cellular processes 
including cell cycle arrest,
102,110,119
 apoptosis,
120,121
 epithelial to mesenchymal transition,
122
 
cellular differentiation,
101,123
 circadian rhythm,
112
 stress response,
102,103,113
 and immune system 
function. Bhlhe40 typically mediates these effects by transcriptional repression and several 
mechanisms of action have been reported. Direct binding to the class B E-box DNA motif 
11 
 
CACGTG allows Bhlhe40 to repress transcription, likely by occluding other transcription 
factors.
112,124
 Bhlhe40 can also associate with other transcription factors and inhibit their ability 
to bind DNA and activate transcription
102,112,125,126
 or recruit histone deacetylases to modify 
chromatin accessibility.
102,127
 Many of the stimuli that that induce Bhlhe40 expression are 
present in the Mtb infected lung, suggesting that it may be operative in lung resident and 
recruited cells during infection. 
 
Bhlhe40 in the immune system 
 Study of Bhlhe40 in the context of the immune system has been limited to lymphoid cell 
types and multiple studies have identified it as an important regulator of cytokine production, 
particularly in T cells and in the context of autoimmunity. Naïve Bhlhe40
-/-
 mice appear 
phenotypically similar to wild-type (WT) mice.
109
 Bhlhe40 expression has no effect on αβ T cell 
polarization but promotes expression of many pro-inflammatory cytokines such as IL-2, IL-4, 
IL-17, IFN-γ, and GM-CSF while suppressing anti-inflammatory IL-10.109,114,128,129 Bhlhe40 
expression is also required for production of IFN-γ by invariant natural killer T cells111 and GM-
CSF by γδ T cells.128 Bhlhe40 may also promote systemic immune regulatory functions by 
associating with the transcription factor Runx1 to sustain IL-2Rα (CD25) expression, thus 
enabling long-term maintenance of regulatory T cells.
130
 Aged Bhlhe40
-/-
 mice exhibit an 
accumulation of activated B cells that may be due to a role for Bhlhe40 in inhibiting B cell 
activation and proliferation by blocking cell cycle progression.
110
 Notably, Bhlhe40-deficient 
mice are highly resistant to the induction of experimental autoimmune encephalomyelitis (EAE), 
a T cell-driven model of multiple sclerosis-like neuroinflammation.
108,114,128,129
 Resistance to 
EAE in Bhlhe40
-/-
 mice is attributed to their decreased Csf2 (GM-CSF) and increased Il10 (IL-
12 
 
10) transcription in T cells and is dependent on signaling through the IL-10 receptor.
114,128
 
Collectively, these studies demonstrate that Bhlhe40 regulates multiple T cell functions 
important for control of Mtb infection, such as production of IL-10 and IFN-γ. Despite its 
potential impact on Mtb infection, no prior studies had examined the role of Bhlhe40 in the 
context of an infectious disease. 
Irg1 
 
Immune-responsive Gene 1 (Irg1, also known as cis-aconitate decarboxylase 1 [Acod1]) 
is an enzyme that links cellular metabolism to immune system functionality. It is distinct from 
the similarly named Immunity-Related GTPase (IRG) proteins that play a prominent role in 
Toxoplasma gondii infection. Innate immune cells such as macrophages, microglia, and 
neutrophils strongly express Irg1 upon activation,
131–133
 whereupon it localizes to the 
mitochondria.
134,135
 Irg1 is also inducible in non-hematopoietic cell types such as uterine 
epithelial cells in response to progesterone signaling
136
 and neurons.
137
 Many types of pro-
inflammatory stimuli such as lipopolysaccharide (LPS)
131,138
 and CpG methylated DNA,
134
 as 
well as viral,
137,139
 parasitic,
132,134
 and bacterial infection
135,140
 are able to induce Irg1 expression. 
Notably, such bacterial species include both pathogenic and non-pathogenic mycobacteria.
141,142
 
Induction by these stimuli is likely mediated by inflammatory cytokines such as IFN-α, IFN-β, 
IFN-γ, TNF-α, IL-1β, and IL-17.134,135 Upon its expression, Irg1 catalyzes the decarboxylation of 
cis-aconitate, a metabolic intermediate of the tricarboxylic acid (TCA) cycle, thus producing the 
metabolite itaconic acid. This enzymatic activity is mediated by its five cis-aconitate 
decarboxylase domains (CADs), all of which are fully conserved in mouse and human Irg1.
143
 
Itaconic acid is often referred to as itaconate, its neutral salt. Dimethyl itaconate (DI), an 
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itaconate derivative with increased membrane permeability, has been used to study the biological 
functions of itaconate.
138
  Thus far, Irg1 is only known source of itaconate in mammalian cells 
and no itaconate-independent functions for Irg1 have been described. Reports of Irg1 induction 
during mycobacterial infection and the presence of Irg1-inducing cytokines in Mtb infected lungs 
strongly suggest that Irg1 is expressed during Mtb infection. 
 
Antibacterial roles for Irg1 
Irg1 has gained attention for the potential of its metabolite product, itaconate, to function 
as an endogenous antibacterial effector molecule by inhibiting isocitrate lyase (ICL).
144
 ICLs 
function in two important metabolic pathways, the glyoxylate shunt and the methylcitrate 
cycle.
145,146
 The glyoxylate shunt enables certain bacteria and fungi to utilize fatty acids as 
alternative carbon sources and persist under what would otherwise be nutrient-limiting 
conditions by modifying their tricarboxylic acid (TCA) cycle.
147
 The TCA cycle generates the 
essential cellular energy source adenosine triphosphate (ATP), but its intermediates can also be 
diverted into biosynthetic pathways. The glyoxylate shunt is an anaplerotic pathway that 
bypasses two decarboxylation reactions of the TCA cycle, allowing Mtb to use even-chain fatty 
acid substrates, such as host-derived lipids, to replenish TCA cycle intermediates that are 
diverted to biomass production.
147
 ICLs in Mtb also possess methylisocitrate lyase activity that 
allows them to function in the methylcitrate cycle.
148
 The methylcitrate cycle enables 
regeneration of the TCA cycle intermediates oxaloacetate and malonate while also preventing 
build-up of toxic propionyl-CoA and methylmalonyl-CoA that result from β-oxidation of odd-
chain fatty acids such as cholesterol.
146
 Loss of methylcitrate cycle function can lead to defects in 
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Mtb TCA cycle activity, pH homeostasis, and membrane potential homeostasis but it may not be 
essential for in vivo survival of Mtb.
146,148
 
The glyoxylate shunt is an important metabolic pathway for persistence in pathogenic 
Mycobacteria, Salmonella, and Yersinia species.
145,149
 The commonly studied Mtb Erdman strain 
has two isocitrate lyases, ICL1 and ICL2, encoded by the genes icl1 and icl2 (also known as 
aceA). ICL1-deficient (Δicl1) Mtb exhibits a persistence defect during chronic in vivo infection 
of mice but ICL2-deficient (Δicl2) Mtb exhibits no defects, suggesting that while ICL1 and ICL2 
have some level of functional redundancy ICL1 plays a slightly more important role.
145,150
 In 
contrast, Δicl1/Δicl2 Mtb is dramatically attenuated in vivo and is cleared from the lung by two 
weeks post-infection.
145
 An antibacterial role for itaconate was supported by the findings that it 
inhibits purified Mtb ICL proteins in vitro
151
 and that itaconate concentrations two- to three-fold 
higher than those observed in activated macrophages had bacteriostatic effects on Mtb growth in 
liquid culture under conditions requiring the glyoxylate shunt.
143
 Irg1 has also been reported to 
promote the generation of potentially bactericidal mitochondrial reactive oxygen species (ROS) 
during Salmonella infection of zebrafish.
152
 However, Irg1 had no effect on ROS production in 
murine Legionella infection,
135
 suggesting that this capability may be pathogen- or species-
dependent. These reports suggested that Irg1 might restrict Mtb growth by promoting ROS 
production or inhibiting the glyoxylate shunt through itaconate production. 
 
Irg1 as a modulator of inflammation 
Recent studies have linked Irg1-mediated itaconate production to modulation of immune 
cell metabolism and inflammatory responses, with the majority of studies finding that it has a net 
anti-inflammatory effect. In bone marrow-derived macrophages (BMDMs), itaconate suppressed 
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a subset of pro-inflammatory cytokines including IFN-β, IL-1β, IL-6, IL-12, and IL-18 through 
several different mechanisms.
138,153,154
 Inhibition of succinate dehydrogenase by itaconate 
reduces production of IL-1β and IL-18,138,155 while suppression of IL-6 and IL-12 is mediated by 
Atf3-induction that results in a translation-level block of IκBζ, a transcription factor promoting 
Il6 and Il12b expression.
153
 Itaconate and its derivatives were also found to limit IL-1β and IFN-
β production by promoting post-translational modification-mediated degradation of KEAP1, a 
repressor of the anti-inflammatory transcription factor Nrf2.
156
 Irg1 has also been proposed to 
suppress IL-1β and IL-6 production through induction of the anti-inflammatory transcription 
factor TNFAIP3 (also known as A20).
154,157
 These anti-inflammatory effects on cytokine 
production are associated with improved outcomes in sepsis and psoriasis models in which 
pathology is mediated by excessive inflammation.
153,156
 
Irg1 has been linked to the generation of ROS but reports vary as to whether it promotes 
or inhibits ROS production and the resulting effect on inflammation. ROS can mediate pro- or 
anti-inflammatory effects and the amount produced may be the determining factor.
158,159
 
Decreased ROS levels have been associated with itaconate-mediated inhibition of succinate 
dehydrogenase activity and protection from ischemic reperfusion injury.
138
 During respiratory 
syncytial virus infection Irg1 is reported to increase ROS levels, leading to increased 
inflammation and lung injury.
160
 
Macrophage-produced itaconate can also be secreted into the extracellular environment, 
suggesting that it may mediate immunomodulatory effects in trans on other cell types in the 
inflammatory environment.
138,161,162
 The capacity of Irg1 and itaconate to modulate cell-
autonomous and nonautonomous effects on inflammation suggested that it could have an 
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important role in the context of Mtb infection wherein immune responses must be precisely 
calibrated to balance bacterial clearance and prevention of tissue pathology.
24,32
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Abstract 
 
The cytokine IL-10 antagonizes pathways that control Mycobacterium tuberculosis (Mtb) 
infection. Nevertheless, the impact of IL-10 during Mtb infection has been difficult to decipher 
because loss-of-function studies in animal models have yielded only mild phenotypes. We have 
discovered that the transcription factor basic helix-loop-helix family member e40 (Bhlhe40) is 
required to repress Il10 expression during Mtb infection. Loss of Bhlhe40 in mice results in 
higher Il10 expression, higher bacterial burden, and early susceptibility similar to that observed 
in mice lacking IFN-γ. Deletion of Il10 in Bhlhe40-/- mice reverses these phenotypes. Bhlhe40 
deletion in T cells or CD11c
+
 cells is sufficient to cause susceptibility to Mtb. Bhlhe40 represents 
the first transcription factor found to be essential during Mtb infection to specifically regulate 
Il10 expression, revealing the importance of strict control of IL-10 production by innate and 
adaptive immune cells during infection. Our findings uncover a previously elusive but significant 
role for IL-10 in Mtb pathogenesis. 
Introduction 
 
 Host immune responses mediate both bacterial control and pathology during 
Mycobacterium tuberculosis (Mtb) infection. IFN-γ signaling through the transcription factor 
STAT1 is essential for the control of mycobacterial infections in humans and mice.
22,23,34,35
 IL-10 
is an immunoregulatory cytokine produced by a wide variety of innate and adaptive immune cell 
types
44,75
 that antagonizes IFN-γ–associated pathways by suppressing macrophage 
responsiveness to IFN-γ,39 modulating T-helper (TH) 1 cell IFN-γ production,
40,42,43
 and 
restricting production of the hallmark TH1-inducing cytokine IL-12.
48–50
 IL-10 can also inhibit 
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dendritic cell (DC) migration
49
 and limit secretion of myeloid cell-derived proinflammatory 
cytokines.
52
 Global loss-of-function studies have demonstrated a detrimental role for Il10 
expression in the control of chronic Mtb infection in mice, although the magnitude of this effect 
appears dependent on genetic background and is generally mild.
42,43,48
 More recently, conditional 
deletion of Il10 in T cells or CD11c
+
 cells showed that IL-10 production by these two cell types 
exacerbates Mtb infection.
44
 Overexpression studies in mice have also supported a negative role 
for IL-10 in controlling mycobacterial infection, although differences in genetic background, 
transgenic (Tg) promoters, and mycobacterial species used have resulted in an unclear 
picture.
40,50,163,164
 
Given the potential for IL-10 to negatively impact protective immune responses, cell-
autonomous mechanisms likely exist to regulate IL-10 expression. However, the factors required 
for this regulation remain poorly understood. Mtb directly stimulates IL-10 production from 
monocytes, macrophages, DCs, and neutrophils via pattern-recognition receptor signaling.
165
 In 
addition, different TH cell subsets produce IL-10 in response to distinct combinations of 
cytokines.
75
 These signals lead to the binding of diverse transcription factors at various promoter 
and enhancer elements within the Il10 locus to activate transcription within myeloid and 
lymphoid cells.
75–77
 Less is known about transcriptional pathways that limit production of IL-
10.
166
  
The transcription factor basic helix-loop- helix family member e40 (Bhlhe40) has been 
shown to regulate production of cytokines, including IL-10, by T cells in the experimental 
autoimmune encephalomyelitis model, a T cell-driven model of neuroinflammation.
108,114,128
 
Prior to this study Bhlhe40 was uncharacterized in an infectious disease context. We utilized 
mice with genetic deletions of Bhlhe40 to characterize its importance and function during in vivo 
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Mtb infection. Here we report that Bhlhe40 serves an essential role in resistance to Mtb infection 
by repressing Il10 expression in both T cells and myeloid cells. 
Results 
 
Lower BHLHE40 expression is associated with active tuberculosis 
When we analyzed publicly available whole-blood gene expression datasets,
92,167,168
 we 
found that BHLHE40 transcripts were present at a significantly lower abundance in patients with 
active tuberculosis as compared with healthy controls, those with latent tuberculosis infection, or 
those with lung cancer, pneumonia, or sarcoidosis (Fig. 1A). This expression pattern contrasted 
with that of STAT1, whose expression was significantly increased in active tuberculosis patients 
(Fig. 1B) as previously noted.
92,168
 
 
Bhlhe40 is required to control mycobacterial infection  
Our finding that BHLHE40 expression is decreased in patients with active tuberculosis 
infection led us to investigate a role for this transcription factor during Mtb infection in mice. We 
infected WT, Bhlhe40
+/−
, and Bhlhe40
−/−
 mice on the C57BL/6J background with the Mtb 
Erdman strain and monitored morbidity and mortality. WT and Bhlhe40
+/− 
mice displayed no 
signs of morbidity and survived beyond 100 days post-infection (dpi). Bhlhe40
−/−
 mice began 
losing weight around 21 dpi and succumbed to infection between 32 and 40 dpi with a median 
survival time of 33 dpi (Fig. 2A, B). This severe susceptibility phenotype is similar to that of 
mice lacking STAT1
23
 and is more severe than that of mice lacking NF-κB p50,169 both of which 
are central transcriptional regulators of the immune system. By 21 dpi, Mtb colony-forming units 
(CFUs) in Bhlhe40
−/− 
mice were 23-fold higher in the lung and 5-fold higher in the spleen as  
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Figure 1. Lower BHLHE40 expression is specifically associated with active tuberculosis. 
Expression of (A) BHLHE40 and (B) STAT1 in human whole blood from healthy controls or 
patients with latent tuberculosis (TB), active TB, or other lung diseases. Data are derived from 
the analysis of the indicated publicly available GEO microarray datasets using the indicated 
probe sets. Each point represents data from one human. The mean ± SEM is graphed. Statistical 
differences were determined by two-tailed unpaired Student’s t test or unpaired one-way 
ANOVA for normally distributed groups and unpaired Kruskal-Wallis test or two-tailed unpaired 
Mann-Whitney test for non-normally distributed groups. *, P < 0.05; **, P < 0.01; ***, P < 
0.001; ****, P < 0.0001. Previously published in Huynh and Lin et al., 2018. 
 
compared with WT mice (Fig. 2C, D). The differences in Mtb CFUs in both organs became even 
more pronounced at 28 dpi, demonstrating an ongoing defect in the ability of Bhlhe40
−/−
 mice to 
control Mtb replication. We next tested the requirement for two important Mtb virulence factors, 
the ESX-1 secretion system and the membrane lipid phthiocerol dimycoserosate (PDIM), to 
cause susceptibility in Bhlhe40
−/−
 mice. Bhlhe40-deficient mice infected with isogenic Mtb 
22 
 
strains lacking ESX-1 (ΔESX-1) or PDIM (ΔPDIM) exhibited no susceptibility over 80 days of 
infection (Fig. 2E). At 81 dpi, lung CFU counts for PDIM-deficient Mtb were below the limit of 
detection in Bhlhe40
−/−
 mice while ESX-1 deficient Mtb counts trended higher in Bhlhe40
−/−
 
lungs compared to WT Mtb (Fig. 2F). These experiments lack the statistical power to draw 
strong conclusions but suggest that expression of ESX-1 and PDIM by Mtb is required for the 
acute susceptibility of Bhlhe40
−/−
 mice. Bhlhe40
−/− 
mice may also have a defect in control of 
ΔESX-1 Mtb, though not to the same extent as WT Mtb.  
We next tested whether Bhlhe40
−/−
 mice were susceptible to a related mycobacterial 
species, Mycobacterium bovis Bacillus Calmette-Guérin (BCG) (Fig. 2G). No survival defect 
was observed prior to nine weeks post-infection but BCG lung titers were significantly higher in 
the lungs of Bhlhe40
−/−
 mice. This demonstrated that Bhlhe40
−/−
 mice have a reduced capacity to 
control lung infection by multiple mycobacterial species, although their susceptibility is species- 
and virulence-factor dependent. Upon infection with the intracellular bacterial pathogen Listeria 
monocytogenes, Bhlhe40
−/−
 mice showed no increased susceptibility (Fig. 2H) and mounted a 
robust response to secondary L. monocytogenes challenge (Fig. 2I), indicating that their impaired 
immune response may be specific to mycobacterial infection. 
 
Bhlhe40 deficiency leads to severe lung inflammation  
Shortly before succumbing to infection, it was evident by gross examination that 
Bhlhe40
−/−
 lungs had developed larger lesions than WT lungs (Fig. 3A). Histological analysis 
confirmed that although there were no differences in pulmonary inflammation before infection, 
the lungs of Bhlhe40
−/−
 mice had developed larger neutrophil- and acid-fast bacilli-rich lesions 
with more widespread inflammation than WT lungs by 21 dpi (Fig. 3B, C). 
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Figure 2. Bhlhe40 is required to control mycobacterial infection. 
(A-D) Mice were infected with WT Mtb and monitored for changes in (A) body weight, (B) 
survival, (C) lung Mtb burden, and (D) spleen Mtb burden. (E-F) Mice were infected with WT, 
ΔESX-1, and ΔPDIM Mtb then monitored for (E) survival and (F) lung Mtb burden at 81 dpi. 
Bhlhe40
−/−
 mice infected with WT Mtb did not survive to 81 dpi and thus could not be assessed 
at this time point. (G) Mice were infected intranasally with M. bovis BCG and monitored for 
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lung BCG burden at 62 and 65 dpi. Data from 62 and 65 dpi is graphed and analyzed together. 
(H) Mice were intravenously infected with 10
6
 or 10
7
 CFU of L. monocytogenes and monitored 
for survival. (I) Mice were intravenously infected with 10
6
 CFU and L. monocytogenes burden in 
the spleen and liver was assessed at 3 days after primary or secondary infection. Dotted lines 
indicate limits of detection ([B] 500, [B] 50 and 500, and [I] 100 CFU). The mean ± SEM is 
graphed. Statistical differences were determined by log-rank Mantel-Cox test (B, E, H), two-
tailed unpaired Student’s t test for normally distributed groups, and two-tailed unpaired Mann-
Whitney test for non-normally distributed groups (C, D, G, I). *, P < 0.05; **, P < 0.01; ***, P < 
0.001; ****, P < 0.0001. Data are from one (E, F, G, I) or two independent experiments (A-D, 
G). Panels (A-D, H-I) were previously published in Huynh and Lin et al., 2018. 
 
 
 
Figure 3. Bhlhe40 deficiency leads to severe lung inflammation. 
(A-C) Mice were left uninfected or were infected with Mtb. (A) Gross lung pathology was 
assessed at 33 dpi. Lung histopathology in (B) naïve mice or (B, C) at 21 dpi was assessed by 
H&E staining. Images shown are at 4X magnification. (C) Acid-fast bacteria in lung samples 
were visualized by Ziehl-Neelsen stain at 21 dpi. Scale bars indicate 5 mm (A), 500 µm (B), 100 
µm (C, H&E), or 50 µm (C, Ziehl-Neelsen). Images are representative of two independent 
experiments with three biological replicates per experiment. Previously published in Huynh and 
Lin et al., 2018. 
25 
 
We analyzed these histological differences further by performing flow cytometry on the 
immune cell populations present in the lungs of mice before and after Mtb infection. By 21 dpi, 
neutrophils were the predominant CD45
+
 cell type in the lungs of Bhlhe40
−/−
 mice, and the 
absolute number of neutrophils in Bhlhe40
−/−
 lungs was three times greater than in WT lungs 
(Fig. 4A, D). The number and frequency of neutrophils in the lungs of Bhlhe40
−/−
 mice further 
increased as the infection progressed (Fig. 4C, D). The number of CD11b
+
Ly6C
high
 monocyte-
derived DCs (moDCs) was 12-fold lower and CD8
+
 T cell counts trended downward in 
Bhlhe40
−/−
 mice at 21 dpi, suggesting that Bhlhe40 may regulate the development, recruitment, 
or survival of these populations (Fig. 4A). There were no significant differences in the 
populations sizes of other myeloid or lymphoid cell types analyzed at 21 dpi (Fig. 4A), nor were 
there any differences in the frequency of Mtb antigen-specific T cells in lungs or mediastinal 
lymph nodes (Fig. 4B). 
 The timing of the increased inflammation correlated with our initial observation of 
higher Mtb burden in the lungs of Bhlhe40
−/−
 mice, leading us to investigate whether the 
accumulating myeloid cells were infected with Mtb. We infected WT and Bhlhe40
−/−
 mice with a 
strain of Mtb Erdman that stably expresses GFP and monitored the number and frequency of 
Mtb-infected cells at 21 dpi. Neutrophils, CD11b
+
 macrophages, inflammatory monocytes, 
moDCs, and CD11b
+
 DCs were all infected at a higher frequency in Bhlhe40
−/−
 lungs compared 
with WT lungs (Fig. 4E). Absolute numbers of infected neutrophils, inflammatory monocytes, 
and CD11b
+
 DCs were also significantly higher in Bhlhe40
−/−
 lungs (Fig. 4F), suggesting that 
Mtb residing within these cell types accounts for the difference in pulmonary Mtb burden in 
Bhlhe40
−/−
 lungs at 21 dpi. Infected Bhlhe40
−/−
 neutrophils, inflammatory monocytes, moDCs, 
and CD11b
+
 DCs also exhibited an increase in mean fluorescence intensity (MFI) for GFP 
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compared with infected WT neutrophils, suggesting that they harbored more Mtb on a per-cell 
basis (Fig. 4H). 
 
Neutrophil and monocyte inflammation do not drive susceptibility in Bhlhe40
-/-
 mice. 
To test whether the influx of neutrophils contributed to the susceptibility of Bhlhe40
−/−
 
mice, we used an anti-Ly6G monoclonal antibody to specifically deplete neutrophils between 10 
and 30 dpi.
32
 Neutrophil-depleted Bhlhe40
−/−
 mice did not exhibit any improvements in 
morbidity, survival time, or control of Mtb replication (Fig. 5A-C). We further tested a role for 
neutrophils in susceptibility by infecting Bhlhe40
−/−
 mice lacking granulocyte colony stimulating 
factor receptor (G-CSFR, Csf3r) (Fig. 5D). Csf3r
−/−
 mice are reported to have basal 
neutropenia
170
 although we did not confirm neutropenia in this setting. Csf3r
-/-
Bhlhe40
-/-
 mice 
exhibited a statistically significant extension of survival time compared to Csf3r
+/-
Bhlhe40
-/-
 
mice, and the difference in survival time between Bhlhe40
-/-
 and Csf3r
-/-
Bhlhe40
-/-
 mice 
approached significance (p = 0.052), suggesting that loss of G-CSFR signaling is partially 
protective in the context of Bhlhe40-deficiency. Csf3r
−/−
 mice were susceptible in chronic Mtb 
infection, demonstrating that G-CSFR-signaling is host-protective in WT mice (Fig. 5D). We 
next tested a role for monocytes in susceptibility by infecting Bhlhe40
−/−
 mice lacking C-C motif 
chemokine receptor 2 (CCR2, Ccr2) (Fig. 5E). CCR2 is essential for survival of high dose Mtb 
infection and Ccr2
−/−
 mice exhibit defects in inflammatory monocyte recruitment,
171
 although we 
did not confirm reduced monocyte recruitment in this setting. CCR2-deficiency had no impact on 
the susceptibility of Bhlhe40
−/−
 mice. These results show that although neutrophils and 
monocytes are prominent replicative niches for Mtb and neutrophils may have a detrimental role, 
these cell types are not the sole cause of susceptibility to Mtb infection in Bhlhe40
−/−
 mice. 
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Figure 4. Bhlhe40 deficiency leads to neutrophil-dominated inflammation. 
(A-G) Mice were infected with Mtb. (A) Absolute cell counts for pulmonary immune cells 
before infection and at 21 dpi. MoDC counts in four naive WT and three naive Bhlhe40
−/−
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samples were below the limit of detection (∼100 cells). (B) Frequency of Mtb antigen-specific 
CD4
+
 T cells at 21 dpi. (C) Representative flow cytometry plots for neutrophils as a percentage 
of the total CD45
+
 population. (D) Absolute count and percentage of the total CD45
+
 population 
for lung neutrophils. (E) Representative flow cytometry plots for GFP
+
 (Mtb
+
) neutrophils at 21 
dpi. (F) Frequency of GFP
+
 (Mtb
+
) cells in myeloid lung populations at 21 dpi. (G) Absolute 
count for GFP
+
 (Mtb
+
) lung myeloid cells at 21 dpi. Four WT alveolar macrophage, four WT and 
five Bhlhe40
−/−
 CD103
+
 DC, and two WT and one Bhlhe40
−/−
 eosinophil samples were below the 
limit of detection (∼850 cells). (H) MFI for FITC in GFP+ (Mtb+) lung cell populations at 21 dpi. 
Mac., macrophage; Inf. Mono., inflammatory monocyte.  The mean ± SEM is graphed. 
Statistical differences were determined by two-tailed unpaired Student’s t test for normally 
distributed groups or two-tailed unpaired Mann-Whitney test for nonnormally distributed groups 
as appropriate. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from or 
representative of two (A-D) or five (E-H) independent experiments. Previously published in 
Huynh and Lin et al., 2018. 
 
Bhlhe40 is required within hematopoietic cells  
Bhlhe40 is expressed in specific immune cell populations and in nonhematopoietic cell 
types.
172
 To dissect which cells required Bhlhe40 expression during Mtb infection, we infected 
reciprocal bone marrow chimeric mice with Mtb and monitored survival (Fig. 6A). As expected, 
all but one WT→WT chimeric mouse survived past 100 dpi, and Bhlhe40−/−→Bhlhe40−/− 
chimeras succumbed 27-35 dpi (median survival time of 33 days). WT→Bhlhe40−/− chimeras 
also survived past 100 dpi, whereas Bhlhe40
−/−→WT chimeras died between 29-37 dpi (median 
survival time of 32 days), similar to Bhlhe40
−/−→Bhlhe40−/− chimeras. These data demonstrate a 
specific role for Bhlhe40 in radiosensitive hematopoietic cells during Mtb infection.  
To determine which hematopoietic cells express Bhlhe40 during Mtb infection, we used 
Bhlhe40-GFP reporter mice (Bhlhe40
GFP
).
108,173
 We monitored GFP expression as a proxy for 
Bhlhe40 expression in the lungs of naive and Mtb infected Bhlhe40
GFP
 mice. Sizeable fractions 
of neutrophils, alveolar macrophages, CD11b
+
 DCs, CD103
+
 DCs, and eosinophils expressed 
GFP both before infection and at 21 dpi (Fig. 6B-D), with smaller fractions of CD11b
+
 
macrophages, moDCs, B cells, and CD8
+
 T cells also showing this pattern of expression. Similar  
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Figure 5. Neutrophils and monocytes do not drive susceptibility in Bhlhe40
−/−
 mice. 
(A-C) Mice were infected with Mtb and treated with rat IgG or anti-Ly6G mAb from 10-30 dpi. 
Mice were monitored for changes in (A) body weight, (B) survival, and (C) lung Mtb burden at 
21 dpi. (D, E) Mice were infected with Mtb and monitored for survival. The mean ± SEM is 
graphed. Statistical differences were determined by log-rank Mantel-Cox test (B, D, E) or 
unpaired Kruskal-Wallis test with Dunn’s multiple comparison test (B). *, P < 0.05; **, P < 0.01; 
***, P < 0.001; ****, P < 0.0001. Data are from one (E) or two (A-D) independent experiments. 
Panels (A-C) were previously published in Huynh and Lin et al., 2018. 
 
 
trends were observed at 14 dpi (data not shown). Therefore, these cell types constitutively 
express Bhlhe40, and this expression pattern does not change during Mtb infection. In contrast, 
CD4
+
 T cells in naive mice expressed very little Bhlhe40 but at 21 dpi, Bhlhe40 levels increased 
in this cell type (Fig. 6B-D). These data show that Bhlhe40 is expressed in both myeloid and 
lymphoid cells during Mtb infection.  
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Figure 6. Bhlhe40 is expressed and required in hematopoietic cells. 
(A) WT or Bhlhe40
−/− 
mice were lethally irradiated, reconstituted with WT or Bhlhe40
−/− 
bone 
marrow, and monitored for survival after Mtb infection. (B) Frequency of GFP
+
 (Bhlhe40
+
) cells  
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for lung cell populations in non-transgenic (Tg) and Bhlhe40
GFP
 mice before infection and at 21 
dpi. (C, D) Representative flow cytometry plots for GFP (Bhlhe40) in immune cells from the 
lungs of non-Tg WT and Tg Bhlhe40
GFP
 mice before infection (C) or at 21 dpi (D). Bold 
numbers are the percentages of cells that fall within the gate. Mac., macrophage; Inf. Mono., 
inflammatory monocyte; Alv. Mac., alveolar macrophage. Data are from or representative of two 
(A) or three (B-D) independent experiments. The mean ± SEM is graphed. Statistical differences 
were determined by log-rank Mantel-Cox test (A) and one-way unpaired ANOVA with Tukey’s 
post-test for normally distributed groups or unpaired Kruskal-Wallis test with Dunn’s multiple 
comparison test for non-normally distributed groups (B).   *, P < 0.05; **, P < 0.01; ***, P < 
0.001; ****, P < 0.0001. Previously published in Huynh and Lin et al., 2018. 
 
 
Bhlhe40 enables control of Mtb in the context of T cell deficiency 
Bhlhe40 expression is required in CD4
+
 T cells to regulate cytokine production in the 
experimental autoimmune encephalomyelitis (EAE) model of autoimmunity.
114,128
 However,  
Bhlhe40
−/− 
mice succumbed to Mtb infection between 32 and 40 dpi, which is earlier than 
Rag1
−/−
 mice that lack mature B and T cell and succumb to Mtb infection between 46 and 50 
dpi.
24
 The timing of the death of Mtb infected Bhlhe40
−/−
 mice suggests that there is a defect in 
the innate immune response to Mtb, as it preceded the point at which adaptive immunity is 
required, or the presence of pathological T cells is leading to earlier death than would occur in 
the absence of T cells, as previously observed in Pdcd1
−/−
 mice.
89
 
To measure the contribution of Bhlhe40 to host resistance in the absence of B and T cells, 
we used anti-CD4 and anti-CD8 monoclonal antibodies to deplete CD4
+
 and CD8
+
 T cells in WT 
and Bhlhe40
−/−
 mice, infected with Mtb, and measured Mtb burden at 22 dpi (Fig. 7A). CFU 
counts in T cell-depleted WT and Bhlhe40
−/−
 mice were not significantly different from 
undepleted mice of the same genotype. However, when we assessed the numbers of lung CD4
+
 
and CD8
+
 T cells we found that although depletion led to significant reductions, most mice 
retained a sizable number of T cells at 22 dpi (Fig. 7B). This suggested that the absence of 
observable differences in Mtb burden after depletion might be due to effects from residual T 
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cells. To avoid the potentially cofounding effects of residual T cells we utilized Rag1
-/-
 mice that 
lack mature adaptive immune cells. We compared the survival of Mtb infected WT, Bhlhe40
−/−
, 
Rag1
−/−
, and Rag1
−/−
Bhlhe40
−/−
 mice (Fig. 7C). Rag1
−/−
Bhlhe40
−/− 
mice (median survival time of 
33 days) were significantly more susceptible than Rag1
−/−
 mice (median survival time of 43 
days) to Mtb infection and succumbed to infection at the same time as Bhlhe40
−/−
 mice. These 
data demonstrate that Bhlhe40 is required during the innate immune response in the absence of T 
cells to prolong survival during Mtb infection and suggest that our T cell depletion experiments 
were confounded by the presence of residual T cells. Mtb CFUs were 4-fold higher in 
Rag1
−/−
Bhlhe40
−/− 
mice compared with Rag1
−/−
 mice at 21 dpi (Fig. 7D), and the frequency of 
neutrophils in the lungs of Rag1
−/−
Bhlhe40
−/− 
mice was also significantly elevated (Fig. 7E). The 
frequency of infected neutrophils, CD11b
+
 macrophages, and moDCs was significantly higher in 
Rag1
−/−
Bhlhe40
−/− 
mice at 21 dpi (Fig. 7F). We also observed significantly higher MFIs for GFP 
in Rag1
−/−
Bhlhe40
−/− 
neutrophils, CD11b
+
 macrophages, inflammatory monocytes, and CD11b
+
 
DCs, suggesting that these cell types harbored more Mtb on a per-cell basis compared with 
Rag1
−/− 
cells (Fig. 7G). Therefore, loss of Bhlhe40 in innate immune cells compromises their 
ability to control inflammation and Mtb replication independent of adaptive immunity. 
 
Bhlhe40 is required in CD11c
+
, Zbtb46
+
, and T cells 
To determine more precisely which cells require Bhlhe40 expression to control Mtb 
infection, we infected mice that conditionally delete Bhlhe40 in specific cell types. After Mtb 
infection, Bhlhe40
fl/fl
-Lysm-Cre and Bhlhe40
fl/fl
-Mrp8-Cre mice survived past 100 dpi (Fig. 8A) 
and showed no signs of morbidity over the first 45 days of infection (Fig. 8B), indicating that 
loss of Bhlhe40 in LysM
+
 or Mrp8
+
 cells was not sufficient to generate susceptibility to  
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Figure 7. Bhlhe40 enables control of Mtb in the context of T cell deficiency. 
(A, B) Mice were treated with anti-CD4/anti-CD8 monoclonal antibodies, infected with Mtb, and 
assessed for (A) lung CFUs or (B) lung CD4
+
 and CD8
+
 T cells at 22 dpi. (C-G) Mice were 
infected with Mtb and monitored for (C) survival or analyzed at 21 dpi for (D) lung CFUs, (E) 
neutrophilic inflammation, (F) frequency of GFP
+
 (Mtb
+
) cells, and (G) MFI for GFP in GFP
+
 
(Mtb
+
) cells. Mac., macrophage; Inf. Mono., inflammatory monocyte; Alv. Mac., alveolar 
macrophage. Data are from two (A, B) or five (C-G) independent experiments. The mean ± SEM 
is graphed. Statistical differences were determined by log-rank Mantel-Cox test (C), two-tailed 
unpaired Student’s t test or one-way unpaired ANOVA with Tukey’s post-test for normally 
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distributed groups and two-tailed unpaired Mann-Whitney test or unpaired Kruskal-Wallis test 
with Dunn’s multiple comparison test for non-normally distributed groups, as appropriate (A,B, 
D-G). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Panels (C-G) were previously 
published in Huynh and Lin et al., 2018. 
 
infection. In contrast, Bhlhe40
fl/fl
-Cd11c-Cre and Bhlhe40
fl/fl
-Cd4-Cre mice succumbed to 
infection at 34-62 dpi (median survival time of 56 days) and 31-73 dpi (median survival time of 
52 days), respectively (Fig. 8A). Therefore, Bhlhe40 expression in both T cells and CD11c
+
 cells 
is required to control Mtb infection. Given that the Lysm (also known as Lyz2) promoter can 
drive conditional deletion in alveolar macrophages but deletes poorly in myeloid DCs, whereas 
the Cd11c (also known as Itgax) promoter deletes equally well in both alveolar macrophages and 
DCs,
174
 one interpretation is that loss of Bhlhe40 in alveolar macrophages is not sufficient to 
cause susceptibility and that loss of Bhlhe40 in DCs contributes to the susceptibility observed in 
Bhlhe40
fl/fl
-Cd11c-Cre mice. The Cd11c promoter has also been reported to drive conditional 
deletion in a subpopulation of T cells
174
 that could be contributing to susceptibility. In order to 
examine a role for Bhlhe40 specifically in conventional DCs we infected a Bhlhe40
fl/fl
-Zbtb46-
Cre mouse and found that it succumbed at 116 dpi (Fig. 8A). Although only one mouse was 
tested, its susceptibility demonstrates that loss of Bhlhe40 in conventional DCs is sufficient for 
susceptibility. 
The longer survival times of Bhlhe40
fl/fl
-Cd11c-Cre and Bhlhe40
fl/fl
-Cd4-Cre mice 
compared to Bhlhe40
−/−
 mice indicated that loss of Bhlhe40 in CD11c
+
 and T cells separately did 
not account for the entirety of the defect observed in mice with global Bhlhe40-deficiency. To 
test whether simultaneous loss of Bhlhe40 in CD11c
+
 and T cells accounted for the severe defect 
in Bhlhe40
−/−
 mice we infected Bhlhe40
fl/fl
-Cd4-Cre/Cd11c-Cre mice and tracked survival (Fig. 
8A). Bhlhe40
fl/fl
-Cd4-Cre/Cd11c-Cre were significantly more susceptible than Bhlhe40
fl/fl
-  
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Figure 8. Bhlhe40 is required in CD11c
+
, Zbtb46
+
, and T cells. 
(A-E) Mice were infected with Mtb and monitored for (A) survival and (B) weight loss or (C) 
lung Mtb burden, (D) lung neutrophil and moDC absolute counts and frequency in the total 
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CD45
+
 population, and (E) frequency of GFP
+
 (Mtb
+
) lung cells at 21 dpi. Mac., macrophage; 
Inf. Mono., inflammatory monocyte; Alv. Mac., alveolar macrophage. (F) Mice were vaccinated 
with M. bovis BCG, rested for 30 days, then infected with Mtb and monitored for survival. The 
mean ± SEM is shown. Statistical differences were determined by log-rank Mantel-Cox test (A, 
F) or one-way unpaired ANOVA with Tukey’s post-test for normally distributed groups and 
unpaired Kruskal-Wallis test with Dunn’s multiple comparison test for non-normally distributed 
groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from one to four 
(A), two (B), seven (C-E), or one (F) independent experiments. Parts of panel (A) and all of 
panels (B-D) were previously published in Huynh and Lin et al., 2018. 
 
Cd11c-Cre and Bhlhe40
fl/fl
-Cd4-Cre mice, but not as susceptible as Bhlhe40
−/−
 mice. These 
results confirm that loss of Bhlhe40 in CD11c
+
 and T cells accounts for the majority of 
susceptibility observed in Bhlhe40
−/−
 mice but other cell types make minor contributions to 
resistance. 
To assess the role of myeloid cell expression of Bhlhe40 in a T cell-sufficient context we 
monitored the survival of Bhlhe40
fl/fl
-Lysm-Cre/Cd11c-Cre mice (Fig. 8A). Only two mice were 
tested, but their survival times displayed a trend towards increased susceptibility as compared to 
Bhlhe40
fl/fl
-Cd11c-Cre mice, suggesting that Bhlhe40 expression in LysM
+
 cells plays a 
protective but minor role in resistance to Mtb. 
We next analyzed susceptible Bhlhe40
fl/fl
-Cd11c-Cre and Bhlhe40
fl/fl
-Cd4-Cre mice to 
determine how loss of Bhlhe40 in CD11c
+
 or T cells contributed to phenotypes observed in 
Bhlhe40
−/−
 mice. By 21 dpi, pulmonary Mtb burden in Bhlhe40
fl/fl
-Cd11c-Cre and Bhlhe40
fl/fl
-
Cd4-Cre mice was 3- and 4-fold higher than Bhlhe40
fl/fl
 controls, respectively (Fig. 8C). 
Bhlhe40
fl/fl
-Cd11c-Cre and Bhlhe40
fl/fl
-Cd4-Cre mice also exhibited an increase in the frequency 
and absolute number of lung neutrophils (Fig. 8D). The frequency of moDCs was significantly 
lower in Bhlhe40
fl/fl
-Cd4-Cre and Bhlhe40
fl/fl
-Cd11c-Cre lungs, but the absolute number of  
moDCs was decreased in Bhlhe40
fl/fl
-Cd4-Cre lungs only, suggesting that loss of Bhlhe40 in T 
cells leads to the decreased number of moDCs observed in Bhlhe40
−/−
 mice (Fig. 8D). 
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Neutrophils, inflammatory monocytes, moDCs, and CD11b
+
 DCs were infected at a higher 
frequency in both Bhlhe40
fl/fl
-Cd4-Cre and Bhlhe40
fl/fl
-Cd11c-Cre mice (Fig. 8E). Collectively, 
the survival, Mtb burden, neutrophilic inflammation, and frequency of cellular infection 
phenotypes evident in mice with conditional deletions of Bhlhe40 indicate that expression of 
Bhlhe40 in CD11c
+
 and T cells provides essential and synergistic functions that enable resistance 
to Mtb infection. 
Our identification of an essential role for Bhlhe40 in T cells led us to assess the 
functionality of vaccination-elicited adaptive immune responses in Bhlhe40
−/−
 mice. Mice were 
vaccinated with M. bovis BCG and then monitored for survival after Mtb infection (Fig. 8F). 
Vaccination significantly extended the survival time of Bhlhe40
−/−
 mice, although they remained 
susceptible to Mtb. These data suggested that a pre-existing adaptive immune response in 
Bhlhe40
−/−
 mice can confer a degree of resistance, although it is ultimately insufficient to 
overcome defects that arise during Mtb infection. 
 
Bhlhe40 deficiency alters cytokine transcription after exposure to Mtb  
Bhlhe40 has previously been found to regulate cytokine production by CD4
+
 T cells in 
the EAE model.
114,128
 If Bhlhe40 functions analogously during Mtb infection, Bhlhe40
−/−
 cells 
could exert a dominant effect on WT cells through the production of secreted cytokines. We 
tested this by generating mixed bone marrow chimeric mice. Congenically marked WT 
(CD45.1/.2) recipients were lethally irradiated and reconstituted with a 1:1 mixture of WT 
(CD45.1/.1) and Bhlhe40
−/−
 (CD45.2/.2) bone marrow cells. Control mice included mixed 
chimeras generated with WT (CD45.1/.1) and WT (CD45.2/.2) bone marrow cells as well as 
nonchimeric WT (CD45.2/.2) and Bhlhe40
−/−
 (CD45.2/.2) mice. In mixed chimeras, Bhlhe40
−/−
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Figure 9. Bhlhe40 deficiency alters cytokine transcription after exposure to Mtb. 
(A) Mixed bone marrow chimera mice were generated and the frequency of CD45.1
+
, CD45.2
+
, 
and CD45.1
+
CD45.2
+
 lung cells was assessed before infection. (B-D) Mixed bone marrow 
chimera mice were infected with Mtb. (B, C) The frequency of infected lung neutrophils and (D) 
lung Mtb burden was assessed in nonchimeric and mixed bone marrow chimeric mice infected 
with GFP-Mtb at 21 dpi. (E-G) Cytokine transcript levels in total lung samples were assessed by 
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qRT-PCR (E) prior to infection, (F) at 14 dpi, and (G) at 21 dpi. The mean ± SEM is graphed. 
Statistical differences were determined by two-tailed unpaired Student’s t test for normally 
distributed groups or two-tailed unpaired Mann-Whitney test for nonnormally distributed groups. 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from one (A) or two (B-G) 
independent experiments. Panels (A-D, G) were previously published in Huynh and Lin et al., 
2018. 
 
bone marrow cells were capable of normal reconstitution of the hematopoietic compartment 
within the lung (Fig. 9A). Chimeric mice were infected with GFP-expressing Mtb and analyzed 
at 21 dpi. WT + WT chimeras controlled Mtb infection with a low frequency of neutrophil 
infection (Fig. 9B, C). Neutrophils of both genotypes displayed a high frequency of Mtb 
infection (Fig. 9B, C), which correlated with a trend toward higher CFUs in the lungs of mixed 
WT + Bhlhe40
−/−
 chimeras (Fig. 9D). These results demonstrate that Bhlhe40
−/−
 cells, even when 
present as only half of all hematopoietic cells, exert a dominant influence in trans on the ability 
of WT cells to control neutrophil accumulation and Mtb infection. These data indicate that 
Bhlhe40 likely regulates secreted factors such as cytokines or chemokines, which can impact 
other cells. Therefore, we analyzed cytokine and chemokine levels in total lung samples from 
WT and Bhlhe40
−/−
 mice by quantitative RT-PCR. In the lungs of naive WT and Bhlhe40
−/−
 
mice, there were no differences in the levels of Csf3 (G-CSF), Il10 (IL-10), Il12b (IL-12/23p40), 
or Ifng (IFN-γ) transcript (Fig. 9E), indicating that loss of Bhlhe40 does not impact expression of 
these genes in naive mice. At 14 dpi, transcripts for Il12b and Ifng were significantly decreased 
in the lungs of Bhlhe40
−/−
 mice (Fig. 9F). At 21 dpi, transcripts for the neutrophil-associated 
cytokines Csf3, Ccl3 (MIP-1α), and Ccl4 (MIP-1β) were up-regulated in Bhlhe40−/− lungs (Fig. 
9G) as expected given the neutrophil-dominated inflammation observed. We also found that at 
21 dpi, Il10 transcript levels were 3-fold higher in Bhlhe40
−/−
 lungs, while Il12b and Ifng 
transcript levels were 3- and 2-fold lower in Bhlhe40
−/−
 lungs, respectively, compared with WT 
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lungs (Fig. 9G). This finding was of particular interest because Bhlhe40 represses Il10 
transcription in CD4
+
 T cells in the EAE model
128
 and IL-10 has been shown to inhibit IL-
12/23p40 and IFN-γ expression during Mtb infection.40,43,48,50 
 
Bhlhe40 suppresses IL-10 production during in vivo Mtb infection  
The increased Il10 transcript levels in conjunction with decreased Il12b and Ifng 
transcript levels in Bhlhe40
−/−
 lungs at 21 dpi indicated that Bhlhe40 could be regulating Il10 
expression. To identify the cell types responsible for the increased Il10 expression in Bhlhe40
−/−
 
lungs, we used Il10 bacterial artificial chromosome (BAC)-in transgene (10BiT) IL-10 reporter 
mice,
175
 where Il10-expressing cells dis- play Thy1.1 on their surface. We observed a similar 
distribution of Il10-expressing cells in 10BiT
+
 WT mice as reported in a recent study that used 
these reporter mice to characterize sources of IL-10 before and after Mtb infection.
44
 We crossed 
10BiT and Bhlhe40
−/−
 mice to generate a Bhlhe40
−/−
 10BiT
+
 strain, and then we analyzed Thy1.1 
expression as a proxy for Il10 expression. We observed low levels of Thy1.1 expression in naive 
10BiT
+
 WT and 10BiT
+
 Bhlhe40
−/−
 mice (Fig. 10). At 21 dpi, the frequency of Thy1.1
+
 
neutrophils, inflammatory monocytes, moDCs, CD11b
+
 DCs, B cells, CD4
+
 T cells, and CD8
+
 T 
cells was significantly higher in Bhlhe40
−/−
 mice (Fig. 11A, C), but no differences were observed 
when comparing the absolute number of Thy1.1
+
 cells (Fig. 11B). In addition, when we 
compared MFIs for Thy1.1 on Thy1.1
+
 cells, we found that not only were a higher percentage of 
Bhlhe40
−/−
 moDCs and B cells expressing Thy1.1, but these cell types also expressed more 
Thy1.1 on a per-cell basis during Mtb infection (Fig. 11D). Significantly higher Thy1.1 MFI was 
also observed on Bhlhe40
−/−
 Thy1.1
+
 alveolar macrophages and CD11b
+
 macrophages (Fig. 
11D). The increased frequency of Thy1.1 positivity observed in Bhlhe40
−/−
 CD4
+
 T cells was  
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Figure 10. Bhlhe40 deficiency does not cause IL-10 overexpression in the absence of 
infection. 
(A-B) Uninfected 10BiT
+
 mice were analyzed for the frequency of Thy1.1
+
 (IL-10
+
) lung 
immune cells was assessed in uninfected mice. Mac., macrophage; Inf. Mono., inflammatory 
monocyte; Alv. Mac., alveolar macrophage. The mean ± SEM is graphed. Statistical differences 
were determined by two-tailed unpaired Student’s t test for normally distributed groups or two-
tailed unpaired Mann-Whitney test for non-normally distributed groups. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; ****, P < 0.0001. Data are from one experiment (A, B). 
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Figure 11. Bhlhe40 deficiency causes overexpression of IL-10 during Mtb infection. 
(A-E) Mice were infected with Mtb and assessed for (A, B) frequency and (C) absolute number 
of Thy1.1
+
 (IL-10
+
) lung immune cells at 21 dpi. (D) MFI for FITC (Thy1.1 [IL-10]) on Thy1.1
+
 
lung cells at 21 dpi . Mac., macrophage; Inf. Mono., inflammatory monocyte; Alv. Mac., 
alveolar macrophage. Thy1.1
+
 (E) Ag85B- or ESAT6-specific CD4
+
 T cells as a percentage of 
the total Ag85B- or ESAT6-specific CD4
+
 T cell population in the lung or mediastinal lymph 
node at 21 dpi. The mean ± SEM is graphed. Statistical differences were determined by two-
tailed unpaired Student’s t test for normally distributed groups or two-tailed unpaired Mann-
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Whitney test for non-normally distributed groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001. Data are from two independent experiments (A-E). Panels (A-E) were 
previously published in Huynh and Lin et al., 2018. 
 
even more pronounced in Bhlhe40
−/−
 Mtb-specific CD4
+
 T cells in the mediastinal lymph node 
and lung, indicating that Mtb-specific CD4
+
 T cells take on an immunosuppressive phenotype in 
the absence of Bhlhe40 (Fig. 11E). These data demonstrated that the frequency and per-cell 
expression of Il10 was increased in multiple Bhlhe40
−/−
 myeloid and lymphoid populations. 
 
Bhlhe40 suppresses IL-10 expression in myeloid cells in vitro  
We next sought to identify an in vitro myeloid cell culture system that recapitulates the 
effects of Bhlhe40 deficiency on IL-10 production in response to Mtb. We cultured WT bone 
marrow cells with GM-CSF or macrophage colony stimulating factor (M-CSF) and determined 
by Western blot analysis that only cells cultured with GM-CSF, which comprise a mixture of 
granulocytes, macrophage-like cells, and DC-like cells,
176,177
 express Bhlhe40 (Fig. 12A). 
Analysis of GM-CSF- and M-CSF-cultured cells from Bhlhe40
GFP
 reporter mouse bone marrow 
confirmed that only GM-CSF-cultured bone marrow-derived cells expressed GFP (Fig. 12B). 
This expression of Bhlhe40 in granulocytes, macrophage-like cells, and DC-like cells cultured 
with GM-CSF may relate to the expression of Bhlhe40 by these cell types in the lung (Fig. 
6),
108,178
 where GM-CSF is abundant and plays an important part in the development and 
function of lung myeloid cells.
179
 
We next assessed IL-10 expression from WT and Bhlhe40
−/−
 cells cultured with GM-
CSF. In the absence of stimulation with heat-killed Mtb, minimal IL-10 protein was detected in 
culture supernatants (Fig. 12C). In contrast, Bhlhe40
−/−
 GM-CSF-cultured bone marrow-derived  
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Figure 12. Bhlhe40 represses IL-10 in myeloid cells after Mtb stimulation.  
(A-B) Bone marrow cells were differentiated in the presence of M-CSF or GM-CSF and 
analyzed for expression of Bhlhe40 by (A) immunoblot (IB) with HDAC1 as a loading control or 
(B) GFP as a reporter for Bhlhe40 expression. MW, molecular weight. (C)  GM-CSF-cultured 
bone marrow-derived cells were left unstimulated or were stimulated with heat-killed (HK) Mtb 
for 24 hrs, and culture supernatants were analyzed for IL-10 production by ELISA. IL-10 
expression in six unstimulated WT and 12 unstimulated Bhlhe40
−/−
 samples was below the limit 
of detection (∼0.1 ng/ml). (D-F) 10BiT+ WT and Bhlhe40−/− bone marrow cells were 
differentiated in the presence of GM-CSF and stimulated with heat-killed Mtb antigen for 24 hrs. 
Thy1.1 was assessed on three subpopulations of cells within the GM-CSF cultures. These 
included Ly6G
+
 cells, GM-macrophages (GM-Macs; identified as CD11c
+
CD11b
high
MHC-II
mid
), 
and GM-DCs (identified as CD11c
+
CD11b
mid
MHC-II
high
). (D) Frequency of Thy1.1
+
 (IL-10
+
) 
cells after 24 hrs of stimulation. (E)  MFI for Thy1.1 on Thy1.1
+
 cells after 24 hrs of stimulation. 
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(F) Culture supernatants were analyzed for IL-10 production by ELISA. IL-10 expression in four 
unstimulated 10BiT
+
 WT and five unstimulated 10BiT
+
 Bhlhe40
−/−
 samples was below the limit 
of detection (∼0.1 ng/ml). (G)  GM-CSF-cultured bone marrow-derived cells were infected with 
Mtb, in some cases treated with IFN-γ, and CFUs were measured. The mean ± SEM is graphed. 
Statistical differences were determined by two-tailed unpaired Student’s t test for normally 
distributed groups or two-tailed unpaired Mann-Whitney test for non-normally distributed 
groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from or 
representative of two (A, B, D-F), five (C), or one (G) independent experiments. Panels (A-G) 
were previously published in Huynh and Lin et al., 2018. 
 
cells stimulated with heat-killed Mtb for 24 hours produced significantly more IL-10 than WT 
cells (Fig. 12C). We also stimulated 10BiT
+
 WT and Bhlhe40
−/−
 GM-CSF-cultured cells with 
heat-killed Mtb, assessed Thy1.1 expression by flow cytometry, and measured IL-10 in culture 
supernatants by ELISA. Mtb stimulation increased the frequency of Thy1.1
+
 cells in both WT 
and Bhlhe40
−/−
 cultures relative to unstimulated cultures, and this increase was greater in 
Bhlhe40
−/−
 cells compared with WT cells (Fig. 12D). Mtb stimulation also increased the amount  
of Thy1.1 expression on a per-cell basis, where Bhlhe40
−/−
 CD11c
+
CD11b
+
MHC-II
high
 (GM- 
DC) cells exhibited a 1.7-fold higher MFI than WT GM-DCs (Fig. 12E).ELISAs confirmed that 
10BiT
+
 Bhlhe40
−/−
 cells secreted more IL-10 than 10BiT
+
 WT cells after stimulation with heat-
killed Mtb (Fig. 12F). These experiments confirm that loss of Bhlhe40 in GM-CSF-cultured cells 
results in higher levels of IL-10 production. Loss of Bhlhe40 did not significantly affect the 
ability of GM-CSF-cultured cells to control Mtb replication in the presence or absence of IFN-γ 
(Fig. 12G), suggesting that Bhlhe40 is dispensable for the ability of these cell types to control 
Mtb replication in vitro. 
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Figure 13. Bhlhe40 directly binds the Il10 locus in myeloid and lymphoid cells.  
(A-D) Bone marrow cells were differentiated in the presence of GM-CSF and stimulated with 
heat-killed Mtb for 4 hrs. CD4
+
 T cells were isolated from the spleen of naïve mice and TH1 
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polarized in vitro for 4 days. DNA was immunoprecipitated using anti-Bhlhe40 antibody and 
sequenced. (A) Sequence motifs present within DNA bound by Bhlhe40 were analyzed by 
MEME-ChIP. (B) Bhlhe40 binding sites were annotated using ChIP-seeker v3.5. (C) Functions 
of cis-regulatory regions were predicted for Bhlhe40 binding site data using GREAT. The top 
five most highly enriched gene sets with minimum region-based fold enrichment of 2 and 
binomial and hypergeometric false discovery rates of ≤0.05 in the Gene Ontology (GO) 
Biological Process and MSigDB Pathway gene sets are displayed for each dataset (in GM-CSF–
cultured cells, only three MSigDB Pathway gene sets met these criteria). NFAT, nuclear factor 
of activated T cells. (D) ChIP-seq binding tracks for Bhlhe40 at the Bhlhe40, Il10, and Ifng loci 
in WT and Bhlhe40
−/−
 myeloid and lymphoid cells. Vertebrate conservation of each genomic 
region is displayed in blue, and peaks identified by MACS are indicated by arrows. Bracketed 
numbers indicate the trace height range. Data are from a single experiment. Panels (A-D) were 
previously published in Huynh and Lin et al., 2018. 
 
 
Bhlhe40 binds directly to the Il10 locus in TH1 cells and myeloid cells  
We performed chromatin immunoprecipitation sequencing (ChIP-seq) experiments in in 
vitro-polarized TH1 cells and GM-CSF-cultured bone marrow-derived cells to interrogate 
whether Bhlhe40 directly binds to the Il10 locus in these cells as well as to identify other genes 
that may be directly regulated by Bhlhe40. We performed these studies with WT and Bhlhe40
−/−
 
cells, where Bhlhe40
−/−
 cells served as controls for nonspecific binding by the anti-Bhlhe40 
antibody. Bhlhe40 bound 379 sites in WT GM-CSF-cultured cells and 5,532 sites in WT TH1-
polarized T cells. Of these sites, 273 were found in both datasets. Bhlhe40 can directly bind to 
regulatory DNA elements as a homodimer through recognition of E-box sites, with a preference 
for the sequence CACGTG.
180
 Motif finding identified the expected E-box (CACGTG) as the 
most frequent motif present within the peaks identified in both cell types (Fig. 13A). Analysis of 
binding sites revealed that Bhlhe40 predominantly bound promoters within 1 kb of the 
transcriptional start site, introns, and distal intergenic regions (Fig. 13B). Pathway analysis of 
predicted Bhlhe40-regulated genes revealed an enrichment in immune activation and cytokine 
response pathways in both datasets (Fig. 13C). Bhlhe40 is known to bind a conserved 
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autoregulatory site in the Bhlhe40 promoter,
102
 and this binding site was identified as a peak in 
both datasets (Fig. 13D). Importantly, our ChIP-seq experiment identified a Bhlhe40 binding site 
at +6 kb relative to the transcriptional start site of Il10 in both datasets, coinciding with an 
evolutionarily conserved region that is close to a +6.45 kb site previously identified as an 
enhancer element in TH2 cells (Fig. 13D).
181
 These data suggest that Bhlhe40 directly represses 
Il10 transcription in myeloid and lymphoid cells through direct binding of a downstream cis-
regulatory element. ChIP-seq analysis did not reveal binding of Bhlhe40 to the Il12b locus in 
either dataset. Bhlhe40 did not bind the Ifng locus in GM-CSF-cultured cells but bound two sites 
distal (−33.5 kb and +53.2 kb) to the Ifng transcriptional start site in TH1 cells (Fig. 13D). These 
findings suggest that the transcriptional down-regulation of Il12b in Bhlhe40
−/−
 total lung 
samples (Fig. 9F, G) is indirect and likely a result of increased IL-10 signaling, whereas the 
decreased levels of Ifng may result from either increased IL-10 signaling or T cell-intrinsic loss 
of direct regulation by Bhlhe40. 
 
IL-10 deficiency protects Bhlhe40
−/−
 mice from Mtb infection  
To investigate the role of IL-10 production in the susceptibility of Bhlhe40
−/−
 mice, we 
generated Il10
−/−
Bhlhe40
−/−
 mice and compared their survival to WT, Bhlhe40
−/−
, and Il10
−/−
 
mice after Mtb infection. The absence of IL-10 signaling resulted in near-complete rescue of the 
acute susceptibility phenotype caused by Bhlhe40 deficiency as shown by the significant 
increase in the median survival time of Il10
−/−
Bhlhe40
−/−
 mice (122 days) compared with 
Bhlhe40
−/− 
mice (31 days) (Fig. 14A). The increased survival of Il10
−/−
Bhlhe40
−/−
 mice was 
accompanied by decreased Mtb titer in Il10
−/−
Bhlhe40
−/−
 lungs (8-fold) and spleens (5-fold)  
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Figure 14. IL-10 deficiency protects Bhlhe40
−/−
 mice from Mtb infection.  
(A-F) Mice were infected with Mtb and monitored for (A) survival and (B) lung and spleen 
CFU, (C, D) frequency and absolute number of lung neutrophils, and (E) cytokine transcript 
levels in total lung samples at 21 dpi. (F, G) Mice were infected with Mtb and treated with IL-12 
three times per week for the first 4 weeks of infection. (F) Weight loss and (G) survival were 
monitored. The mean ± SEM is graphed. Statistical differences were determined by log-rank 
Mantel-Cox test (A, B) and one-way unpaired ANOVA with Tukey’s post-test for normally 
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distributed groups or unpaired Kruskal-Wallis test with Dunn’s multiple comparison test for non-
normally distributed groups (B, D, E). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 
0.0001. Data are from or representative of two (A, E), four (B, C, D), or one (F, G) independent 
experiments. Parts of panels (A, B) and all of panels (C-E) were previously published in Huynh 
and Lin et al., 2018. 
 
 
compared with Bhlhe40
−/−
 mice at 21 dpi (Fig. 14B). These data demonstrate that the inability of 
Bhlhe40
−/−
 mice to control acute phase Mtb replication is likely caused in large part by higher IL-
10 levels. When compared with Bhlhe40
−/−
 lungs, Il10
−/−
Bhlhe40
−/−
 lungs contained a 
significantly lower frequency and total number of neutrophils (Fig. 14C, D). However, the 
frequency of neutrophils in Il10
−/−
Bhlhe40
−/−
 lungs remained higher than in WT or Il10
−/−
 lungs 
(Fig. 14C, D). Il10
−/−
Bhlhe40
−/−
 lungs also contained 2-fold more Il12b and Ifng transcripts than 
Bhlhe40
−/− 
lungs at 21 dpi, demonstrating that IL-10 signaling was at least partially responsible 
for the decreased expression of these genes in Bhlhe40
−/−
 lungs (Fig. 14E). The association of 
higher Il12b transcript levels and increased resistance in Il10
−/−
Bhlhe40
−/−
 mice suggested that an 
early defect in IL-12 production might contribute to the susceptibility of Bhlhe40
−/−
 mice. We 
tested this with an IL-12 administration regimen previously shown to extend the susceptibility of 
Il12b
-/-
 mice.
182
 Bhlhe40
−/−
 mice were treated with IL-12 during Mtb infection and weight loss 
(Fig. 14F) and survival (Fig. 14G) were monitored. IL-12 administration had no effect on weight 
loss or survival, suggesting that lower Il12b levels are not limiting protective immunity or that 
there are additional obstacles to protective immunity. These data establish Bhlhe40 as an 
essential regulator of Il10 expression in myeloid cells and lymphocytes during Mtb infection and 
reveal the importance of IL-10 regulation for innate and adaptive immune responses that control 
Mtb infection. 
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Discussion  
We have identified Bhlhe40 as a transcription factor that is essential for coordinating 
immune responses that protect the host from Mtb infection. Based on our research, we propose 
the following model (Fig. 15). During the acute phase of infection, CD11c
+
 cells encounter Mtb 
antigens that trigger a putative transcriptional activator to induce Il10 expression, the activity of 
which is restricted by the binding of Bhlhe40 to a cis-acting regulatory region +6 kb downstream 
of the Il10 transcriptional start site. The identity of the activator that induces Il10 transcription in 
the absence of Bhlhe40 during Mtb infection is currently unknown but may be one of the 
activators previously described.
75
 In addition, Bhlhe40 is induced in T cells during Mtb infection, 
where it also represses Il10 transcription. The repression of Il10 expression by Bhlhe40 in these 
cell types allows for higher expression of Il12b and Ifng, both of which are essential for control 
of Mtb replication.
34,35,183,184
  
These findings represent the first study of roles for Bhlhe40 in the immune response to an 
infection and within myeloid cells, although a report that T cell expression of Bhlhe40 is 
essential for control of Toxoplasma gondii infection was published concurrently.
129
 Additionally, 
although other negative regulators of Il10 transcription have been described,
78–81,83,84
 Bhlhe40 is 
the first transcription factor that has been shown to be essential during Mtb infection specifically 
to regulate Il10 expression. Our findings reveal the importance of controlling IL-10 generation 
by both innate and adaptive immune cells and shed light on how different levels of IL-10 could 
impact tuberculosis disease in humans. Survival experiments showed that about one quarter of 
Bhlhe40
fl/fl
-Cd11c-Cre and Bhlhe40
fl/fl
-Cd4-Cre mice recapitulated the very early susceptibility 
of Bhlhe40
−/−
 mice (Fig. 8A), with the remainder of these Bhlhe40 conditionally deleted mice 
dying between 50 and 75 dpi. In the case of the Bhlhe40
fl/fl
-Cd4-Cre strain, the finding that 4 out 
52 
 
of 12 of these mice succumbed at 31-38 dpi (Fig. 8A), whereas Rag1
−/−
 mice succumbed at ∼45 
dpi (Fig. 7C), indicates that Bhlhe40
−/−
 T cells can be actively pathological and generate a worse 
outcome than the absence of T cells, likely through the production of a factor such as IL-10. 
However, the extension of survival observed in BCG-vaccinated Bhlhe40
−/−
 mice (Fig. 8F) 
suggests that Bhlhe40
−/−
 T cells may have some protective capacity in specific contexts. The 
delay in susceptibility of most of the Bhlhe40
fl/fl
-Cd11c-Cre and Bhlhe40
fl/fl
-Cd4-Cre mice as 
compared with Bhlhe40
−/−
 mice could indicate that the susceptibility of Bhlhe40
−/−
 mice is a 
result of the combination of loss of Bhlhe40 in both CD11c
+
 and T cells, insufficient ability of 
the Cd11c and Cd4 promoters to drive Bhlhe40 exon deletion in all Cre-expressing cells, or the 
ability of Bhlhe40 deficiency in a non-CD11c
+
 or -CD4
+
 cell type to enhance susceptibility. 
Although only one Bhlhe40
fl/fl
-Zbtb46-Cre mouse was tested, it proved to be susceptible during 
chronic infection, demonstrating the requirement for Bhlhe40 expression in DCs. The delayed 
susceptibility of Bhlhe40
fl/fl
-Zbtb46-Cre mice compared to Bhlhe40
fl/fl
-Cd11c-Cre mice may be 
due to incomplete deletion in all DCs, Cd11c promoter-driven deletion of Bhlhe40 in non-DCs, 
or a protective role for Bhlhe40 in alveolar macrophages when other CD11c
+
 cell lack Bhlhe40. 
IL-10 production by T cells and CD11c
+
 cells during Mtb infection in mice was recently shown 
to contribute to host susceptibility,
44
 further supporting the notion that regulation of Il10 
expression in these cell populations would be important during Mtb infection.  
Our analyses of Il10
−/−
Bhlhe40
−/−
 mice revealed that IL-10 deficiency conferred a near-
complete rescue of multiple phenotypes associated with the acute susceptibility of Bhlhe40
−/−
 
mice (Fig. 14), indicating that the up-regulation of Il10 transcription in the absence of Bhlhe40 is 
a major contributor to the acute susceptibility of these mice. Nonetheless, some phenotypes 
partially remained in the absence of Il10. For example, nearly all Il10
−/−
Bhlhe40
−/−
 mice 
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succumbed by 200 dpi (Fig. 14A) and Il10
−/−
Bhlhe40
−/−
 mice had a significantly higher 
frequency of lung neutrophils at 21 dpi compared with WT mice (Fig. 14C, D). The incomplete 
rescue of these phenotypes indicates that Bhlhe40 likely regulates the expression of other genes 
during Mtb infection that impact pathogenesis. Future studies will explore the other Bhlhe40-
bound loci identified by ChIP-seq to identify additional Bhlhe40 targets that contribute to the 
control of Mtb infection.  
Patients with active tuberculosis have increased levels of IL-10 in their serum
65,66
 and 
lungs,
61,63,64,185
 suggesting a link between increased IL-10 levels and tuberculosis disease.
165
 
Although it is unclear whether the reduced expression of BHLHE40 in the blood of patients with 
active tuberculosis (Fig. 1A) is a cause or effect of their disease or related to the higher IL-10 
levels found in this form of tuberculosis, this correlation agrees with the increased susceptibility 
of mice lacking Bhlhe40 and suggests that our experiments could be relevant to human Mtb 
infection. 
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Figure 15. Model of Bhlhe40 function during Mtb infection.  
During Mtb infection of WT cells, Il10 transcription is restricted by Bhlhe40 in CD11c
+
 DCs and 
T cells through direct binding to an enhancer site +6 kb downstream of the Il10 transcriptional 
start site (TSS). The resulting amount of IL-10 expression is insufficient to compromise host 
resistance, leading to an immunological stalemate in which Mtb replication is controlled for the 
remainder of the lifetime of the host. In Bhlhe40
−/−
 mice, the absence of Bhlhe40 in CD11c
+
 DCs 
and T cells allows for high levels of Il10 expression. Excessive IL-10 signaling then acts on lung 
immune cells to suppress the production and protective effects of IL-12 and IFN-γ, both of which 
are essential for control of Mtb pathogenesis. As a result, Mtb lung burdens are higher and 
neutrophil-dominated inflammation is uncontrolled in Bhlhe40
−/−
 mice, ultimately resulting in 
susceptibility. Previously published in Huynh and Lin et al., 2018. 
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Experimental Procedures 
Bacterial strains and cultures  
Mtb strain Erdman and its derivatives were cultured at 37°C in 7H9 broth (Sigma-
Aldrich) or on 7H11 agar (BD) medium supplemented with 10% oleic 
acid/albumin/dextrose/catalase (OADC), 0.5% glycerol, and 0.05% Tween-80 (broth only). Mtb-
GFP was generated by transforming Mtb strain Erdman with a plasmid (pMV261-kan-GFP) that 
drives constitutive expression of GFP under the control of the hsp60 promoter. Cultures were 
grown in the presence of kanamycin to ensure plasmid retention. ΔPDIM Mtb was generated by 
transducing Mtb strain Erdman with a phage containing homology to nucleotides 3243062-
3243567 and 3272196-3272718. ΔESX-1 Mtb was generated by transducing Mtb strain Erdman 
with a phage containing homology to nucleotides 4349945-4350677 and 4356534-4357206. 
Phage transduction was used to replace the endogenous fadD26 and ppsABCDE (ΔPDIM strain) 
and pe35, ppe68, esxAB, espI, and eccD1 (ΔESX-1 strain) genes with a hygromycin resistance 
cassette. Mutants were selected by culture on hygromycin-containing 7H11 agar. Individual 
hygromycin-resistant colonies were expanded by inoculation into hygromycin-supplemented 
7H9 media. Replacement of target genes with the hygromycin resistance cassette was confirmed 
by Southern blotting of genomic DNA from expanded cultures. 
M. bovis BCG was a gift from S. Khader (Washington University in Saint Louis, Saint 
Louis, MO). Bacteria were not cultured and were used directly after thawing. 
L. monocytogenes expressing chicken ovalbumin (LM-Ova) on the 10403S genetic 
background was a gift from H. Shen (University of Pennsylvania, Philadelphia, PA). Bacteria 
were grown to mid-logarithmic phase with shaking at 37°C in brain-heart infusion broth 
(HiMedia Laboratories) before washing and storage as glycerol stocks at −80°C. 
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Mouse strains 
All mice used were on a C57BL/6 background. C57BL/6 (Taconic), B6.SJL (CD45.1; 
Taconic), Bhlhe40
GFP
 BAC Tg (N10 to C57BL/6),
108
 Bhlhe40
−/−
 (N10 to C57BL/6),
109
 Rag1
−/−
, 
Il10
−/−
, and 10BiT IL-10 reporter mice
175
 were maintained in a specific pathogen-free facility. 
Bhlhe40
−/−
 mice were crossed to Ccr2
−/−
, Csf3r
−/−
, Il10
−/−
, Rag1
−/−
, or 10BiT mice for some 
experiments. Bhlhe40
fl/fl
 mice were generated with two loxP sites flanking exon 4 of Bhlhe40. 
These mice originated as a KO-first promoter-driven mouse line from the Knockout Mouse 
Project (KOMP) and were purchased from The Jackson Laboratory (Bhlhe40
tm1a(KOMP)Wtsi
; 
024395). These initial mice contained a Bhlhe40 allele with a splice acceptor-LacZ reporter and 
a Neo cassette flanked by two Frt sites, which were removed by crossing them to B6N.129S4-
Gt(ROSA)26Sor
tm1(FLP1)Dym/J 
mice (016226; The Jackson Laboratory), leaving behind an allele of 
Bhlhe40 with a loxP-flanked exon 4. Subsequent crosses yielded Bhlhe40
fl/fl
 mice with no 
residual Rosa26-Flp transgene. Bhlhe40
fl/fl
 mice were crossed with one of four mouse strains, 
Mrp8-Cre (B6.Cg-Tg(S100A8-cre,-EGFP)1Ilw/J; 021614), Lysm-Cre (B6N.129P2(B6)-
Lyz2
tm1(cre)Ifo
/J; 018956), Cd11c-Cre (B6. Cg-Tg(Itgax-cre)1-1Reiz/J; 008068), and Cd4-Cre 
(B6.Cg-Tg(Cd4- cre)1Cwi/Bflu/J; 022071), all from The Jackson Laboratory.  
Age-matched littermate adult mice (9-23 weeks of age) of both sexes were used, and 
mouse experiments were randomized. No blinding was performed during animal experiments. 
All procedures involving animals were conducted following the National Institutes of Health 
guidelines for housing and care of laboratory animals, and they were performed in accordance 
with institutional regulations after protocol review and approval by the Institutional Animal Care 
and Use Committee of The Washington University in St. Louis School of Medicine (protocol 
20160094, Immune System Development and Function, and protocol 20160118, Analysis of 
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Mycobacterial Pathogenesis). Washington University is registered as a research facility with the 
United States Department of Agriculture and is fully accredited by the American Association of 
Accreditation of Laboratory Animal Care. The Animal Welfare Assurance is on file with Office 
for Protection from Research Risks–National Institutes of Health. All animals used in these 
experiments were subjected to no or minimal discomfort. All mice were euthanized by CO2 
asphyxiation, which is approved by the American Veterinary Association Panel on Euthanasia. 
 
Generation of bone marrow chimeric mice  
Bone marrow chimeric mice were generated by lethal irradiation (1,000 rads) of WT or 
Bhlhe40
−/−
 recipients and reconstitution with 1-2 x 10
7
 bone marrow cells from WT or 
Bhlhe40
−/−
 donors. Mixed bone marrow chimeric mice were generated by lethal irradiation 
(1,000 rads) of WT (CD45.1/.2) recipients and reconstitution with 1-2 x 10
7
 bone marrow cells 
from WT (CD45.1/.1) and either WT (CD45.2/.2) or Bhlhe40
−/−
 (CD45.2/.2) donors mixed at a 
1:1 ratio before transfer. Mice received drinking water containing 1.3 mg sulfamethoxazole and 
0.26 mg trimethoprim per ml for 2 weeks after reconstitution and were allowed to reconstitute 
for at least 8 weeks before infection with Mtb. 
 
Cell culture 
Bone marrow cells were isolated from femurs and tibias of mice and treated with ACK 
lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA) to lyse red blood cells. To 
generate M-CSF bone marrow-derived macrophages, bone marrow cells were cultured in 
complete IMDM (10% heat-inactivated FBS + 2 mM l-glutamine + 1X penicillin/streptomycin + 
55 µM β-mercaptoethanol + 1X MEM nonessential amino acids + 1 mM sodium pyruvate) in 
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Petri dishes with the addition of 20 ng/ml M-CSF (PeproTech). To generate GM-CSF-cultured 
bone marrow-derived DCs and macrophages, bone marrow cells were cultured in complete 
RPMI (10% heat-inactivated FBS + 2 mM l-glutamine + 1X penicillin/streptomycin + 55 µM β-
mercaptoethanol) in six-well plates with the addition of 20 ng/ml GM-CSF (PeproTech). Cells 
were incubated at 37°C in 8% CO2 for 8-9 days. At the end of the cultures, cells were harvested, 
counted, and adjusted to the desired cell concentrations. For flow cytometry analysis and ELISA 
assays, cells were seeded at a concentration of 5 x 10
5
 cells/well in 96-well plates and were 
stimulated with or without 50 µg/ml heat-killed Mtb (H37Ra strain; Difco) for 18 (FACS) or 24 
(ELISA) hrs. In some experiments, suspension cells were stimulated in the presence of 10 µg/ml 
heat-killed Mtb (H37Ra strain; Difco) for 4 hrs for ChIP assays.  
To generate in vitro-polarized TH1 cells, naive splenic CD4
+
 T cells (Easysep mouse 
naive CD4
+
 T cell isolation kit, typical purity ∼90-96%; StemCell Technologies, Inc.) were 
cultured in IMDM with plate-bound anti-CD3 (2 µg/ml; clone 145-2C11; BioLegend) and anti-
CD28 antibodies (2 µg/ml; clone 37.51; BioLegend) in the presence of IL-12 (10 ng/ml; 
BioLegend) and anti-IL-4 (20 µg/ml; Leinco). Cultures were split on day 3 and used for ChIP-
seq on day 4.  
 
Bone marrow-derived GM-CSF-cultured cell infections 
For Mtb infection, cells were seeded at a concentration of 2.5 x 10
5
 cells/well in 96-well 
plates. Mtb was washed with PBS + 0.05% Tween-80, sonicated to disperse clumps, diluted in 
antibiotic-free cell culture media, and added to cells at a multiplicity of infection of 1. After 4 hrs 
of incubation, cells were pelleted and washed twice with PBS, fresh culture media was added, 
and cells were incubated at 37°C in 5% CO2. In some cases, cells were pre-treated with 50 ng 
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IFN-γ (BioLegend)/ml for 12 hrs before infection. CFUs were enumerated by pelleting cells, 
removing supernatant, lysing with PBS + 0.5% Triton X-100, and plating serial dilutions on 
7H11 agar. Colonies were counted after 3 weeks of incubation at 37°C in 5% CO2. 
 
Mouse infections  
Mtb cultures in logarithmic growth phase (OD600 nm = 0.5-0.8) were washed with PBS + 
0.05% Tween-80, sonicated to disperse clumps, and diluted in sterile water. Mice were exposed 
to 1.6 x 10
8
 Mtb CFUs, a dose chosen to deliver 100–200 CFUs of aerosolized Mtb per lung 
using an Inhalation Exposure System (Glas-Col). Within the first 24 hrs of each infection, lungs 
were harvested from at least two control mice, homogenized, and plated on 7H11 agar to 
determine the input CFU dose. The mean dose determined at this time point was assumed to be 
representative of the dose received by all other mice infected simultaneously. At each time point 
after infection, Mtb titers were determined by homogenizing the superior, middle, and inferior 
lobes of the lung or the entire spleen and plating serial dilutions on 7H11 agar. Colonies were 
counted after 3 weeks of incubation at 37°C in 5% CO2. 
 M. bovis BCG was thawed and diluted in PBS. Mice were sedated with ketamine (Henry 
Schein) and xylazine (Akorn) and intranasally infected with 2 x 10
5
 CFU. BCG titers were 
determined by homogenizing the superior, middle, and inferior lobes of the lung and plating 
serial dilutions on 7H11 agar. Colonies were counted after 3 weeks of incubation at 37°C in 5% 
CO2.  
LM-Ova was diluted into pyrogen-free saline for i.v. injection into mice. For experiments 
involving secondary infection, some mice were initially infected with a sublethal dose of 10
4
 
LM-Ova i.v. and rested for 30 d before secondary challenge with 10
6
 LM-Ova i.v. After 3 days, 
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spleens and livers were homogenized separately in PBS + 0.05% Triton X-100. Homogenates 
were plated on brain-heart infusion agar, and L. monocytogenes CFUs were determined after 
growth at 37°C overnight. 
 
Flow cytometry  
Lungs were perfused with sterile PBS before harvest. Lungs and lymph nodes were 
digested at 37°C with 630 µg/ml collagenase D (Roche) and 75 U/ml DNase I (Sigma-Aldrich). 
All antibodies were used at a dilution of 1:200. Single-cell suspensions were preincubated with 
anti-CD16/CD32 Fc Block antibody (BD) in PBS + 2% heat-inactivated FBS for 10 min at RT 
before surface staining. The following anti–mouse antibodies were obtained from BioLegend: 
PE-Cy7 anti-CD4 (RM4-5), APC-Cy7 anti-CD8α (53–6.7), APC anti-CD11b (M1/70), BV605 
anti-CD11c (N418), BV605 anti-CD19 (6D5), APC anti-CD45.2 (104), FITC anti-CD90.1 (Thy-
1.1; OX-7), PerCP-Cy5.5 anti-CD103 (2E7), Pacific blue (PB) or PerCP-Cy5.5 anti-Ly6C 
(HK1.4), PE anti-Ly6G (1A8), PB anti-TCRβ (H57-597), and APC anti-TCRγδ (GL3). The 
following anti-mouse antibodies were purchased from BD: PB anti-CD3ε (145-2C11), BV510 
anti-CD45 (30F11), and PE anti–Siglec F (E50-2440). The following anti–mouse antibodies 
were obtained from Tonbo Biosciences: redFluor710 anti-CD44 (IM7), V450 or PerCP-Cy5.5 
anti-CD45.1 (A20), PE-Cy7 anti-Ly6G (1A8), and redFluor710 anti-I-A/I-E (M5/114.15.2).  
Cells were stained for 20 min at 4°C, washed, and fixed in 4% paraformaldehyde 
(Electron Microscopy Sciences) in PBS for 20 min at 4°C. Cell counts were determined by 
hemocytometer.  
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Figure 16. Flow cytometry gating strategy used in Bhlhe40 experiments. 
(A) Gating strategy for innate immune cell types in the lung. (B) Gating strategy for adaptive 
immune cell types in the lung. Previously published in Huynh and Lin et al., 2018. 
 
 
For identification of antigen-specific T cells, APC-conjugated tetramers of Ag85B280–294 
peptide (FQDAYNAAGGHNAVF) or ESAT64–17 peptide (QQWNFAGIEAAASA) bound to 
MHC-II
I-A(b) 
(National Institutes of Health Tetramer Core) were added to digested cells at final 
dilutions of 1:25 or 1:100, depending on the age of the tetramer stock, and incubated at RT for 75 
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min. Cells were then surface stained as above. Antigen-specific cells were defined as 
CD45
+/CD3ε+/CD4+/CD44+/tetramer+.  
Flow cytometry data were acquired on an LSR Fortessa cytometer (BD) and analyzed 
using FlowJo software (TreeStar). Gating strategies are depicted in Figure 16. Gates for 
transgenic (Bhlhe40
GFP
 and 10BiT) mice were set using non-transgenic mice to control for 
background staining.  
 
In vivo cell depletions  
For neutrophil depletion, mice were i.p. injected with 200 µg monoclonal anti-Ly6G 
antibody (clone 1A8; BioXCell or Leinco) or 200 µg polyclonal rat serum IgG (Sigma-Aldrich) 
diluted in sterile PBS (HyClone) every 48 hrs beginning at 10 dpi and ending at 30 dpi. 
For T cell depletion, mice were i.p. injected with 250 µg anti-CD4 (clone GK1.5; Leinco) 
and 250 µg anti-CD8 (clone YTS-169; Leinco) monoclonal antibody diluted in sterile PBS 
beginning 2 days before infection then at 4, 11, and 18 dpi. 
 
IL-12 administration 
 Mice were treated using the protocol published by Feng et al 2005.
182
 Mice were i.p. 
injected with 0.25 μg recombinant IL-12p70 (Leinco) diluted in PBS. Treatment was initiated at 
0 dpi and mice were injected three times per week (Monday, Wednesday, Friday) for 4 weeks. 
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BCG vaccination 
 Mice were sedated with ketamine (Henry Schein) and xylazine (Akorn) then 
subcutaneously injected with 2 x 10
5
 CFUs of M. bovis BCG. Mice were infected with Mtb 30 
days after vaccination. 
 
Quantitative RT-PCR  
Lung samples were lysed by bead-beating in TRIzol reagent (Invitrogen), pelleted to 
remove beads, and stored at −80°C until RNA extraction. RNA was purified from TRIzol using 
the Direct-zol RNA miniprep kit (Zymo Research) and immediately reverse transcribed with 
SuperScript III reverse transcription using Oligo-dT primers (Thermo Fisher Scientific). 
Quantitative RT-PCR was performed using iTAQ SYBR green (Bio-Rad Laboratories) on a 
C1000 thermal cycler with the CFX96 real-time system (Bio-Rad Laboratories). Transcript 
levels were analyzed using the 2
ΔΔCt
 method normalized to Actb (β-actin) as the reference gene. 
Primer sequences are listed in Table 1.  
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Target Orientation Primer sequence (5'-3') 
Actb Forward ACCTTCTACAATGAGCTGCG 
Actb Reverse CTGGATGGCTACGTACATGG 
Ccl3 Forward ACACTCTGCAACCAAGTCTTC 
Ccl3 Reverse AGGAAAATGACACCTGGCTG 
Ccl4 Forward CTGTTTCTCTTACACCTCCCG 
Ccl4 Reverse TGTCTGCCTCTTTTGGTCAG 
Csf2 Forward GCCATCAAAGAAGCCCTGAA 
Csf2 Reverse GCGGGTCTGCACACATGTTA 
Csf3 Forward GCAGGCTCTATCGGGTATTTC 
Csf3 Reverse CACCCCTAGGTTTTCCATCTG 
Ifnb Forward CTCGAGCAGCTGAATGGAAAG 
Ifnb Reverse CTTCTCCGTCATCTCCATAGGG 
Ifng Forward CCTAGCTCTGAGACAATGAACG 
Ifng Reverse TTCCACATCTATGCCACTTGAG 
Il6 Forward CAAAGCCAGAGTCCTTCAGAG 
Il6 Reverse GTCCTTAGCCACTCCTTCTG 
Il10 Forward AGCCTTATCGGAAATGATCCAGT 
Il10 Reverse GGCCTTGTAGACACCTTGGT 
Il12a Forward ACAGATGACATGGTGAAGACG 
Il12a Reverse TCGTTCTTGTGTAGTTCCAGTG 
Il12b Forward ACTCCCCATTCCTACTTCTCC 
Il12b Reverse CATTCCCGCCTTTGCATTG 
Il17a Forward TCCAGAATGTGAAGGTCAACC 
Il17a Reverse TATCAGGGTCTTCATTGCGG 
Il23a Forward CCCGTATCCAGTGTAAGATG 
Il23a Reverse GGCTCCCCTTTGAAGATGTC 
Nos2 Forward TTGCTCATGACATCGACCAG 
Nos2 Reverse ACATCAAAGGTCTCACAGGC 
Tnf Forward CTTCTGTCTACTGAACTTCGGG 
Tnf Reverse CAGGCTTGTCACTCGAATTTTG 
 
Table 1. Primers used for qRT-PCR in Bhlhe40 experiments. 
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Western blots  
Bone marrow-derived cells were counted and lysed at 10
6
/40 µl in Laemmli sample 
buffer (Bio-Rad Laboratories) containing 2.5% β-mercaptoethanol. Cell lysates were loaded and 
separated by 12% SDS-PAGE (Bio-Rad Laboratories) and transferred to Bio-Blot–
polyvinylidene difluoride membranes (Costar). Blots were incubated with anti-Bhlhe40 (1:1,000; 
NB100-1800, Lot A; Novus Biologicals) or anti-HDAC1 (1:2,000; Abcam) primary antibodies at 
4°C overnight with shaking. Blots were washed four to five times before incubation with anti–
rabbit IgG-HRP (clone 5A6- 1D10 [light chain specific]; Jackson ImmunoResearch 
Laboratories, Inc.) at RT for 60 min with shaking. After five washes, Clarity Western ECL 
substrate (Bio-Rad Laboratories) was applied, and blots were placed on blue basic 
autoradiography film (Gene-Mate). Film was developed with a medical film processor (model 
SRX-101A; Konica Minolta). 
 
Cytokine ELISAs  
IL-10 ELISA assays were performed on Nunc Maxisorp plates using IL-10 ELISPOT 
antibody pairs (BD). The enzyme reaction was developed with streptavidin-HRP (BioLegend) 
and 3,3′,5,5′-tetramethylbenzidine substrate (BioLegend). Recombinant mouse IL-10 
(BioLegend) was used to generate the standard curve. 
 
Histology  
Lung samples were fixed in 10% buffered formalin (Thermo Fisher Scientific), 
embedded in paraffin, sectioned, and stained with H&E or Ziehl-Neelsen stain to identify acid-
fast bacilli. 
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Chromatin inmmunoprecipitation Sequencing (ChIP-seq) 
Anti-Bhlhe40 ChIP was modified from the protocol published by Chou et al. 2016.
186
 
GM-CSF-cultured cells were harvested after 9 days and stimulated with 10 µg/ml heat-killed 
Mtb (strain H37Ra; Difco) for 4 hrs. In vitro–polarized TH1 cells were stimulated with PMA (50 
ng/ml; Enzo Life Sciences) and ionomycin (1 µM; Enzo Life Sciences) for 1.5 hrs. Stimulated 
cells were fixed for 10 min at RT with 1% paraformaldehyde with shaking. Cross-linked 
chromatin was fragmented by sonication and then immunoprecipitated with polyclonal rabbit 
anti-Bhlhe40 antibody (NB100-1800, Lot A or Lot C1; Novus Biologicals). After 
immunoprecipitation, DNA was purified by the GenElute PCR cleanup kit (Sigma-Aldrich). 
Purified DNA was used for library construction followed by single-read sequencing on a 
HiSeq3000 system (Illumina) at the Genome Technology Access Center at Washington 
University in St. Louis. Read lengths were 101 bp and 50 bp in the case of GM-CSF-cultured 
bone marrow cells and TH1 cells, respectively. Fastq files were provided by the Genome 
Technology Access Center sequencing facility. Quality control of fastq files was performed 
using FastQC (0.11.3). Raw reads were mapped on the mm10 mouse reference genome using 
Bowtie (1.1.1). Bhlhe40
−/−
 samples were used as input samples for peak calling on WT samples. 
Peak calling was performed using MACS v1.4
187
 with the following flags: macs14-t WT-cKO-f 
BAM-g mm-n WTvsKO-p 0.00001. BEDtools (2.6; bedClip and bedGraphToBigWig) were used 
to visualize raw alignments. Normalized tracks were built using Deeptools (2.5.3). The UCSC 
Genome Browser was used for visualization. R package ChIPseeker (1.14.1) was used for peak 
annotation. Multiple EM for Motif Elicitation (MEME)-ChIP (4.12.0)
188
 was used for motif 
enrichment analysis using all acquired peaks. Genomic Regions Enrichment of Annotations Tool 
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(GREAT; 3.0.0) was used to predict the function of cis-regulatory regions for Gene Ontology 
Biological Process and MSigDB Pathway gene sets.
189
 Links for raw sequencing data are 
available at GSE113054. All primary processed data (including mapped reads) for ChIP-seq 
experiments are also available there. 
 
Analysis of human expression microarrays  
We used the GEO2R web tool (www.ncbi.nlm.nih.gov/geo/geo2r) to query the 
expression of genes in three publicly available GEO datasets (GSE19491
92
, GSE28623
167
, and 
GSE42834
168
) that compared the whole-blood transcriptomes of humans with active tuberculosis 
to other humans with either no disease, latent tuberculosis, or in some cases, lung cancer, 
pneumonia, or sarcoidosis. The following probesets were used to examine the expression of 
BHLHE40 (previously called BHLHB2): for GSE19491 and GSE42834, ILMN_1768534; and 
for GSE28623, Agilent Technologies feature number 37383. The following probesets were used 
to examine the expression of STAT1: for GSE19491 and GSE42834, ILMN_1690105, 
ILMN_1691364, and ILMN_1777325; and for GSE28623, Agilent Technologies feature 
numbers 1928, 4610, 4763, 15819, 24587, 29771, 37967, and 42344. For analysis of GSE19491, 
the training and test sets, both encompassing samples from the United Kingdom, were combined, 
and the validation set containing samples from South Africa was analyzed separately. GSE28623 
contained samples from The Gambia. For analysis of GSE42834, the training, test, and 
validation sets encompassing samples from the United Kingdom and France were combined. 
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Data and statistics  
Samples represent biological (not technical) replicates of mice randomly sorted into each 
experimental group. No blinding was performed during animal experiments. Mice were excluded 
only when pathology unrelated to Mtb infection was present (i.e., weight loss caused by 
malocclusion or cage flooding). Statistical differences were calculated using Prism (7.0; 
GraphPad Software) using log-rank Mantel-Cox tests (survival), unpaired two-tailed Student’s t 
tests (to compare two groups with normal distributions), unpaired two-tailed Mann-Whitney tests 
(to compare two groups with non-normal distributions), one-way ANOVA with Tukey’s multiple 
comparisons tests (to compare more than two groups with normal distributions), or unpaired 
Kruskal-Wallis tests with Dunn’s multiple comparisons tests (to compare more than two groups 
with non-normal distributions). Normality was determined using a D’Agostino-Pearson omnibus 
normality test. Sample sizes were sufficient to detect differences as small as 10% using the 
statistical methods described. When used, center values and error bars represent means ± SEM. 
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Chapter 3 
 
 
The role of Irg1 in control of  
Mycobacterium tuberculosis infection 
 
 
 
 
Portions of this chapter are excerpted from 
Nair and Huynh et al. J. Exp. Med. 215 (4), 1035-1045 (2018). 
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Abstract 
 Immune-Responsive Gene 1 (Irg1) is a mitochondrial enzyme that produces itaconate 
under inflammatory conditions principally in cells of myeloid lineage. Cell culture studies 
suggest that itaconate regulates inflammation through its inhibitory effects on cytokine and 
reactive oxygen species production. To evaluate the functions of Irg1 in vivo, we challenged 
wild-type (WT) and Irg1
-/-
 mice with Mycobacterium tuberculosis (Mtb) and monitored disease 
progression. Irg1
-/-
 but not WT mice succumbed rapidly to Mtb, and mortality was associated 
with increased infection, inflammation, and pathology. Infection of Irg1
fl/fl
-Lysm-Cre, Irg1
fl/fl
-
Mrp8-Cre, and Irg1
fl/fl
-Cd11c-Cre conditional knockout mice along with neutrophil depletion 
experiments revealed a role for Irg1 in LysM
+
 myeloid cells in preventing neutrophil-mediated 
immunopathology and disease. RNA-sequencing analyses suggest that Irg1 and its production of 
itaconate temper Mtb-induced inflammatory responses in myeloid cells at the transcriptional 
level. Thus, an Irg1 regulatory axis modulates inflammation to curtail Mtb-induced lung disease. 
 
Introduction 
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis (TB), causes up to 
10.4 million new clinical infections and 1.3 million deaths annually.
3
 Following inhalation of 
Mtb, the interplay between the immune response and the bacilli determines whether infection 
leads to active disease or latency. Although innate immune pathways that are triggered early can 
limit disease, myeloid cells also serve as a niche for Mtb replication.
190
 Indeed, Mtb has adapted 
to its human host to persist in myeloid cells despite their ability to induce an antibacterial 
inflammatory immune response.  
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In the mouse model of tuberculosis, pulmonary infection is established after exposure to 
aerosolized bacteria. The acute phase of infection is marked by exponential growth of the 
bacteria in the lungs. In its persistence phase, Mtb undergoes a metabolic shift triggered by 
changes in nutrient availability, as substrates for glycolysis become limited.
191
 The bacterial 
glyoxylate shunt pathway, which is absent in mammals, is an alternative anaplerotic pathway 
that facilitates the use of fatty acids derived from host lipids and cholesterol as a carbon source 
for biosynthetic pathways and generation of ATP. Mtb strains encode at least one and sometimes 
two isocitrate lyases, ICL1 (icl1) and ICL2 (icl2 or aceA) that function within the glyoxylate 
shunt.
151
 The in vivo attenuation exhibited by Mtb mutants lacking ICL expression has provided 
evidence for a role of the glyoxylate shunt in Mtb pathogenesis.
145,150
 
The host Immune-Responsive Gene 1 (Irg1, also called Acod1) is a mitochondrial 
enzyme induced under inflammatory conditions that produces the metabolite itaconate by 
decarboxylating cis-aconitate, a tricarboxylic acid (TCA) cycle intermediate.
143
 Since itaconate 
production in activated myeloid cells reportedly inhibits the activity of bacterial ICLs, it has 
gained interest as an endogenous antibacterial effector molecule.
143,144
 This role was supported 
by a study showing that non-physiologically relevant (25 to 50 mM) concentrations of 
exogenously administered itaconate had bacteriostatic effects on Mtb growth during liquid 
culture under conditions requiring the glyoxylate shunt pathway.
143
 Some bacteria such as 
Yersinia pestis and Pseudomonas aeruginosa have genes that can metabolize itaconate, thereby 
avoiding its antimicrobial activity and achieving persistence in the host.
149
 Thus, one hypothesis 
is that Irg1 produced itaconate would act as a direct antimicrobial molecule during Mtb infection. 
Beyond its possible antibacterial functions, itaconate also links immune cell metabolism 
and inflammatory responses. Irg1 mRNA is highly expressed in macrophages in response to pro-
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inflammatory stimuli that induce type I and type II interferon (IFN) signaling.
134,135,138,143,192
 
Experiments in bone marrow-derived macrophages (BMDM) showed that itaconate suppressed 
the production of mitochondrial reactive oxygen species (ROS) as well as pro-inflammatory 
cytokines, including IL-1β, IL-6 and IL-12p70.138 This capacity to modulate inflammation could 
be of particular importance during Mtb infection because excessive immune responses can 
prevent bacterial clearance and cause pathology.
24,32
 Thus, Irg1 and its production of itaconate 
could modulate Mtb infection and pathogenesis indirectly through their signaling and regulatory 
functions. 
We addressed the in vivo function of Irg1 in regulating immune responses and Mtb 
pathogenesis using mice with global and conditional deletions of Irg1. A complete absence of 
Irg1 during Mtb infection resulted in severe pulmonary disease and ultimately death, with greater 
numbers of infected myeloid cells and higher production of inflammatory cytokines and 
chemokines. Bone marrow chimera studies suggested that Irg1 expression in hematopoietic cells 
was necessary to control neutrophil recruitment, Mtb infection, and immune-mediated tissue 
injury. This data was supported by experiments in mice with conditional deletion of Irg1 in 
myeloid cells. Transcriptional profiling of Mtb infected WT and Irg1
-/-
 BMDM and neutrophils 
ex vivo and in vivo revealed a principal role for Irg1 and itaconate in regulating the expression of 
genes associated with inflammation. Collectively, our studies define a key role for Irg1 in 
regulating immune cell metabolism in subsets of myeloid cells, which minimizes the 
pathological neutrophil-mediated immune response that contributes to pulmonary disease caused 
by Mtb. 
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Results 
Irg1 enables resistance to a subset of pathogenic mycobacteria.  
To determine the role of Irg1 during Mtb infection, Irg1
-/-
 C57BL/6N mice
138
 were 
monitored for clinical and bacterial outcomes following aerosol inoculation with the Mtb Erdman 
strain. Whereas all WT and Irg1
+/-
 mice survived past 80 days post-infection (dpi), 
approximately 75% of Irg1
-/-
 mice succumbed to Mtb 30-40 dpi, a phenotype similar to animals 
lacking IFN-γ signaling (Fig. 17A).24,34,35 The timing of the susceptibility of Irg1-/- mice to Mtb 
infection is earlier than Rag1
-/-
 mice that lack mature B and T cells and succumb between 46 and 
50 dpi,
24
 suggesting there is a defect in the innate immune response to Mtb that precedes the time 
point at which adaptive immunity is required. At 21 dpi, the lungs of Irg1
-/-
 mice infected with 
Mtb had larger numbers and size of macroscopic lesions compared to infected WT mice (Fig. 
17B). To determine whether Irg1 controls Mtb infection, we monitored bacterial burdens in Mtb 
infected WT and Irg1
-/-
 mice. Although bacterial levels were similar in the lung and spleen of 
both mouse strains at 10 dpi, by 14 and 21 dpi Mtb burden was 3- and 25-fold higher, 
respectively, in the lungs of Irg1
-/-
 compared to WT mice (Fig. 17C). At 21 dpi, Mtb burden also 
was 8-fold higher in the spleens of Irg1
-/-
 compared to WT mice (Fig. 17C).  
Having found that Irg1 played an essential role in restricting Mtb infection, we next asked 
whether it was important for control of two other pathogenic mycobacteria, Mycobacterium 
abscessus (strain L948) and Mycobacterium avium (strain TMC724). Irg1
-/-
 mice infected 
intranasally with M. abscessus showed no signs of morbidity (Fig. 17D) but bacterial burden was 
nearly 100-fold higher in the lung as compared to WT at 10 dpi (Fig. 17E). After plating M. 
abscessus from the lungs of WT and Irg1
-/-
 mice at 10 dpi we observed a significantly lower 
frequency of colonies with a rough morphotype in Irg1
-/-
 mice (Fig. 17F). The M. abscessus  
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Figure 17. Irg1 enables resistance to a subset of pathogenic mycobacteria. 
(A-C) Mice were infected with aerosolized Mtb and monitored for (A) survival, (B) gross lung 
pathology at 21 dpi, and (C) Mtb burden in lung and spleen at 10, 14, and 21 dpi. (D-F) Mice 
were intranasally infected with M. abscessus and monitored for (D) weight loss and (E) lung 
CFUs at 10 dpi. (F) The frequency of M. abscessus rough morphotype colonies in WT and Irg1
-/-
 
lungs at 10 dpi was assessed. (G-H) Mice were intranasally infected with M. avium and 
monitored for (G) weight loss and (H) lung CFUs at 10 dpi. (I) Mice were intravenously infected 
with L. monocytogenes (LM) and monitored for survival. (J-K) Mice were intranasally infected 
with IAV and monitored for (J) survival and weight loss, as well as (K) lung viral burden at 5 
dpi. The median ± SEM is graphed. Statistical differences were determined by log-rank Mantel-
Cox test (A, I, J) and two-tailed unpaired Student’s t test for normally distributed groups or two-
tailed unpaired Mann-Whitney test for non-normally distributed groups (C, E, F, H, J, K). n.s., 
not significant, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from or 
representative of two (A-C, I-K) or one (D-H) independent experiments. Panels (A-C, I-K) were 
previously published in Nair and Huynh et al., 2018. 
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rough morphotype is associated with increased virulence and ability to persist in vivo
193,194
 and 
its decreased frequency suggests that M. abscessus may be encountering a less restrictive host 
environment in the Irg1
-/-
 lung that allows improved persistence of the less virulent smooth 
morphotype. Intranasal M. avium infection did not induce morbidity in Irg1
-/-
 mice (Fig. 17G) 
and they were able to restrict infection to the same extent as WT mice (Fig. 17H). These results 
demonstrate that Irg1 is important for control of a subset of pathogenic mycobacteria.  
We also tested the effects of Irg1 on two other pathogens, the intracellular bacterium, 
Listeria monocytogenes (strain EGD) and Influenza A virus (IAV strain A/California/04/2009 
H1N1), a respiratory pathogen (Fig. 17D-F). Loss of Irg1 expression in mice did not result in 
altered susceptibility to L. monocytogenes (Fig. 17I) or IAV infection (Fig. 17E-F). These 
results suggest that Irg1 is not broadly protective in bacterial and viral infections but rather has a 
more specific role in restricting a subset of mycobacterial infections. 
 
Figure 18. GFP-Mtb is as virulent as WT Mtb. 
Mice were infected with WT or GFP-Mtb and bacterial burden was analyzed in the lung and 
spleen at 21 dpi. The mean ± SEM is graphed. Statistical differences were determined by one-
way ANOVA with Tukey’s post-test. n.s., not significant. Data are from three independent 
experiments. Previously published in Nair and Huynh et al., 2018. 
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Figure 19. Irg1 modulates cellular inflammation after Mtb infection. 
(A-H) Mice were infected with Mtb. (A) Histopathology was visualized by H&E staining of 
lungs at 21 dpi. Bars: 2.5 mm (1.25x); 50 µm (40x). (B) Representative flow cytometry plots for 
neutrophils as a percentage of total lung CD45
+
 cells in lungs before Mtb infection and at 10, 14, 
and 21 dpi. Absolute number of innate immune cell populations in lungs at (C) 10 dpi, (D) 14 
dpi, and (E) 21 dpi. (F) Absolute number of adaptive immune cell populations in lungs at 21 dpi. 
(G) Acid-fast bacilli in Mtb-infected lungs at 21 dpi. Bars, 10 µm. (H) Representative flow 
cytometry plots for GFP
+
 (Mtb
+
) neutrophils in lungs at 10, 14, and 21 dpi. SSC, side scatter. (I) 
Frequency of GFP
+
 (Mtb
+
) cells in indicated cell types at 10, 14, and 21 dpi. The median ± SEM 
is graphed. Statistical differences were determined by Mann-Whitney test. Ns, not significant; *, 
P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Mφ, macrophages. Data are from or 
representative of two (A, C, D, G, I) or three (B, E, F, H) independent experiments. Previously 
published in Nair and Huynh et al., 2018. 
77 
 
Irg1 modulates lung inflammatory responses after Mtb infection.  
Since Irg1 has been reported to regulate inflammatory responses
138
 we next evaluated 
cellular inflammation in the lungs of WT and Irg1
-/-
 mice infected with a strain of Mtb Erdman 
that stably expresses GFP and has the same virulence properties as WT Mtb (Fig. 18). 
Histological analysis at 21 dpi showed that lung lesions in Irg1
-/-
 mice were larger and contained 
denser cellular infiltrates than those in WT mice (Fig. 19A). To define the composition of these 
infiltrates, we performed a kinetic analysis of immune cells in infected lungs by flow cytometry 
(gating strategy defined in Fig. 29). At 10 dpi, no differences in the number of neutrophils, 
inflammatory monocytes, infiltrating (CD11b
+
) macrophages, alveolar macrophages, CD11b
+
 
and CD103
+
 DCs, NK and NKT cells, or eosinophils were detected in the lungs of WT and 
Irg1
-/-
 mice (Fig. 19B, C). However, by 14 dpi infected lungs from Irg1
-/-
 mice had 4-fold more 
neutrophils and 3-fold more eosinophils compared to WT mice, and this difference remained at 
21 dpi for neutrophils (Fig. 19B, D, E). At 21 dpi, lungs from Irg1
-/-
 mice also had 1.3-fold 
fewer alveolar macrophages and 3-fold fewer NK1.1
+
 cells. Analysis of other innate immune cell 
populations in the lungs at 14 and 21 dpi revealed no significant differences in numbers of 
inflammatory monocytes, infiltrating macrophages, and DCs between WT and Irg1
-/-
 mice. In 
addition, no differences in the numbers of CD4
+
 T cells, CD8
+
 T cells, and B cells were found 
between WT and Irg1
-/-
 mice at 21 dpi (Fig. 19F). 
As the timing of the increased myeloid cell inflammation correlated with the higher Mtb 
burden in the lungs of Irg1
-/-
 mice, we evaluated whether the accumulating myeloid cells were 
infected with Mtb. Acid-fast staining of tissue sections at 21 dpi revealed that bacilli were 
predominantly found in lung lesions, with greater numbers of bacilli present in Irg1
-/-
 mice (Fig. 
19G). To analyze the extent of infection in each myeloid cell type, we monitored the presence of 
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Mtb-GFP in the various cell populations by flow cytometry. At 10 and 14 dpi myeloid cell types 
in WT and Irg1
-/-
 lungs were infected at similar frequencies (Fig. 19H, I). However, by 21 dpi 
lungs from Irg1
-/-
 mice had higher percentages of infected neutrophils (8-fold), inflammatory 
monocytes (19-fold), infiltrating macrophages (19-fold), and CD11b
+
 DCs (3-fold) compared to 
WT mice. Collectively, this data suggests that Irg1 regulates inflammatory responses during Mtb 
infection and controls the recruitment of multiple types of myeloid cells, many of which become 
targets for subsequent rounds of infection. 
 
 
Figure 20. Irg1 modulates inflammatory cytokine production after Mtb infection. 
(A-C) Cytokine and chemokine levels in Mtb infected lungs at (A) 10 dpi, (B) 14 dpi, and (C) 21 
dpi. (D) Lung TNF-α levels. The median ± SEM is graphed. Statistical differences were 
determined by Mann-Whitney test. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001). Mφ, macrophages. Data are from or representative of two (A, B, D) or three 
(C) independent experiments. Previously published in Nair and Huynh et al., 2018. 
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 Given the increased inflammatory cell recruitment in Irg1
-/-
 mice, we measured the effect 
of Irg1 on the accumulation of inflammatory mediators in the lung during Mtb infection. 
Equivalent levels of chemokines and pro-inflammatory cytokines were detected in lung 
homogenates of WT and Irg1
-/-
 mice at 10 dpi (Fig. 20A, D), a time point at which we observed 
no difference in the numbers of lung immune cells. By 14 dpi, higher levels of several pro-
inflammatory cytokines (IL-1β, IL-6, IL-17, G-CSF) and chemokines (CXCL1, CCL3, CCL4) 
were detected in the lungs of Irg1
-/-
 mice compared to WT mice (Fig. 20B), although TNF-α 
levels remained unchanged (Fig. 20D). By 21 dpi, all eleven pro-inflammatory cytokines (IL-1β, 
IL-6, IL-12p70, IL-17, IFN-γ, TNF-α, G-CSF) and chemokines (CCL2, CXCL1, CCL3, CCL4) 
measured were higher in the lungs of Irg1
-/-
 mice compared to WT mice (Fig. 20C, D). Thus, 
enhanced accumulation of immune cells in the lungs of infected Irg1
-/-
 mice at 14 and 21 dpi 
correlated with increased expression of pro-inflammatory cytokines and chemokines. 
 
Neutrophil depletion extends the survival of Irg1
-/-
 mice during Mtb infection. 
Excessive neutrophil recruitment is associated with tissue damage and progression of Mtb 
disease.
24,32
 We speculated that the susceptibility of Irg1
-/-
 mice to Mtb infection was related to 
the increased accumulation of neutrophils in their lungs. To test this hypothesis, we administered 
a neutrophil depleting anti-Ly6G (αLy6G) or isotype control monoclonal antibody to WT and 
Irg1
-/-
 mice every other day, beginning at 10 dpi and ending at 34 dpi. Flow cytometry analysis 
demonstrated that anti-Ly6G treatment of Irg1
-/-
 mice led to a 7-fold reduction in the number of 
lung neutrophils compared to isotype control-treated mice at 21 dpi (Fig. 21A, F). Neutrophil 
depleted Irg1
-/-
 mice exhibited less weight loss (Fig. 21B) and extended survival time (Fig. 21C)  
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Figure 21. Neutrophil depletion enhances the survival of Irg1
-/-
 mice. 
(A-G) Mice were infected with Mtb and treated with anti-Ly6G (αLy6G) or isotype control 
antibodies beginning at 10 dpi. (A) Representative flow cytometry for lung neutrophils at 21 dpi. 
(B) Weight loss kinetics. (C) Survival analysis. (D) Lung and spleen Mtb burden at 21 dpi. (E) 
Lung histopathology and acid-fast bacilli at 21 dpi were visualized with H&E (top) and acid-fast 
(bottom) stains. Bars: 1 mm (top); 100 µm (bottom). (F) Innate immune cell populations in the 
lung at 21 dpi. (G) Lung cytokine levels at 21 dpi. Statistical differences were determined by 
one-way ANOVA with Tukey’s post-test (D, F) and Mann-Whitney test (G). ns, not significant; 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from or representative of 
two (A-G) independent experiments. Panels (A, C-G) were previously published in Nair and 
Huynh et al., 2018. 
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after Mtb infection. Once neutrophil depletion was halted and neutrophils were allowed to 
accumulate in the lung, disease ensued and all Irg1
-/-
 mice succumbed to infection (mean time to 
death for isotype control and anti-Ly6G-treated Irg1
-/-
 mice was 30 and 62 days, respectively).  
This demonstrated that the excessive accumulation of neutrophils contributed to the early 
susceptibility of Irg1
-/-
 mice and that Irg1 is required to restrict neutrophilic inflammation during 
acute and chronic Mtb infection. Neutrophil depletion also reduced lung Mtb burden in Irg1
-/-
 
mice by 19-fold at 21 dpi, but had no effect on splenic Mtb burden (Fig. 21D). However, lung 
Mtb levels in neutrophil-depleted Irg1
-/-
 mice remained higher (9-fold) than in anti-Ly6G-treated 
WT mice (Fig. 21D), indicating incomplete neutrophil depletion or that recruitment and infection 
of neutrophils only partially contributed to the higher bacterial burden in Mtb infected Irg1
-/-
 
mice. Correspondingly, diminished numbers of acid-fast bacilli were present in lung sections of 
neutrophil depleted Irg1
-/-
 mice compared to controls (Fig. 21E). Histological analysis showed 
that lung lesions from infected, neutrophil depleted Irg1
-/-
 mice were smaller than their isotype 
treated counterparts (Fig. 21E). Other than a 1.5-fold decrease in inflammatory monocytes, the 
recruitment of which could be altered by decreases in lung cytokine and chemokine expression 
caused by neutrophil depletion, all other innate immune cell subsets (infiltrating and alveolar 
macrophages, NK1.1
+
 cells, DCs, eosinophils) were unaffected by neutrophil depletion in Irg1
-/-
 
mice (Fig. 21F). Cytokine (IL-1β, IL-6, IL-12p70, G-CSF, IFN-γ) and chemokine (CCL2, 
CCL3, CCL4, CXCL1) levels in the lung also were decreased in neutrophil depleted Irg1
-/-
 mice 
at 21 dpi, demonstrating that neutrophils contributed to the heightened inflammatory response at 
this time point (Fig. 21G). Collectively, these experiments show that depletion of neutrophils 
mitigates the bacterial and pro-inflammatory pathological phenotypes observed at 21 dpi in  
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Figure 22. Expression of Irg1 in myeloid cell subsets enables survival of Mtb infection. 
(A, B, D-J) Mice were infected with Mtb. (A) Survival analysis of bone marrow chimeric mice. 
(B) Lung Mtb burden in one-way and mixed bone marrow chimeric mice at 21 dpi. (C) Cells 
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were isolated from naive Irg1
fl/fl
 and Irg1
fl/fl
-Cre-expressing mice. mRNA was then extracted and 
reverse transcribed, and a section of the Irg1 gene spanning exon 4 was amplified by PCR. Non-
recombined transcript yields a 490 bp amplicon, whereas Cre recombinase-mediated excision of 
exon 4 results in a 290 bp amplicon. Recombined Irg1 exon 4 in cells from Cre-negative Irg1
fl/fl
, 
Irg1
fl/fl
-Mrp8-Cre (bone marrow neutrophils), Irg1
fl/fl
-Cd11-Cre (alveolar macrophages from 
BAL and total splenic CD11c
+
 cells), and Irg1
fl/fl
-Lysm-Cre mice (bone marrow neutrophils, 
alveolar macrophages from BAL, splenic monocytes, and total splenic CD11c
+
 cells). (D) 
Survival analysis of conditional deletion mice. (E) Lung and spleen Mtb burden at 21 dpi. (F) 
Neutrophils as a percentage of the total lung CD45
+
 population. (G-I) Quantitation of lung 
myeloid cells at 21 dpi in (G) Irg1
fl/fl
-Mrp8-Cre, (H) Irg1
fl/fl
-Cd11c-Cre, and (I) Irg1
fl/fl
-Lysm-
Cre. Mφ, macrophages. (J) Lung cytokine levels at 21 dpi. The median ± SEM is graphed. 
Statistical differences were determined by log-rank Mantel-Cox test (A, D), one-way ANOVA 
with Tukey’s post-test (B, E, F, J), or Mann-Whitney test (G-I). n.s., not significant, *, P < 0.05; 
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from or representative of two (A-C, I-
K) or one (D-H) independent experiments. Panels (A, C-E, G-J) and parts of panel (B) were  
previously published in Nair and Huynh et al., 2018. 
 
 
Irg1
-/-
 mice and suggest that a dysfunctional neutrophil response contributes to the susceptibility 
of these mice to Mtb infection. 
 
Expression of Irg1 in LysM
+
 and CD11c
+
 cells enables survival of Mtb infection.  
In order to define the cell types that require Irg1 expression for control of Mtb infection, 
we generated reciprocal bone marrow chimeric mice, infected them with Mtb, and monitored 
survival (Fig. 22A). Whereas WT→WT and WT→Irg1-/- mice survived past 80 dpi, Irg1-/-→WT 
mice succumbed by 32 dpi, similar to the phenotype observed with Irg1
-/-
 mice. This result 
demonstrated that the protective effects of Irg1 were derived from radio-sensitive cells, likely in 
the hematopoietic compartment. Consistent with the survival data, Mtb titers in the lungs and the 
spleen of Irg1
-/-→WT mice were higher than WT→WT mice at 21 dpi (lung, 10-fold; spleen, 3-
fold) (Fig. 22B). Intriguingly, lung and spleen CFU counts in mixed WT + Irg1
-/-→WT chimeras 
were similar to those of WT→WT chimeras and significantly lower than in Irg1-/-→WT 
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chimeras. This result suggested that the presence of Irg1-expressing cells could compensate for 
the defective ability of Irg1
-/- 
cells to control Mtb infection. However, the proportions of WT and 
Irg1
-/-
 cells in the lungs of mixed bone marrow chimera mice prior to infection were not assessed 
and phenotypes observed in these mice could be due to differences in the engraftment ability of 
WT and Irg1
-/-
 cells. 
Since bone marrow chimera experiments revealed a role for Irg1 in hematopoietic cells, 
we sought to identify the Irg1-expressing cell types that modulated neutrophil accumulation and 
Mtb disease pathogenesis. Because Irg1 is expressed principally in cells of myeloid 
lineage,
134,138,143,152
 we used conditional deletion mice to test its role in myeloid cells during Mtb 
infection. Mice with a loxP site-flanked exon of Irg1 (Irg1
fl/fl
) were crossed to mice that 
expressed Cre recombinase under the control of various myeloid cell-specific promoters and 
targeted cells were isolated and assessed for Irg1 exon deletion (Fig. 22C). As expected, we did 
not detect Irg1 exon deletion in Cre-negative Irg1
fl/fl
 mice. The expected patterns of deletion 
were detected in Irg1
fl/fl
-Mrp8-Cre (deletion in neutrophils) and Irg1
fl/fl
-Lysm-Cre mice (deletion 
in monocytes, alveolar macrophages, neutrophils, and some DCs). However, we found that 
Irg1
fl/fl
-Cd11c-Cre mice exhibited strong deletion in alveolar macrophages and poor deletion in 
splenic DCs, suggesting that lung DCs might have a similarly low level of deletion. Conditional 
deletion mice were infected with Mtb and monitored for survival (Fig. 22D). All Cre-negative 
Irg1
fl/fl
 and Irg1
fl/fl
-Mrp8-Cre mice survived past 150 dpi, but Irg1
fl/fl
-Lysm-Cre mice succumbed 
within 40 dpi, a phenotype similar to that of Irg1
-/-
 mice (Fig. 17A). In comparison, all Irg1
fl/fl
-
Cd11c-Cre mice succumbed by 135 dpi. Consistent with these survival results, Mtb levels in the 
lungs of Irg1
fl/fl
-Mrp8-Cre mice were similar to littermate Cre-negative Irg1
fl/fl
 controls, whereas 
Irg1
fl/fl
-Lysm-Cre and Irg1
fl/fl
-Cd11c-Cre mice both had greater higher lung Mtb burden at 21 dpi 
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(14-fold and 4-fold respectively) (Fig. 22E). Splenic Mtb burdens were also higher in Irg1
fl/fl
-
Lysm-Cre and Irg1
fl/fl
-Cd11c-Cre mice at 21 dpi compared to controls (Fig. 22E). 
We next assessed cellular inflammation in the lung at 21 dpi and found that Irg1
fl/fl
-Lysm-
Cre had a higher frequency (Fig. 22F) and absolute number (Fig. 22I) of neutrophils in the lung 
as compared to Cre-negative Irg1
fl/fl
 controls, although their neutrophil frequency remained 
lower than that of Irg1
-/-
 mice. Irg1
fl/fl
-Cd11c-Cre mice had greater numbers of lung neutrophils 
compared to Cre-negative Irg1
fl/fl
 mice, but Irg1
fl/fl
-Mrp8-Cre mice did not (Fig. 22G, H). Loss 
of Irg1 expression in myeloid cells (Irg1
fl/fl
-Lysm-Cre mice) resulted in higher levels of 
cytokines and chemokines in the lungs at 21 dpi (Fig. 22J). Loss of Irg1 expression in alveolar 
macrophages and some DCs (Irg1
fl/fl
-Cd11c-Cre mice) also resulted in greater amounts of 
inflammatory cytokines and chemokines. In contrast, deletion of Irg1 in neutrophils (Irg1
fl/fl
-
Mrp8-Cre mice) had little effect on cytokine responses. These data show that Irg1 expression in 
CD11c
+
 and LysM
+
 cell subsets regulates neutrophil recruitment and inflammation. Although 
neutrophils mediate Mtb-induced immunopathology in Irg1
-/-
 mice, their cell-intrinsic expression 
of Irg1 is dispensable for this process. 
 
Susceptibility of Irg1
-/-
 mice is dependent on Mtb expression of PDIM and ESX-1, but not 
ICL1 
We next investigated the requirement for key Mtb virulence factors in the susceptibility 
of Irg1
-/-
 mice. The ESX-1 secretion system and the Mtb membrane lipid phthiocerol 
dimycoserosate (PDIM) enable Mtb to modulate host immune responses
195–197
 and thus may have 
important effects on the inflammatory response observed in Irg1
-/-
 mice. Irg1
-/-
 mice infected 
with isogenic Mtb strains lacking ESX-1 (ΔESX-1) or PDIM (ΔPDIM) exhibited no  
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Figure 23. Susceptibility of Irg1
-/-
 mice is dependent on Mtb expression of PDIM and ESX-
1, but not ICL1. 
(A-B) Mice were infected with WT, ΔPDIM or ΔESX-1 Mtb and monitored for (A) survival or 
(B) lung Mtb burden at 81 dpi. Dotted lines in (B) indicate limit of detection (WT, 50 CFU; Irg1
-
/-
, 500 CFU). (C-G) Mice were infected with WT or Δicl1 Mtb and monitored for (C) weight loss 
kinetics, (D) survival, (E) lung and spleen burden at 21 dpi, (F) myeloid lung cell populations at 
21 dpi, and (G) lung cytokines at 21 dpi. The median ± SEM is graphed. Statistical differences 
were determined by log-rank Mantel-Cox test (A, D), one-way unpaired Student’s t test (B), or 
Mann-Whitney test (C, E-G). n.s., not significant, *, P < 0.05; **, P < 0.01; ***, P < 0.001; 
****, P < 0.0001. Data are from or representative of one (A, B) or two (C-G) independent 
experiments. 
 
susceptibility over 80 days of infection (Fig. 23A). At 81 dpi lung CFU counts for ΔPDIM Mtb 
were below the limit of detection in Irg1
-/-
 mice while ΔESX-1 Mtb counts were 25-fold higher 
in Irg1
-/-
 lungs compared to WT mice (Fig. 23B). These experiments show that expression of 
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ESX-1 and PDIM by Mtb is required for the acute susceptibility of Irg1
-/-
 mice, but ESX-1 is not 
required for defective control of Mtb by Irg1
-/-
 mice. 
Since Irg1 catalyzes the production of itaconate, a metabolite that can inhibit the 
glyoxylate shunt enzymes ICL1 and ICL2, it has been suggested that Irg1 restricts Mtb infection 
by blocking the glyoxylate shunt.
143
 The strain of Mtb used in this study, Erdman, encodes two 
ICL genes, ICL1 and ICL2, although ICL1 is considered functionally dominant.
145,150
 In vivo, 
Δicl1 Mtb replicates normally during the acute phase but is attenuated during the chronic phase 
of infection, whereas Δicl2 Mtb shows no defects during in vivo infection.145,150 In comparison, 
Δicl1/Δicl2 strains grow poorly in liquid culture and are completely avirulent in vivo.145 To test 
the impact of Irg1 on restriction of ICL1 activity in vivo, we infected WT and Irg1
-/-
 mice with 
WT and isogenic Δicl1 Mtb strains. As anticipated, WT mice infected with WT or Δicl1 Mtb 
showed no signs of morbidity (Fig. 23C) and survived past 80 dpi (Fig. 23D). In contrast, all 
Irg1
-/-
 mice infected with Δicl1 Mtb succumbed to infection with weight loss (Fig. 23C) and 
survival (Fig. 23D) patterns highly similar to that of Irg1
-/-
 mice infected with an isogenic WT 
Mtb strain. Moreover, Δicl1 Mtb titers were higher in the lung (83-fold) and spleen (12-fold) of 
Irg1
-/-
 mice compared to WT mice (Fig. 23E). Our findings that Δicl1 Mtb is still virulent in 
Irg1
-/-
 mice suggest that the susceptibility of Irg1
-/-
 mice is independent of ICL1 activity and that 
Irg1 likely restricts in vivo Mtb infection independently of its activity on ICL1. 
 Since Irg1
-/-
 mice infected with WT or Δicl1 Mtb succumbed to infection at equivalent 
rates (Fig. 23D), we asked whether the pattern of inflammatory responses in these mice also was 
similar. Indeed, Irg1
-/-
 mice infected with WT or Δicl1 Mtb showed similarly increased 
accumulation of neutrophils in their lungs at 21 dpi (Fig. 23F). Correspondingly, pro-
inflammatory cytokines (IL-1β, IL-6, IL-12p70, IL-17, G-CSF, IFN-γ) and chemokines (CCL2, 
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CCL3, CCL4, CXCL1) were higher in Δicl1 Mtb-infected Irg1-/- mice compared to WT mice 
(Fig. 23G). The similar inflammatory responses to WT and Δicl1 Mtb in Irg1-/- mice further 
supports the hypothesis that the defective control of Mtb infection in these mice is independent 
of ICL1 activity. 
 
Figure 24. Irg1 is not required for induction of ROS, NOS2, or control of Mtb in BMDMs. 
(A-B) Mice were infected with Mtb and at 21 dpi lung neutrophils were assessed for (A, B) 
reactive oxygen species by MitoSOX Red dye or intracellular NOS2 expression. (C) BMDMs 
were IFN-γ pretreated or not, infected with Mtb (multiplicity of infection = 1), and CFUs were 
assessed at 0, 24, and 96 hpi. The median ± SEM is graphed. Statistical differences were 
determined by Mann-Whitney test (B) or one-way ANOVA with Tukey’s post-test (C). n.s., not 
significant, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Data are from or 
representative of three (A, B) or two (C) independent experiments. 
 
Irg1 is not required for induction of ROS and NOS2 or control of Mtb in macrophages 
Reactive oxygen species (ROS) have been proposed as a cell autonomous antibacterial 
mechanism during Mtb infection
198
 and Irg1 has been reported to promote production of 
antibacterial reactive oxygen species during Salmonella enterica infection.
152
 However, 
overproduction of ROS has been linked to inflammatory pathology and exogenous itaconate 
suppresses ROS production by macrophages in vitro.
138,160
 We asked whether neutrophils might 
be contributing to susceptibility through altered ROS production and addressed this question by 
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quantifying ROS-producing lung neutrophils  in WT and Irg1
-/-
 mice at 21 dpi using a dye that 
reports ROS production, MitoSOX Red. We observed an increase in intracellular ROS (Fig. 
24A) and a higher number of ROS
+ 
(MitoSOX
+
) neutrophils in Irg1
-/-
 mice, but no difference in 
the frequency of ROS
+
 neutrophils (Fig. 24B). The increased number of ROS
+
 neutrophils was 
expected, given the higher number of neutrophils present in the lung at this time point (Fig. 
19E). No differences in ROS expression were detected in Ly6G-negative immune cells (data not 
shown). These data suggest Irg1
-/-
 neutrophils and macrophages are not failing to produce 
potentially bactericidal ROS and neutrophils may be contributing to lung pathology through 
overproduction of ROS. 
Inducible nitric oxide synthase (NOS2) restricts pathologic, granulocyte-dominated 
inflammatory responses
33,96
 that appear grossly similar to the neutrophil-dominated inflammation 
we observe in Irg1
-/-
 mice. However, overexpression of NOS2 by macrophages has been 
associated with a hyperinflammatory state and tissue pathology.
138
 We asked whether the 
susceptibility of Irg1
-/-
 mice might be associated with alterations in NOS2 expression and 
addressed this by measuring expression of NOS2 in lung neutrophils at 21 dpi. The frequency 
and absolute number of NOS2
+
 neutrophils were significantly higher in Irg1
-/-
 mice (Fig. 24A, 
B). No differences in NOS2 expression were detected in Ly6G-negative immune cells (data not 
shown). These data suggest that Irg1
-/-
 neutrophils may be in a pathologic, hyper-inflamed state. 
We next investigated whether Irg1 deficiency impacted control of Mtb by macrophages, a 
cell type identified as a key expresser of Irg1 by the susceptibility of Irg1
fl/fl
-Lysm-Cre mice 
(Fig. 22D-J). Irg1 had no effect on IFN-γ-independent or -dependent control of Mtb in vitro, as 
no differences in Mtb titer were detected in WT and Irg1
-/-
 bone marrow-derived macrophages 
(BMDMs) (Fig. 24C). These data suggest that Irg1 is dispensable for control of Mtb in  
90 
 
 
Figure 25. Irg1 alters transcription of inflammatory and metabolic genes in neutrophils 
during Mtb infection. 
Neutrophils were infected ex vivo and analyzed at 0 (naïve), 2, and 6 hpi. Experiments were 
performed in triplicate for each cohort. (A) PCA plot: PCA component 1 indicates difference 
between naive and infected samples. PCA component 2 shows a time-dependent change in 
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infected samples. (B) Heat map shows the relative expression intensity of the indicated 
inflammatory genes in WT and Irg1
-/-
 neutrophils. (C) Diagram shows the numbers of 
differentially expressed genes between WT and Irg1
-/-
 neutrophils over the time course of ex vivo 
infection. (D) Venn diagrams show comparison of differentially expressed genes between WT 
and Irg1
-/-
 neutrophils at 2 hpi versus those at 6 hpi. Tables show the top enriched pathways as 
indicated for each diagram. (E-G) Transcriptome data from WT and Irg1
-/-
 neutrophils purified 
from lungs at 16 dpi or from the bone marrow of naïve mice (as baseline comparison) (n = 3 per 
cohort). (E) PCA plot. PCA component 1 indicates the difference between samples derived from 
infected lungs and naive bone marrow. The second component indicates difference between WT 
and Irg1
-/-
 neutrophils after infection. (F) Data sets from WT and Irg1
-/-
neutrophils in vivo were 
compared to data sets from WT and Irg1
-/- 
neutrophils ex vivo (2 and 6 hpi combined). Genes that 
are upregulated in ex vivo infected Irg1
-/-
 neutrophils also are enriched in Irg1
-/-
neutrophils 
isolated from lung at 16 dpi. Left plot shows gene expression table of WT and Irg1
-/-
neutrophils 
from infected mice. Columns and rows show conditions and genes, respectively. Genes are 
ranked according to significance of differential expression and direction of change. Orange bars 
(right side) represent genes that become upregulated in the combined transcriptome of Irg1
-/- 
neutrophils at 2 + 6 hpi. Right plot shows the running score for the gene set as the analysis 
moves down the ranked list. The score at the peak of the plot (the score furthest from 0.0) is the 
score for the gene set. (G) Gene set enrichment analysis comparison between WT and Irg1
-/- 
neutrophils from infected lungs described above. Each dot on volcano plot (left) represents a 
pathway and is characterized by two values: NES (normalized enrichment score) shows direction 
and strength of change; minus logarithm of adjusted P value represents the significance of the 
pathway. Significantly enriched pathways are highlighted in red and listed on the table along 
with adjusted P values. (H) Heat map of selected inflammatory genes in neutrophils isolated 
from WT and Irg1
-/- 
lungs at 16 dpi. 
 
macrophages. Collectively, these findings indicate that Irg1
-/-
 cells are in a hyper-inflamed state, 
rather than being defective in cell autonomous control of Mtb. 
 
Irg1 regulates inflammatory responses in myeloid cells during Mtb infection.  
To gain insight into why a lack of Irg1 expression in myeloid cells resulted in excessive 
accumulation of neutrophils and hyper-inflammation in Irg1
-/-
 mice during Mtb infection we 
examined the expression profiles of Mtb-infected WT and Irg1
-/-
 neutrophils and BMDMs. 
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Ex vivo analysis of naïve neutrophils isolated from WT and Irg1
-/- 
bone marrow showed a 
highly overlapping gene expression profile (Fig. 25A), indicating that the basal gene expression 
pattern of both genotypes was similar. Within 2 hrs of Mtb infection ex vivo, Irg1
-/- 
neutrophils 
had higher expression of Nos2, Il6, Il1b, and Nlrp3 but not Tnfa and Cxcl2 transcripts (Fig. 25B), 
indicating that Irg1 expression in neutrophils controls expression of a subset of pro-inflammatory 
genes. Indeed, Irg1
-/-
 neutrophils exposed to Mtb induced the differential expression of twice as 
many transcripts as WT cells (Fig. 25C). Pathway enrichment analysis of samples at 2 hours 
post-infection (hpi) revealed that infected Irg1
-/- 
neutrophils had prominent inflammatory 
response transcriptional signatures compared to WT cells (Fig. 25D). At 6 hpi, Irg1
-/- 
neutrophils 
had down-regulated transcripts of several genes involved in the electron transport chain, TCA 
cycle, and oxidative phosphorylation (Fig. 25D), which is consistent with the reported metabolic 
functions of Irg1.
138,155
 We then analyzed neutrophils isolated directly from lungs of mice at 16 
dpi (Fig. 25E-G). WT and Irg1
-/- 
neutrophils were distinguished by global gene expression 
patterns (Fig. 25E), confirming a marked effect of Irg1 on neutrophil responses during Mtb 
infection in vivo. Genes that were upregulated in Irg1
-/- 
neutrophils ex vivo after Mtb infection 
were also upregulated in Irg1
-/- 
neutrophils isolated from the lung at 16 dpi (Fig. 25F). 
Neutrophils in Irg1
-/- 
mice at 16 dpi upregulated transcriptional signatures associated with 
inflammation, including NF-κB and pro-inflammatory signaling pathways downstream of 
cytokine receptors and interferons (Fig. 25G, H). This pronounced pro-inflammatory phenotype 
of Irg1
-/-
 neutrophils isolated in vivo was accompanied by altered expression of genes involved in 
oxidative phosphorylation, which links the anti-inflammatory action of Irg1 with its control of 
cellular metabolic activity. 
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Figure 26. Irg1 alters the transcriptional signature of Mtb infected BMDMs. 
(A-C) Transcriptomic data from WT, Irg1
-/-
, and Irg1
-/-
 + itaconate (ITA)-treated BMDMs 
infected with Mtb and analyzed at 4 hrs post-infection (hpi). (A, left) Heat map comparing the 
transcriptional changes that occur at 4 hpi in Irg1
-/-
 BMDMs ± ITA and WT BMDMs. Genes that 
are up-regulated in WT BMDMs also are enriched in Irg1
-/-
 + ITA BMDMs at 4 hpi. Columns 
and rows show conditions and genes, respectively. Genes are ranked according to significance of 
differential expression and direction of change. (A, right) Plot shows the running score for NF-
κB gene set as the analysis moves down the ranked list. (B) Gene set enrichment analysis 
comparison for genes in NF-κB signaling and (C) inflammatory chemokines Cxcl11 and Il1b 
between WT versus Irg1
-/-
, WT versus Irg1
-/-
 + ITA, and Irg1
-/-
 versus Irg1
-/-
 + ITA BMDMs. 
The median ± SEM is graphed. Data is from one experiment. 
 
We next compared the expression profiles of Mtb infected WT and Irg1
-/-
 BMDMs. 
Within just 4 hours of Mtb infection, the transcriptional signature in Irg1
-/-
 BMDMs differed 
markedly from WT BMDMs. Many of the genes that were upregulated in Irg1
-/-
 cells after Mtb 
94 
 
infection were reciprocally downregulated in WT BMDMs (Fig. 26A, B). Exogenous addition of 
itaconate (ITA) to Mtb infected Irg1
-/-
 BMDMs switched their transcriptional signature to one 
similar to Mtb infected WT BMDMs (Fig. 26A, B), suggesting that the effect of Irg1 deletion on 
transcriptional profiles was due principally to the loss of itaconate production. Pathway 
enrichment analysis indicated that a lack of Irg1 expression in Mtb infected BMDMs resulted in 
induction of inflammatory and chemoattractant genes downstream of NF-κB signaling, and 
correspondingly, addition of itaconate to Irg1
-/-
 BMDMs reverses this effect (Fig. 26B, C). 
Nonetheless, and consistent with our in vivo experiments (Fig. 20D), Tnfa expression levels were 
similar in Mtb infected WT and Irg1
-/-
 BMDMs in the presence or absence of itaconate 
treatment. Collectively, this data shows that Irg1 and its product itaconate function to limit 
inflammation during Mtb infection at the transcriptional level. 
 
 
Figure 27. Irg1 is the sole source of lung itaconate during Mtb infection and i.p. 
administration of dimethyl itaconate fails to rescue Irg1
-/-
 susceptibility. 
(A-C) Mice were infected with Mtb. (A) Relative abundance of itaconate in total lung samples 
from 21 dpi. (B-C) Mice were administered dimethyl itaconate (DI) i.p. daily from 10-20 dpi and 
monitored for (B) weight loss kinetics and (C) Mtb burden in lung and spleen. The mean ± SEM 
is graphed. Statistical differences were determined by two-tailed unpaired Student’s t test (A) or 
unpaired Kruskal-Wallis test (C). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
Data are from two independent experiments. 
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Irg1 is the sole source of itaconate in the lung during Mtb infection 
 The ability of exogenous itaconate to restore the transcriptional profile of Irg1
-/-
 BMDMs 
to a profile resembling that of WT BMDMs raised the questions of whether there were Irg1-
independent sources of itaconate during Mtb infection and if administration of an exogenous 
itaconate analog could rescue the susceptibility of Irg1
-/-
 mice to Mtb. We performed liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) on methanol-soluble extracts of total 
lung samples taken from Mtb infected mice to quantify relative levels of itaconate. Itaconate was 
not detected in WT mice at 7 dpi (data not shown) but was detected at 21 dpi. In contrast to WT 
mice, no itaconate was detected in any Irg1
-/-
 lung samples, demonstrating that Irg1 is the sole 
source of itaconate in the lung during Mtb infection (Fig. 27A). 
 We next attempted to complement the susceptibility associated phenotypes in Irg1
-/-
 mice 
through exogenous delivery of dimethyl itaconate (DI), a more cell permeable analog of 
itaconate. Daily intraperitoneal administration of DI had no effect on weight loss kinetics (Fig. 
27B) or Mtb burden in the lung or spleen (Fig. 27C). Additionally, DI administration was poorly 
tolerated by mice and induced hunching and temporary hind limb paralysis. Presence of DI in the 
lung was not evaluated and thus it is unclear whether it failed to rescue Irg1
-/-
 susceptibility 
because DI did not reach the lung, was not consistently present at an effective concentration, did 
not have the same effect as itaconate in this context, or because Irg1 is required for itaconate-
independent functions. Experiments that utilize alternative routes of delivery (for example, 
intranasal) and monitor bioavailability of itaconate in the lung will be necessary to draw 
conclusions about the ability of exogenously administered itaconate to rescue Irg1
-/-
 mouse 
susceptibility. 
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Discussion  
Active Mtb infection in humans induces a potent inflammatory response characterized by 
neutrophilia in the blood.
199
 Studies in mice have shown that regulation of neutrophil recruitment 
to the lung during early stages of Mtb infection is a determinant of Mtb pathogenesis, as these 
cells can exert protective
200,201
 or deleterious
24,32
 effects. Our results demonstrate that Irg1 has an 
important role in hematopoietic cells in regulating inflammation to prevent neutrophil-mediated 
immunopathology during Mtb infection in mice. Whereas infection of WT mice with Mtb 
induced an inflammatory response that resulted in long-term survival, infection of mice lacking 
Irg1 led to heightened inflammation characterized by increased production of pro-inflammatory 
cytokines and chemokines and recruitment of granulocytes (neutrophils and eosinophils) by 14 
dpi. By 21 dpi uncontrolled accumulation of neutrophils provided an expanded niche for Mtb 
replication that extended to infection of other myeloid cells subsets recruited to the lung. Loss of 
Irg1 expression in CD11c
+
 and LysM
+
 cells led to increased neutrophil accumulation in the lung 
by 21 dpi. Together, these bacterial and immune consequences contributed to the severe lung 
pathology and subsequent death of Irg1
-/-
 mice within 40 days. As depletion of neutrophils in 
Irg1
-/-
 mice reduced bacterial burden, prolonged survival, and dampened lung inflammation, we 
suggest that neutrophils are a principal cell type contributing to the immunopathology of Irg1
-/-
 
mice after Mtb infection. 
 Several groups have reported Irg1 as a highly induced protein in activated 
macrophages.
131,134,138
 We observed that Irg1 regulates expression of pro-inflammatory and 
chemoattractant genes in macrophages within 4 hours of Mtb infection. Irg1 may be regulating 
inflammation during Mtb infection in several ways. Irg1 has been reported to suppress 
production of Toll-like receptor (TLR)-triggered NF-κB-dependent cytokines by promoting the 
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activity of anti-inflammatory factors such as TNFAIP3 (also known as A20), Nrf2, and 
Atf3.
153,154,156
 Although an increased inflammatory response was detected in the lungs of Irg1
-/-
 
mice at 14 dpi, we failed to detect differences in TNF-α, a cytokine regulated by TNFAIP3,154,157 
compared to WT lung homogenates. Thus, in the context of Mtb infection Irg1 appears to 
modulate inflammatory responses by dampening expression of a selected subset of NF-κB 
regulated genes in both macrophage and neutrophils, perhaps through Nrf2- or Atf3-dependent 
mechanisms. Irg1 also has been implicated in inducing the production of reactive oxygen 
species, which can have antibacterial or immunomodulatory effects in vivo.
152,160
 The neutrophil-
dependent pathology in Irg1
-/-
 mice infected with Mtb could be due to overproduction of NOS2 
production in neutrophils or the increased number of ROS-producing neutrophils. 
An established function of Irg1 is its cis-aconitate decarboxylase activity, which produces 
itaconate through the decarboxylation of the TCA intermediate, cis-aconitate.
143
 Irg1 has been 
proposed to have an important protective role in Mtb infection through production of itaconate, 
which blocks the glyoxylate shunt by inhibiting ICL1 and ICL2.
143,144,202
 Our experiments with 
Δicl1 Mtb suggest that in vivo, Irg1 exerts its action against Mtb by regulating inflammatory 
responses, rather than by inhibiting ICL1. The Δicl1 Mtb strain was as virulent as WT Mtb in 
Irg1
-/-
 mice even though its glyoxylate shunt capacity is suboptimal.
150
 However, we cannot rule 
out an effect of Irg1 on the glyoxylate shunt because Mtb Erdman encodes a second ICL enzyme, 
ICL2, which could compensate for loss of ICL1. Nonetheless, our immunologic and 
transcriptional profiling data are more consistent with a model where the dominant role for Irg1 
is to restrict production of pro-inflammatory chemokines and accumulation of myeloid cells that 
provide a niche for Mtb replication. Consistent with this hypothesis, we observed no difference 
in the ability of WT and Irg1
-/-
 BMDMs to restrict Mtb growth in vitro. Intriguingly, Mtb, M. 
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abscessus, and M. avium all possess ICL homologs
151,203
 but the susceptibility and degree of 
bacterial control observed in Irg1
-/-
 mice varied dramatically by species. This suggests that the 
protective function of Irg1 may vary by mycobacterial species. Future studies can address this 
topic by comparing host inflammatory responses and species-specific requirements for the 
glyoxylate shunt. 
 Our data support a model (Fig. 28) where CD11c
+
 and LysM
+
 cells requires Irg1 to 
dampen pro-inflammatory cytokine production and subsequent neutrophil inflammation. Our 
transcriptomic analysis after Mtb infection of Irg1
-/-
 BMDMs revealed a pro-inflammatory 
signature that was reversed by the addition of exogenous itaconate. Thus, the distinct gene 
expression profiles in Irg1-sufficient and Irg1-deficient cells likely are due to differences in the 
production of itaconate, a metabolite that is absent in the lung homogenates of Mtb infected 
Irg1
-/-
 mice. Collectively, our data suggest a key role for Irg1 and itaconate in regulating 
inflammation in the context of Mtb infection. Infection studies in gene-edited mice expressing 
forms of Irg1 that lack the ability to generate itaconate will be the focus of future work to 
confirm this hypothesis. 
 In summary, our experiments establish an essential role for Irg1 in regulating neutrophil-
dependent inflammation during Mtb infection of the lung. We show that Irg1, likely through its 
ability to convert the TCA cycle intermediate cis-aconitate to itaconate, shapes the host immune 
responses through an immunometabolism axis to curtail Mtb-induced lung disease. As murine 
Irg1 is ~80% identical in amino acid sequence to human IRG1 with all five predicted cis-
aconitate decarboxylase domains fully conserved,
143
 the development of pharmacological agents 
that enhance Irg1 function or promote itaconate production might minimize pathological 
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inflammatory responses that cause severe lung injury associated with tuberculosis disease 
progression. 
 
Figure 28. Model of Irg1 function during Mtb infection.  
During Mtb infection of WT mice, Irg1 is induced in LysM
+
 and CD11c
+
 cells such as 
macrophages, monocytes, and DCs. Irg1 acts to suppress transcriptional upregulation of pro-
inflammatory cytokines and NK-κB-regulated genes, likely through production of itaconate. This 
prevents recruitment of pathologic neutrophils and enables survival. In Irg1
-/- 
mice, Mtb infection 
strongly induces pro-inflammatory cytokine production by LysM
+
 and CD11c
+
 cells, resulting in 
excessive neutrophil recruitment that promotes Mtb growth and causes lung pathology, 
ultimately resulting in susceptibility. 
 
Experimental Procedures 
Ethics statement  
All procedures involving animals were conducted following the National Institutes of 
Health (NIH) guidelines for housing and care of laboratory animals and performed in accordance 
with institutional regulations after protocol review and approval by the Institutional Animal Care 
and Use Committee of the Washington University in St. Louis School of Medicine (protocol no. 
20160118). Washington University is registered as a research facility with the United States 
Department of Agriculture and is fully accredited by the American Association of Accreditation 
of Laboratory Animal Care. The Animal Welfare Assurance is on file with Office for Protection 
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from Research Risks–NIH. All animals used in these experiments were subjected to no or 
minimal discomfort. All mice were euthanized by CO2 asphyxiation, which is approved by the 
American Veterinary Association Panel on Euthanasia. 
 
Mouse strains 
C57BL/6N (WT) mice were either purchased from Charles River or bred in-house. No 
differences in survival or disease progression during Mtb infection were observed in Irg1
+/+
 
littermate controls or Irg1
+/+
 C57BL/6N mice obtained from Charles River in three independent 
experiments. B6.SJL (CD45.1) mice were obtained from Jackson Laboratories. Irg1
-/-
 mice 
(embryonic stem cells obtained from KOMP [C57BL/6N background reporter-tagged insertion 
with conditional potential, MGI: 103206]) were generated at Washington University and have 
been described previously.
138
 Adult mice (6–13 weeks of age) of both sexes were used, and sex 
was randomized between experiments. Cre-negative Irg1
fl/fl
 mice were generated as described 
previously
204
 with two loxP sites flanking exon 4 of Irg1. Irg1
-/-
 mice were bred with FLPe 
“deleter” mice205 to facilitate deletion of lacZ and neomycin resistance cassettes between FRT 
sites and create Irg1
fl/+
 founder mice. The founder mice were backcrossed to C57BL6/J 
background using speed congenic approaches (>99% purity) and then interbred to generate 
Irg1
fl/fl
 mice. These animals were crossed with Mrp8-Cre
+
, Lysm-Cre
+
, and Cd11c-Cre
+
 (Jackson 
Laboratory) mice to delete exon 4 of Irg1 from specific subsets of myeloid cells. 
 
Generation of bone marrow chimeric mice  
Bone marrow chimeric mice were generated by irradiation (900 Gy) of WT or Irg1
-/-
 
recipients and reconstitution with 10
7
 bone marrow cells from WT or Irg1
-/-
 donors. 6-8 weeks 
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after bone marrow transplantation, Irg1
-/-
 (CD45.2) → WT (CD45.1), WT (CD45.1) → Irg1-/- 
and WT (CD45.1) → WT (CD45.2), and WT (CD45.1) + Irg1-/- (CD45.2) → WT (CD45.1) mice 
were bled to confirm chimerism by flow cytometry before Mtb infection. 
 
Mouse infections  
Mtb cultures in logarithmic growth phase (OD600 nm = 0.5-0.8) were washed with PBS + 
0.05% Tween 80, sonicated to disperse clumps, and diluted in sterile water. Mice were exposed 
to 1.6 × 10
8
 CFUs of Mtb, a dose chosen to deliver 100-200 CFUs of aerosolized Mtb per lung 
using an inhalation exposure system (Glas-Col). For each infection, lungs were harvested from at 
least two control mice, homogenized, and plated on 7H11 agar to confirm the input CFU dose. 
The mean dose determined at this time point was assumed to be representative of the dose 
received by all other mice infected concurrently. Mtb burden was determined after homogenizing 
the superior, middle, and inferior lobes of the lung or the entire spleen and plating serial dilutions 
on 7H11 agar. Colonies were counted after 3 weeks of incubation at 37°C in 5% CO2. 
M. abscessus (strain L948) and M. avium (strain TMC724) cultures in logarithmic growth 
phase (OD600 = 0.5-0.8) were washed with PBS + 0.05% Tween 80, passaged through a 27 G 
needle three times to disperse clumps, and diluted in sterile water. Mice were sedated with 
ketamine (Henry Schein) and xylazine (Akorn), then infected by intranasal inoculation of 1.5 x 
10
7
 CFU. For each infection, lungs were harvested from at least two control mice, homogenized, 
and plated on 7H11 agar to confirm the input CFU dose. The mean dose determined at this time 
point was assumed to be representative of the dose received by all other mice infected 
concurrently. Bacterial burden was determined after homogenizing the superior, middle, and 
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inferior lobes of the lung and plating serial dilutions on 7H11 agar. Colonies were counted after 
5 days (M. abscessus) or 3 weeks (M. avium) of incubation at 37°C in 5% CO2. 
Listeria monocytogenes (strain EGD) was stored at mid-logarithmic growth as frozen 
glycerol stocks. Thawed bacteria were diluted into pyrogen-free saline for intravenous injection 
into mice at a dose of 10
5
 bacteria/mouse in 200 µl.  
Mice were infected with IAV strain A/California/04/2009 H1N1 by intranasal inoculation 
of 10
5
 or 10
6
 tissue culture dose. At 5 dpi viral titer was assessed from bronchoalveolar (BAL) 
fluid by tissue culture dose. 
 
Neutrophil depletions  
Mice were administered 200 µg of anti-Ly6G monoclonal antibody (clone 1A8; 
BioXCell) or rat IgG2a isotype control antibody (clone 2A3; BioXCell) diluted in sterile PBS 
(Hyclone) by intraperitoneal injection every 48 hrs, beginning at 10 dpi and ending at 20 or 34 
dpi, depending on the experiment. For confirmation of depletion during survival experiments, 
lungs from one anti-Ly6G treated Irg1
-/-
 control mouse and one isotype treated Irg1
-/-
 control 
mouse were harvested from each independent experiment and analyzed by flow cytometry for 
reduction in CD45
+
/CD11b
+
/Ly6C
mid
 cells.  
 
In vivo itaconate administration 
 Mice were intraperitoneally administered 500 μl of 250 mM dimethyl itaconate (Alfa 
Aesar) daily, beginning at 10 dpi and ending at 20 dpi. 
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Metabolomics profiling of Mtb infected lung cells 
 The superior, middle, and inferior lobes of the lung were left unperfused, minced with a 
razor blade, and placed into 800 μl 80% HPLC-grade methanol/20% deionized water. Samples 
were bead-beaten three times and kept on ice between cycles. Cell debris were pelleted by 
centrifugation at 17,000 x g for 5 min at room temp. Supernatants were sterilized by filtration 
through two 0.22 μm Spin-X cellulose acetate filters (Costar) and stored at -80°C until analysis 
by liquid chromatography-tandem mass spectrometry. 
 
Infection of neutrophils 
Neutrophils were purified from bone marrow of naïve mice by negative selection using 
magnetic-activated cell sorting beads (Miltenyi). Neutrophil purity (>95%) was assessed by flow 
cytometry as the percentage of Ly6G
+
CD11b
+
 cells. Neutrophils were cultured in RPMI-1640 
supplemented with 10% heat-inactivated FBS, 1% non-essential amino acids at 37°C, 5% CO2. 
Mtb was grown to mid-log phase, washed with PBS, sonicated to disperse clumps, and 
resuspended in neutrophil culture media. Mtb was then was opsonized prior to infection by 
mixing with an equal volume of normal mouse sera (Sigma) and incubation at room temperature 
for 30 min. Neutrophils were mock-infected or infected with opsonized Mtb at MOI 1 and 
incubated at 37°C, 5% CO2. 
 
Infection of BMDMs  
Macrophages were obtained by culturing bone marrow cells in RPMI-1640 (Invitrogen) 
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 1% nonessential amino acids, 
100 U penicillin per ml, 100 µg streptomycin per ml, and 22 ng M-CSF (Peprotech)/ml for 6 
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days at 37°C, 5% CO2. Fresh media was added on day 3 of culture. After 6 days of culture, 
nonadherent cells were discarded. Adherent macrophages were switched into antibiotic-free 
media and seeded at 10
5
 cells per well and 9 x 10
5
 cells per well in tissue culture-treated 96- and 
6-well plates, respectively. In some cases, macrophages were treated with physiologically 
relevant concentrations of 0.25 mM itaconic acid (Sigma) or 50 ng IFN-γ (Peprotech)/ml for 12 
hrs before infection with Mtb.
143
 Mtb was grown to OD600=0.6-0.8, washed with PBS, sonicated 
to disperse clumps, and resuspended in antibiotic-free macrophage culture media. Macrophage 
cultures were infected by adding Mtb-containing media at a multiplicity of infection of 1 and 
centrifuging for 10 min at 200 x g. Cells were washed twice with PBS to remove unbound Mtb, 
fresh culture media was added, and cells were incubated at 37°C, 5% CO2. In some cases, culture 
media was supplemented with 0.25 mM itaconic acid. 
 
Bacterial cultures  
Mtb strain Erdman, mutant Mtb strains, M. abscessus, and M. avium were cultured at 
37°C in 7H9 broth (Sigma) or on 7H11 agar (BD Difco) medium supplemented with 10% oleic 
acid/albumin/dextrose/catalase, 0.5% glycerol, and 0.05% Tween 80 (broth only).  
Listeria monocytogenes was grown in a shaking culture in brain-heart infusion broth at 
37°C to mid-logarithmic growth phase, washed in PBS, and frozen as glycerol stocks at −80°C. 
 
Generation of Mtb mutants 
Mtb-GFP was generated by transforming Mtb strain Erdman with a plasmid (pMV261-
kan-GFP) that drives constitutive expression of GFP under the control of the hsp60 promoter. 
Cultures were grown in the presence of kanamycin to ensure plasmid retention. Δicl1 Mtb was 
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generated by transducing Mtb strain Erdman with a phage containing homology to nucleotides 
556805–557527 and 558797–559447. ΔPDIM Mtb was generated by transducing Mtb strain 
Erdman with a phage containing homology to nucleotides 3243062-3243567 and 3272196-
3272718. ΔESX-1 Mtb was generated by transducing Mtb strain Erdman with a phage containing 
homology to nucleotides 4349945-4350677 and 4356534-4357206. Phage transduction was used 
to replace the endogenous icl1 (Δicl1 strain); fadD26 and ppsABCDE (ΔPDIM strain); and pe35, 
ppe68, esxAB, espI, and eccD1 (ΔESX-1 strain) genes with a hygromycin resistance cassette. 
Mutants were selected by culture on hygromycin-containing 7H11 agar. Individual hygromycin-
resistant colonies were expanded by inoculation into hygromycin-supplemented 7H9 media. 
Replacement of the target genes with the hygromycin resistance cassette was confirmed by 
Southern blotting of genomic DNA from expanded cultures. 
 
Viral cultures  
A/California/04/2009 H1N1 influenza viral stocks were prepared as previously 
described.
206
  
 
Bronchoalveolar lavage (BAL) of IAV infected mice  
For analysis of BAL fluid, mice were sacrificed by Avertin overdose, followed by 
anterior neck dissection and cannulation of the trachea with a 22-G catheter. BAL was performed 
with three washes of 0.8 ml of sterile Hanks’ balanced salt solution. BAL fluid was centrifuged 
and the cell-free supernatant was collected and stored for viral titer analysis. 
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Flow cytometry  
Lungs were perfused with sterile PBS and left lobes of lungs were digested at 37°C with 
630 µg/ml collagenase D (Roche) and 75 U/ml DNase I (Sigma). All antibodies were used at a 
dilution of 1:200. Single cell suspensions were preincubated with Fc Block antibody (BD 
Pharmingen) in PBS + 2% heat-inactivated FBS for 10 min at room before staining. Cells were 
incubated with antibodies against the following markers: V500 anti-CD45.1 (clone A20), AF700 
anti-CD45.2 (clone 104; eBioscience), AF700 anti-CD45 (clone 30 F-11), APC-Cy7 anti-CD11c 
(clone N418), PE anti-SiglecF (clone E50-2440; BD), PE-Cy7 anti-Ly6G (clone 1A8), PB or 
Qdot605 anti-Ly6C (clone AL-21/HK1.4; Biolegend/ BD), PerCP-Cy5.5 anti-CD11b (clone 
M1/70), APC anti-CD103 (clone 2E7; eBioscience), PB anti-CD3 (clone 17A2), PE-Cy7, APC 
anti-CD4 (clone RM4-5), PE-Cy7 anti-CD8 (clone53-6.7), anti-NK1.1 (clone PK136), and APC 
anti-Nos2 (clone CXN FT; all from eBioscience). Intracellular ROS were stained with MitoSOX 
red dye (Thermo Fisher). Absolute cell counts were determined using TruCount beads (BD). 
Cells were stained for 20 min at 4°C, washed, and fixed in 4% paraformaldehyde (Electron 
Microscopy Sciences) in PBS for 20 min at 4°C. Flow cytometry data were acquired on a 
cytometer (LSR Fortessa; BD Biosciences) and analyzed using FlowJo software (Tree Star). 
Gating strategies are depicted in Figure 29.  
 
Cytokine/chemokine quantification 
Lungs were homogenized in 5 ml of PBS supplemented with 0.05% Tween 80. 
Homogenates were filtered (0.22 µm) twice and analyzed by BioPlex-Pro Mouse Cytokine 23-
Plex Immunoassay (Bio-Rad). 
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Histology and imaging  
Lung samples were fixed in 10% buffered formalin (Thermo Fisher). Gross pathology 
images were acquired using a Power Shot G9 camera (Canon). For detailed histological analysis, 
lung lobes were embedded in paraffin, sectioned, and stained with H&E (Pulmonary 
Morphology Core, Washington University). Acid-fast bacilli were stained with Ziehl-Neelsen  
 
Figure 29. Flow cytometry gating strategy used in Irg1 experiments. 
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stain (Pulmonary Morphology Core). Images were acquired using NanoZoomer 2.0-HT System 
(Hamamatsu) or an Eclipse E400 camera (Nikon). 
 
RNA-seq  
Neutrophils were purified by magnetic-activated cell sorting from the bone marrow of 
naïve mice (negative selection) or whole lungs of Mtb infected mice at 16 dpi (selection for 
Ly6G
+
 cells) (Miltenyi). Neutrophil purity was defined by flow cytometry as the percentage of 
Ly6G
+
CD11b
+
 cells (negatively selected samples) or Gr-1
high
CD11b
+
 cells (positively selected 
samples). BMDMs were harvested at 4 h after Mtb infection, and RNA was extracted using 
TriZol reagent (Invitrogen). 
Total RNA was isolated from TriZol by chloroform extraction, precipitated with 
isopropanol and high salt buffer (0.8 M sodium citrate, 1.2 M NaCl in RNase-free water), 
washed with 80% ethanol/20% RNase-free water, dried for 10 min at room temp, and 
resuspended in 20 μl RNase-free water. 
 mRNA was extracted with oligo-dT beads (Invitrogen) and cDNA synthesized using 
custom oligo-dT primer with a barcode and adaptor-linker sequence (CCT ACA CGA CGC TCT 
TCC GAT CT-XXX XXX XX-T15). Samples were pooled based on Actb qPCR values, RNA–
DNA hybrids degraded with acid-alkali treatment and a second sequencing linker (5′-AGA TCG 
GAA GAG CAC ACG TCTG- 3′) was ligated with T4 ligase (NEB). After SPRI bead cleanup 
(Agencourt AMPure XP; Beckman Coulter), the mixture was PCR-enriched (12 cycles) and 
SPRI-purified, yielding final strand-specific RNA-seq libraries. Libraries were sequenced on a 
HiSeq 2500 (Illumina) using 40 x 10 bp paired-end sequencing. Second read (read-mate) was 
used for sample demultiplexing. Files obtained from the sequencing center were demultiplexed 
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with fastq-multx tool. Fastq files for each sample were aligned to mm10 genome (Release M8 
Gencode; GRCm38.p4) using STAR. Each sample was evaluated according to a variety of both 
pre- and postalignment quality control measures with Picard tools. Aligned reads were quantified 
using a quant3p script (Computer Technologies Laboratory, 2016) to account for specifics of 3′ 
sequencing: higher dependency on good 3′ annotation and lower level of sequence specificity 
close to 3′ end. Actual read counts were performed by HTSeq with enriched genome annotation 
and alignment with fixed multimapper flags. DESeq2 was used for analysis of differential gene 
expression. Preranked GSEA analysis was used to identify pathway enrichments in hallmark and 
canonical pathways. 
 
Quantification and statistical analysis 
All data are from at least two independent biological experiments with multiple mice in 
each group. No blinding was performed during animal experiments. Statistical differences were 
calculated using Prism 7 (GraphPad) using log-rank Mantel-Cox tests (survival), unpaired two-
tailed Mann-Whitney tests (to compare two groups with non-normal data distribution), and one-
way ANOVA with Tukey’s multiple comparisons tests (to compare more than two groups with 
normal data distribution). Differences with a p-value of <0.05 were defined as statistically 
significant. 
 
Data and software availability  
RNA-seq data are available in the Gene Expression Omnibus repository under reference 
series number GSE98458. 
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Introduction 
Protective immune responses to Mycobacterium tuberculosis (Mtb) must induce 
bactericidal functions while minimizing damage to the lung. Such responses require precise 
control of pro- and anti-inflammatory factors to regulate the recruitment and function of 
protective immune cells but the mechanisms by which this control is exerted remain 
incompletely defined. Bhlhe40 is a transcription factor known to regulate production of pro- and 
anti-inflammatory cytokines that affect protective immunity to Mtb. Irg1 is an enzyme that 
generates itaconate, a metabolite with potential anti-inflammatory and antibacterial roles during 
Mtb infection.  
We found that Bhlhe40 enables protective immune responses to Mtb in T cells and 
CD11c
+
 cells and enables resistance to acute infection by restricting expression of the anti-
inflammatory cytokine IL-10. Bhlhe40 does so by repressing Il10 transcription, likely by direct 
binding to the Il10 locus. Additionally, we discovered that Irg1 functions in LysM
+
 and CD11c
+
 
cells to prevent neutrophil-mediated immunopathology. Irg1 expression restricts inflammatory 
responses in myeloid cells at a transcriptional level, likely through production of the metabolite 
itaconate. The impact of Bhlhe40 and Irg1 on protective immunity to Mtb was unknown prior to 
the studies detailed in this dissertation. 
Discussion and Future Directions 
Bhlhe40 expression patterns 
Using Bhlhe40
GFP
 transgenic reporter mice that express green fluorescent protein (GFP) 
under the control of the genomic regions flanking the Bhlhe40 gene we demonstrated that 
Bhlhe40 is expressed in multiple innate and adaptive lung immune cell types before infection 
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and during acute infection. Mice with conditional deletions of Bhlhe40 in T cells and CD11c
+
 
cells were susceptible to Mtb, indicating that these are the key cell types that require Bhlhe40 
expression. Studies in other model systems have demonstrated that Bhlhe40 expression is 
dynamic and regulated by multiple stimuli. Given the importance of Bhlhe40 for control of Mtb 
infection, it is possible that these dynamics impact control of Mtb infection. Bhlhe40
GFP
 mice 
could be highly useful in future studies that seek to answer questions about where Bhlhe40-
expressing cells localize within the Mtb infected lung, the infection status of Bhlhe40-expressing 
cells, and patterns of Bhlhe40 expression in specific cell types over a prolonged course of Mtb 
infection. These questions could be answered by flow cytometry and immunohistochemistry 
studies on lung lesions in Bhlhe40
GFP
 mice infected with a Mtb strain that expresses a non-GFP 
fluorescent marker and flow cytometric analysis of Bhlhe40
GFP
 mice at later points in infection. 
Additionally, we did not address the importance of Bhlhe40 in chronic Mtb infection but could 
do so using Bhlhe40
fl/fl
 mice that express Cre recombinase under the control of a tamoxifen-
inducible promoter, such as ERT2-Cre mice.  
Bhlhe40 expression patterns could also be modulated by diet, with potentially important 
effects on control of Mtb infection. Epidemiological
207,208
 and in vitro
209
 studies have suggested 
that vitamin A levels are associated with resistance to Mtb and all-trans retinoic acid, the 
biologically available form of vitamin A, is known to induce Bhlhe40 expression.
106,123
 Together 
with our findings on the importance of Bhlhe40 in control of murine tuberculosis and lower 
BHLHE40 expression in patients with active tuberculosis, these reports raise the possibility of a 
Bhlhe40-mediated link between micronutrient availability, disease severity, and variation in 
long-term control of disease. Experiments characterizing how vitamin A availability modulates 
Bhlhe40 expression and associated control of Mtb in mice in conjunction with prospective 
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studies in humans tracking serum metabolites, Bhlhe40 expression, and progression to active 
tuberculosis could address this relationship. 
 
Bhlhe40 and IL-10-dependent control of Mtb infection 
We assessed the role of Bhlhe40 expression on control of in vivo Mtb infection using 
genetically deficient mice. Bhlhe40 was required in T cells and CD11c
+
 cells and enabled 
protective immune responses to acute Mtb infection by restricting expression of IL-10. Bhlhe40 
does so by repressing Il10 transcription, likely by direct binding to the Il10 locus. Multiple 
groups had previously demonstrated that IL-10 has detrimental effects on control of Mtb 
infection but these phenotypes were mild or occurred late in infection. Our findings show for the 
first time that IL-10 can have major impacts on control of Mtb and that Bhlhe40 is an essential 
regulator of IL-10.  However, it remains unclear exactly how increased IL-10 production causes 
susceptibility in Bhlhe40
-/-
 mice. Our observations of decreased Il12b and Ifng transcript aligns 
with a large body of literature demonstrating that IL-10 interferes with mechanisms involved in 
inducing and responding to IFN-γ, but studies comparing the transcriptional and functional state 
of WT and Bhlhe40
-/-
 cells in vivo will be necessary to fully prove that this is the case. Bhlhe40
-/-
 
cells would be expected to exhibit a transcriptional profile characterized by reduced expression 
of IFN-γ-stimulated genes after the induction of Mtb-specific adaptive immune responses. 
We have identified multiple immune cell populations that overexpress IL-10 as well as 
the key cell types that must express Bhlhe40 during Mtb infection. We also observed increased 
IL-10 expression in non-Bhlhe40-expressing cell types in the context of global Bhlhe40 
deficiency which raises the possibility that non-Bhlhe40-expressing cells may be important 
sources of IL-10. It remains to be determined which of these cell types mediate IL-10 dependent 
114 
 
susceptibility. Cell types that cause susceptibility by overproducing IL-10 in a globally Bhlhe40-
deficient setting can be identified by generating Bhlhe40
-/-
Il10
fl/fl
 mice that express Cre 
recombinase in the cell types we found to be over-producers of IL-10 in our analysis of 
Bhlhe40
-/- 
10BiT
+
 mice. Cell types in which Bhlhe40 is essential to regulate IL-10 production can 
be identified by generating Bhlhe40
fl/fl
Il10
fl/fl
 mice that express Cre recombinase in the cell types 
we identified as expressing Bhlhe40 in our analysis of Bhlhe40
GFP
 mice. Susceptibility-
associated phenotypes such as survival, Mtb burden, and inflammation can then be compared in 
Cre-positive and Cre-negative Bhlhe40
-/-
Il10
fl/fl
 mice or Bhlhe40
fl/fl
Il10
WT/WT
 mice with the same 
Cre expression pattern. Cre-positive Bhlhe40
-/-
Il10
fl/fl
 and Bhlhe40
fl/fl
Il10
fl/fl
 mice that show 
improvement in susceptibility-associated phenotypes will reveal key cell types that mediate IL-
10-dependent susceptibility. 
Additionally, we have yet to identify the cell types that mediate susceptibility by 
responding to the increased IL-10. Such cell types can be identified by comparing susceptibility-
associated phenotypes in Cre-positive and Cre-negative Bhlhe40
-/-
Il10ra
fl/fl
 mice. Key cell types 
will be identified by Cre-positive mice that show improvements in susceptibility associated 
phenotypes as compared to Cre-negative mice.  
 While we have established that Bhlhe40 is a direct regulator of IL-10, the pathway of IL-
10 induction in which Bhlhe40 functions remains to be determined. IL-10 can be induced by a 
wide variety of extracellular signals during Mtb infection
75,165
 and the ability of Bhlhe40 to 
repress IL-10 may vary according to the induction pathway. We found that Bhlhe40
-/-
 cells and 
mice do not overexpress Il10 prior to infection which strongly implies that a transcriptional 
activator is triggered by Mtb infection. The identity of this putative activator is currently 
unknown and there are many possibilities, but c-Maf, AP-1 family members, and IRF4 stand out 
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by virtue of their reported ability to bind the Il10 locus close to the Bhlhe40 binding site we 
identified at Il10 +6 kb. c-Maf (encoded by the Maf gene) is induced in T cells by cytokine 
signals
210,211
 and promotes T cell production of IL-10 in infectious disease, allergy, and 
autoimmune contexts.
212
 Bhlhe40 expression was found to be upregulated in c-Maf-deficient T 
cells
212
 and Maf expression is increased in Bhlhe40-deficient T cells,
129
 suggesting that these 
transcription factors regulate each other. In support of this idea, our ChIP-seq data identified Maf 
as a gene predicted to be regulated by Bhlhe40 in TH1 cells. Binding sites for c-Maf have been 
reported in the Il10 promoter and near the Il10 +6 kb site bound by Bhlhe40.
212
 Interferon 
regulatory factor 4 (IRF4) promotes IL-10 production after T cell activation and has been shown 
to bind a Il10 +6.45 kb enhancer site in TH2 cells.
213
 Several members of the activator protein 
(AP)-1 family of transcription factors have also been reported to bind the Il10 +6.45 kb site in T 
cells after T cell receptor stimulation, including JunB and c-Jun.
181,214
 The AP-1 family member 
c-fos promotes IL-10 production in myeloid DCs after stimulation with toll-like receptor (TLR) 
agonists and could potentially bind to the same AP-1 site as JunB or c-Jun in DCs, but direct 
binding has yet to be demonstrated.
215
 Bhlhe40 has also been reported to interact with histone 
deacetylases (HDACs)
102
 and could be preventing binding of an activator elsewhere in the Il10 
locus by controlling chromatin accessibility. Thus, these transcription factors represent likely 
candidates for the activator of Il10 transcription that is restricted by Bhlhe40. 
CRISPR or small-interfering RNA knock-down approaches could be used to target the 
activator protein candidates mentioned above in Bhlhe40
-/-
 T cells and GM-CSF cultured cells. 
Il10 transcript levels could then be measured after treatment with IL-10-inducing stimuli such as 
anti-CD3/anti-CD28 and PMA/Ionomycin or heat-killed Mtb antigen. Knock-down of the 
activator protein will result in reduced Il10 transcription in Bhlhe40
-/-
 cells. Activator protein 
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redundancy is also a possibility and multiple activator candidates may need to be targeted 
simultaneously. HDAC-dependent mechanisms could be identified through treatment with 
trichostatin A, a pan-HDAC inhibitor, profiling of histone acetylation status, and co-
immunoprecipitation mass spectrometry to identify HDAC interactions or potential activators 
that Bhlhe40 represses through direct binding. The importance of activator candidates in Mtb 
infection can then be tested by generation of Bhlhe40
-/-
 mice that also lack the protein of interest 
and comparison of susceptibility-associated phenotypes with Bhlhe40
-/-
 mice. Once an activator 
protein is identified, the key upstream signaling pathways that trigger it can be identified by 
genetic knock-out or antibody blockade and treatment with IL-10-inducing stimuli.  
 Another IL-10-dependent role for Bhlhe40 concerns clinical tuberculosis diagnostics. 
IFN-γ release assays (IGRAs) are a commonly used method of diagnosing Mtb exposure, but 
more than 10% of culture-positive tuberculosis patients test negative by IGRA.
216
 These patients 
tend to have worse disease outcomes, likely due to delayed treatment. IGRAs work by 
stimulating a sample of peripheral blood with Mtb antigens and measuring IFN-γ production.216 
We found that Bhlhe40-deficiency leads to increased production of IL-10 and that patients with 
active tuberculosis had lower BHLHE40 expression in their peripheral blood. Since IL-10 is well 
established as a suppressor of IFN-γ, our findings suggest that patients with lower expression of 
Bhlhe40 in peripheral blood could produce increased IL-10 with a suppressive effect on IFN-γ 
production. Thus, lower Bhlhe40 expression levels could have an adverse effect on IGRA 
specificity and patient outcomes. Future studies could address this question by obtaining 
peripheral blood samples from discordant active tuberculosis patients who tested negative for 
tuberculosis by IGRA, but positive by bacterial culture and concordant patients who were 
positive by IGRA and culture. Bhlhe40 expression levels in unstimulated and stimulated 
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peripheral blood samples could then be compared in concordant and discordant active 
tuberculosis patients to determine if lower BHLHE40 expression before stimulation is correlated 
with a false negative IGRA result. Stimuli that induce Bhlhe40 expression, such as retinoic acid, 
could be used to treat blood samples from discordant patients and demonstrate an active role for 
Bhlhe40. IL-10-neutralizing antibodies could be used to test the role of IL-10 in any observed 
effects. 
 
IL-10-independent roles for Bhlhe40 in Mtb infection 
 We have demonstrated that the acute susceptibility of Bhlhe40
-/-
 mice is largely IL-10-
dependent, but loss of IL-10 does not confer complete restoration of WT phenotypes. 
Il10
-/-
Bhlhe40
-/-
 mice have more neutrophilic inflammation at 21 dpi and significantly shorter 
survival time compared to WT mice. These findings demonstrate that Bhlhe40 has IL-10-
independent functions that are important during Mtb infection. The key cell types mediating IL-
10-independent functions of Bhlhe40 can be identified by comparison of Cre-positive Bhlhe40
fl/fl
 
and Cre-positive Bhlhe40
fl/fl
Il10
fl/fl
. Susceptibility associated phenotypes found in both strains 
with the same Cre expression pattern would be due to IL-10-independent functions of Bhlhe40 in 
Cre-expressing cells. Identification of IL-10-independent functions for Bhlhe40 could be 
identified in an unbiased manner by transcriptomic comparison of WT, Bhlhe40
-/-
, and 
Il10
-/-
Bhlhe40
-/-
 lung hematopoietic cells at 21 dpi, a time point at which Il10
-/-
Bhlhe40
-/-
 mice 
already have a higher frequency of neutrophils compared to WT mice.  
We have also identified genes that Bhlhe40 is predicted to regulate based on DNA 
binding sites and this data could also be used to address IL-10-independent roles. Bhlhe40 has 
been reported to function in a wide variety of biological processes including cell death and 
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regulation of non-IL-10 cytokine production. Our studies of Irg1 and Bhlhe40 have demonstrated 
the importance of inflammatory control for infection and cell death modalities are known to 
impact control of Mtb.
217
 Perturbation of these processes in Bhlhe40
-/-
 cells could adversely 
affect control of inflammation and Mtb growth in the absence of IL-10. Additionally, we have 
observed that Il10
-/-
Bhlhe40
-/-
 mice have a stronger neutrophil response than WT mice as early as 
21 dpi. Based on literature reports and our data, investigation of Bhlhe40-regulated genes that are 
likely to regulate cytokine production, cell death, or have previously been identified as important 
for control of Mtb should be prioritized. Three candidate genes, all of which were identified as 
potentially regulated by Bhlhe40 in both myeloid and lymphoid cells, are discussed below. 
Tristetraprolin (TTP, encoded by Zfp36) is an RNA-binding protein that regulates mRNA 
stability. TTP has been reported to repress production of  IL-12
218
 and IFN-γ,219 and transcript 
levels for both of these cytokines trend downward in Il10
-/-
Bhlhe40
-/-
 compared to WT mice. TTP 
can also regulate other proinflammatory cytokines of potential importance in Il10
-/-
Bhlhe40
-/-
 
mouse susceptibility during chronic infection.
220
 TTP also regulates RIP1 kinase activity,
221
 and 
decreased RIP1 activity could lead to detrimental cell death pathways.
90
 Forkhead box protein 
O3 (Foxo3) is a transcription factor that exerts predominantly anti-inflammatory effects on 
immune cells. Foxo3 has been reported to promote T cell apoptosis
222
 and to repress pro-
inflammatory responses by DCs and T cells.
223,224
 Dysregulated Foxo3 activity could lead to over 
or underproduction of inflammatory cytokines or be detrimental for survival of effector T cells 
during Mtb infection. Hypoxia inducible factor-1α (Hif-1α) is a transcription factor that mediates 
a wide variety of IFN-γ-stimulated responses and is essential for control of Mtb infection.225 
However, over-expression of Hif-1α can cause proteinase-mediated tissue pathology.226 
Dysregulated Hif-1α activity could compromise protective functions of IFN-γ during Mtb 
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infection or promote immunopathology. Thus TTP, Foxo3, and Hif-1α all modulate key immune 
cell processes involved in control of Mtb and could promote IL-10-independent susceptibility if 
dysregulated in Bhlhe40
-/-
 mice.  
 
Irg1 and restriction of neutrophil-mediated immunopathology 
We have discovered that Irg1 expression restricts neutrophil-dominated inflammatory 
responses in myeloid cells at a transcriptional level, likely through production of the metabolite 
itaconate. In support of itaconate as an anti-inflammatory mediator, we found that exogenous 
itaconate treatment was sufficient to revert Irg1
-/-
 macrophages to a less inflammatory, WT-like 
transcriptional profile and suppressed transcription of the neutrophil recruitment signal CXCL2 
and the broadly inflammatory gene Il1b. Intriguingly, we found that levels of IL-17, a cytokine 
that triggers and sustains neutrophilic inflammation, were also highly upregulated in the lungs of 
Irg1
-/- 
mice. This suggests that Irg1 restricts neutrophilic inflammatory responses by limiting 
production of cytokines such as CXCL2, IL-1β, and IL-17. 
However, the mechanism by which Irg1 exerts its anti-inflammatory effects during Mtb 
infection remains unclear. Studies in other models of immunopathology have reported that Irg1 
or itaconate promotes the activity of anti-inflammatory factors such as TNFAIP3 (also known as 
A20), Nrf2, and Atf3, leading to the repression of a subset of pro-inflammatory cytokines that 
includes IFN-β, IL-1β, IL-6, and IL-12.153,154,156 Unpublished data from our co-authors suggests 
that itaconate may also regulate IL-17 production by interfering with expression of the 
transcription factor BATF (Lampropolou & Artyomov, in preparation). Our findings that IL-1β, 
IL-6, and IL-17 are more highly expressed in Mtb infected Irg1
-/-
 lungs a 14 dpi suggest that they 
might lead to neutrophilic inflammation. Future studies could test this by blockade or genetic 
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deletion of IL-6R and IL-17R and treatment with the IL-1R antagonist anakinra, followed by 
assessment of neutrophil accumulation and other susceptibility-associated phenotypes in Irg1
-/-
 
mice.    
Our studies implicate Irg1-derived itaconate as a key suppressor of neutrophilic 
inflammation. Since neutrophil-dominated responses to Mtb are associated with active 
tuberculosis in humans, itaconate supplementation is a potential therapeutic approach for limiting 
neutrophil-mediated immunopathology in humans. Our efforts to modulate the pulmonary 
response to Mtb through intraperitoneal delivery of dimethyl itaconate were unsuccessful, but 
this may be due to insufficient bioavailability in the lung. Itaconate or an analog could be 
delivered intravenously or intranasally and Irg1
-/-
 mice could be assessed for reduction 
neutrophil recruitment or inflammatory mediators such as IL-6 and IL-17. It is also possible that 
Irg1 has itaconate-independent effects in vivo. Future studies utilizing comparing Irg1
-/-
 mice 
with mice that express a catalytically-inactivated version of Irg1 during Mtb infection will be 
required to identify such effects. 
 
Myeloid cell-specific requirements for Irg1 
We found that although the susceptibility of Irg1
-/-
 mice is mediated by neutrophils, 
neutrophil-specific loss of Irg1 expression was not sufficient for susceptibility to Mtb infection. 
In contrast, loss of Irg1 expression in LysM
+
 and CD11c
+
 cells was sufficient to cause 
susceptibility. These susceptibility patterns point to a requirement for Irg1 in macrophages, 
monocytes, and DCs during Mtb infection. Irg1 deficiency in LysM
+
 cells led to an earlier 
susceptibility than deficiency in CD11c
+
 cells, demonstrating that expression in macrophages 
and monocytes enables survival of acute infection. Neutrophils also express LysM and Irg1-
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deficient neutrophils are likely an important contributor to the acute susceptibility of Irg1
fl/fl
-
Lysm-Cre mice, despite being insufficient for susceptibility when other myeloid cells express 
Irg1. We do not yet know why loss of Irg1 in neutrophils alone has no impact on susceptibility 
but it may be due to the ability of Irg1-expressing cell types to secrete itaconate and thereby 
provide in trans complementation to Irg1-deficient neutrophils.
138
 Transcriptomic comparison of 
neutrophils isolated from Mtb-infected Cre-negative Irg1
fl/fl
, Irg1
fl/fl
-Mrp8-Cre, and Irg1
-/-
 lungs 
would reveal whether Irg1-deficient neutrophils take on a less inflammatory profile when other 
Irg1-sufficient cells are present. 
 
Impact of Irg1 on adaptive immunity 
Irg1 and itaconate exert host-protective effects on innate immune cell function during Mtb 
infection, but no studies have yet examined their impact on adaptive immune cells. The lungs of 
Mtb infected Irg1
-/-
 mice contained increased amounts of IFN-γ and IL-17 at 21 dpi, cytokines 
produced in large quantities by T helper (TH) 1 and TH17-polarized CD4
+
 T cells, respectively. 
IFN-γ and IL-17 have important protective functions in primary- and vaccine-elicited responses 
that control Mtb infection
34,35,227
 but both can cause pathology and susceptibility if over-
produced.
37,228
 The ability of IL-17-producing CD4
+
 T cells to drive pathologic granulocyte-
dominated inflammation during Mtb infection
228
 is of particular interest given that the 
susceptibility of Irg1
-/-
 mice is mediated by neutrophils, a type of granulocyte strongly associated 
with failure to control Mtb infection.
24,32,33
 Our observations of increased IFN-γ and IL-17 and 
neutrophil-mediated susceptibility in Mtb infected Irg1
-/-
 mice suggest that Irg1 may restrict the 
generation of pathologic T cell responses that contribute to susceptibility.  
122 
 
Irg1 could be regulating T cell survival, recruitment, polarization, or effector function. Our 
studies focused on the role of Irg1 in myeloid cells and thus we did not test any of these 
possibilities. Still, some of our observations are suggestive of potential effects. Our finding that 
Irg1
-/-
 mice had no differences in the absolute number of lung CD4
+
 T cells at 21 dpi suggests 
that T cell survival and recruitment are unaffected. The fold increase in IL-17 levels in infected 
Irg1
-/-
 lungs compared to WT was much greater than the fold increase in IFN-γ levels, 
implicating over-production of IL-17 as the dominant effector cytokine and a cause of 
neutrophil-mediated immunopathology. Recently generated data from our co-authors shows that 
secreted itaconate from myeloid cells inhibits TH17 cell effector function (Lampropoulou & 
Artyomov, in preparation). This raises the possibility that loss of itaconate in Irg1
-/-
 mice leads to 
unrestrained TH17 cell production of IL-17 and recruitment of pathologic neutrophils. Future 
studies should assess the role of T cells in Irg1
-/-
 mouse susceptibility by characterizing in vivo 
expression of lineage-defining transcription factors, ability to generate antigen-specific 
responses, antigen-specific cytokine production, and T cell transcriptional profiles. 
If Irg1 is found to be important for regulating T cell responses, follow-up studies could 
utilize Irg1
fl/fl
-Cd4-Cre mice examine a requirement for T cell-intrinsic Irg1 expression and the 
ability of secreted itaconate to modulate T cell metabolism and effector function during Mtb 
infection.  
 
Direct antibacterial roles for Irg1 in Mtb infection 
A direct antibacterial role for Irg1 has been hypothesized based on the ability of itaconate to 
inhibit Mtb ICLs in vitro. We have demonstrated that neutrophil depletion reduces WT Mtb 
burden in Irg1
-/-
 mice but does not restore it to levels observed in WT mice. This partial rescue 
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could be due to incomplete neutrophil depletion, cytokine-mediated reductions in bactericidal 
capacity, or a direct antibacterial role for Irg1. We have also shown that the susceptibility of 
Irg1
-/-
 mice is ICL1-independent and that Irg1
-/-
 BMDMs have no defect in control of WT Mtb. 
These results do not support a direct antibacterial role for Irg1 during Mtb infection but are not 
definitive. Further studies are required and must account for the redundancy of ICL1 and ICL2 as 
well as confounding factors such as host-mediated pathology, the potential for Mtb to degrade 
itaconate, and the involvement of ICLs in other metabolic pathways. 
The compensatory effects of ICL2 in Δicl1 Mtb limit our ability to identify an inhibitory role 
for Irg1. Comparison of bacterial burden and susceptibility in WT and Irg1
-/-
 mice infected with 
Δicl1/Δicl2 Mtb will be necessary to draw more comprehensive conclusions on a role for Irg1 in 
restricting the glyoxylate shunt. However, it is likely that interpreting the results of such an 
experiment will be complicated by the severe in vivo attenuation of Δicl1/Δicl2 Mtb.145 This 
attenuation has attributed to the dual functionality of ICL1 and ICL2 in the glyoxylate shunt for 
carbon assimilation and the methylcitrate cycle for detoxification of propionate.
146
 The finding 
that Irg1
-/-
 mice are equally susceptible to WT and Δicl1/Δicl2 Mtb would demonstrate that 
susceptibility is independent of the glyoxylate shunt and support restraint of inflammation as the 
crucial function for Irg1 in acute infection but would not rule out a simultaneous defect in 
antibacterial activity. An antibacterial role for Irg1 would be supported if Δicl1/Δicl2 Mtb in an 
Irg1
-/-
 mouse is cleared at rates equivalent to a WT mouse, but only if confounding inflammatory 
effects are avoided by limiting neutrophilic inflammation in the Irg1
-/-
 mice to levels comparable 
to a WT mouse. This could be accomplished by neutrophil-specific depletion and antibody-
mediated reduction of over-produced pro-inflammatory cytokines such as IL-17 in the Irg1
-/-
 
mice. Measurement of glyoxylate levels during in vitro or in vivo infection of WT and Irg1
-/-
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macrophages and mice by mass spectrometry would also provide a direct assessment of whether 
Irg1 restricts glyoxylate shunt activity since the glyoxylate cycle is absent from mammals.
147
 
It is also unclear whether the potentially antibacterial activity of itaconate is being blocked by 
itaconate-degrading enzymes in Mtb. Mammals and several Yersinia, Pseudomonas, and 
Salmonella species encode three enzymes that enable detoxification of itaconate: succinyl-
CoA:itaconyl-CoA transferase (ICT), itaconyl-CoA hydratase (ICH), and citramalyl-CoA lyase 
(CCL).
149
 Genes that may provide the same functionality in Mtb include scoAB and 
Rv3551/Rv3552 for ICT; echA1-echA21, Rv1136, and Rv3538 for ICH; and citE for CCL. Future 
studies could test the ability of Mtb to degrade itaconate by radiolabeling itaconate and 
performing mass spectrometry to look for its breakdown products. The necessity of the genes 
listed above for itaconate degradation could be determined by genetic knock-out. However, these 
genes are likely to have roles in multiple processes and the likelihood of pleiotropic effects is 
high. For example, CitE is predicted to generate acetyl-CoA for fatty acid biosynthesis based on 
its genomic location,
229
 and fatty acid biosynthesis is essential for survival of Mtb within 
macrophages.
230
 
 
Explanations for virulence of Δicl1 Mtb in Irg1-/- mice 
The persistence defect of Δicl1 Mtb during chronic infection demonstrates that glyoxylate 
shunt function is suboptimal in this strain.
145
 Since Irg1 is hypothesized to inhibit the glyoxylate 
shunt through itaconate, we asked whether Δicl1 Mtb, a strain with suboptimal glyoxylate shunt 
function, might phenocopy the inhibitory effects of itaconate on the glyoxylate shunt and exhibit 
reduced virulence in Irg1
-/-
 mice and if the susceptibility of Irg1
-/-
 mice was independent of ICL1 
function. ICL1-deficient Mtb proved not to be attenuated in Irg1
-/-
 mice and we found that Irg1
-/-
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mice were equally susceptible to WT and Δicl1 Mtb. There are several possible explanations for 
this lack of a difference. First, it is possible that the glyoxylate shunt is not active during acute 
infection and thus inhibition by itaconate would have no effect on virulence. The essentiality of 
malate synthase (glcB) to detoxify ICL-generated glyoxylate during acute infection suggests that 
ICLs and the glyoxylate shunt are active during acute infection and argues against this 
possibility.
231
 Second, it is possible that ICL2 is compensating for loss of ICL1 during acute 
infection. This is very likely because Δicl1/Δicl2 Mtb is severely attenuated during acute 
infection, while Δicl1 Mtb is not.145 Third, Irg1-/- mice may succumb to inflammatory defects at a 
time point before effects of glyoxylate shunt inhibition by itaconate can be observed. This is 
suggested by the observations that Irg1
-/-
 mice succumb 5-6 weeks post-infection but the 
persistence defect of Δicl1 Mtb is first seen at 8 weeks post-infection. Fourth, the neutrophil-
dominated inflammation observed in Irg1
-/-
 mice may generate a nutrient rich, growth-
permissive environment
33
 in which the glyoxylate shunt is not needed. Such an environment 
could compensate for any attenuation caused by loss of ICL1. A fifth and final possibility is that 
during acute infection itaconate does not inhibit ICL1 or ICL2 enough to affect Mtb growth or 
survival. This idea is supported by the report that Δicl1 Mtb in WT mice is attenuated in chronic 
infection, but we and others find that WT and Δicl1 Mtb reach similar titers by 21 dpi in WT and 
Irg1
-/-
 mice. This lack of an inhibitory effect could be due to the presence of a degradative 
pathway for itaconate in Mtb, as mentioned previously. 
 
Itaconate catabolism and vitamin B12 deficiency 
An intermediate in the metabolic pathway responsible for itaconate catabolism has been 
shown to cause vitamin B12 depletion in human cells.
232
 Since mammals and bacteria utilize a 
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similar pathway for itaconate break down,
149
 vitamin B12 deficiency is likely to occur in bacteria 
as well. As stated previously, it is unclear whether or not Mtb can catabolize itaconate. If so, this 
process could lead to vitamin B12 deficiency that inhibits the methylmalonyl-CoA cycle,
233,234
 
one of several processes used by Mtb to detoxify propionate generated during metabolism of host 
fatty acids. If allowed to accumulate, propionate causes defects in intrabacterial pH and 
membrane potential.
146
 Thus, itaconate could limit vitamin B12 availability, metabolic 
flexibility, and homeostasis in Mtb through its breakdown products. 
Itaconate catabolism-driven consumption of vitamin B12 may also cause localized 
vitamin B12 depletion in host cells. Vitamin B12 is used as a coenzyme by two human enzymes, 
MUT, which recycles carbon from the methylmalonyl cycle back into the TCA cycle and MTR, 
which synthesizes methionine.
232
 Lower circulating vitamin B12 levels are associated with 
increased expression of inflammatory biomarkers.
235,236
 The effect of vitamin B12 deficiency on 
inflammatory responses is currently unclear, but may be important for understanding the 
progression of itaconate-mediated effects. Future studies could address this by treating mice with 
itaconyl-CoA, the vitamin B12-depleting itaconate metabolite, to deplete vitamin B12 in the 
absence of other itaconate-derived effects and analyzing its impact on Mtb-elicited inflammation. 
 
Possible cross-talk between Bhlhe40 and Irg1 
Irg1-sufficient (Irg1
+/+
) bone marrow-derived macrophages generated by culture of bone 
marrow cells with M-CSF (BMDMs) do not express Bhlhe40 before or after Mtb infection. 
However, we found that Bhlhe40 transcript is highly induced in Irg1
-/-
 BMDMs as early as four 
hours after Mtb infection and that itaconate treatment blocks Bhlhe40 induction in Irg1
-/-
 
BMDMs. This demonstrates that expression of Bhlhe40 in certain macrophage subsets is 
127 
 
repressed by Irg1 and itaconate. In conjunction with previous reports that Irg1 and itaconate are 
highly expressed by activated macrophages, these observations may explain why minimal 
Bhlhe40 expression is detected in CD11b
+
 macrophages during in vivo Mtb infection. By 
extension, Irg1 expression in LysM
+
 cells, such as macrophages, during in vivo infection may 
repress Bhlhe40 and explain why loss of Bhlhe40 expression in LysM
+
 cells had no effect on in 
vivo control of Mtb. Irg1 is not predicted to be regulated by Bhlhe40 based on binding site data, 
although it could still be regulated through DNA binding-independent functions of Bhlhe40. 
Future studies could determine whether itaconate suppresses transcription of Bhlhe40 in vivo by 
comparing Mtb infected Bhlhe40
GFP
 and Irg1
-/-
Bhlhe40
GFP
 mice. In vitro studies of GM-CSF-
cultured cells treated with itaconate could use Western blotting and mass spectrometry to 
determine whether itaconate might directly repress Bhlhe40 through post-translational 
modification leading to degradation, as has been shown for KEAP1.
156
 Comparison of the 
resulting transcriptomic changes in WT, Bhlhe40
-/-
, and Irg1
-/-
 cells of the same type would 
enable large scale conclusions on how their effects synergize to promote protective responses to 
Mtb. DCs may be an appropriate starting cell type for such a transcriptional comparison since we 
have demonstrated that expression of both Bhlhe40 and Irg1 in CD11c
+
 cells is essential for 
resistance to Mtb. 
Closing remarks 
 The work presented in this dissertation has relied heavily on insights gained from studies 
on the functions of Bhlhe40 in neuroinflammation and Irg1 in macrophage activation. The 
unexpected roles that these genes had in regulating inflammatory responses provided a rationale 
for investigation of their function during Mtb infection. Using mice with global and conditional 
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deletions of Bhlhe40 and Irg1 in conjunction with in vitro models we have discovered novel and 
essential components of aspects of protective immunity to Mtb.  
Prior to these studies it was unclear why the broadly anti-inflammatory cytokine IL-10 
had such mild effects on control of Mtb infection. A multitude of reports in other disease models 
had demonstrated the potential of IL-10 to suppress protective immune responses but its effects 
on Mtb infection appeared to be limited to chronic infection and varied by genetic background. 
The work presented here has revealed that IL-10 can compromise protective immunity to Mtb if 
overexpressed during acute infection and has identified Bhlhe40 as an essential transcriptional 
regulator that prevents over-expression of IL-10. This regulatory function of Bhlhe40 is one 
mechanism by which the immune system promotes host-protective responses by suppressing 
non-protective responses. 
Irg1 had gained a great deal of interest for its ability to generate a potentially antibacterial 
effector but little attention was given to its immunomodulatory capabilities. We demonstrate here 
that Irg1 has an unexpected and essential role in preventing pathologic inflammation by limiting 
neutrophil recruitment. This selective immunosuppression allows the immune system to avoid 
responses that fail to limit Mtb replication and severely damage the lung. 
These studies establish the ability of Bhlhe40 and Irg1 to directly and indirectly tune the 
inflammatory response to Mtb at a transcriptional level. In summation, my dissertation work 
advances understanding of protective immunity to Mtb by revealing novel mechanisms used by 
specific innate and adaptive immune cell types to promote bactericidal activity and suppress 
pathologic inflammation. 
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